[go: up one dir, main page]

EP0932598A1 - ASPARTATE ESTER INHIBITORS OF INTERLEUKIN-1$g(b) CONVERTING ENZYME - Google Patents

ASPARTATE ESTER INHIBITORS OF INTERLEUKIN-1$g(b) CONVERTING ENZYME

Info

Publication number
EP0932598A1
EP0932598A1 EP97911715A EP97911715A EP0932598A1 EP 0932598 A1 EP0932598 A1 EP 0932598A1 EP 97911715 A EP97911715 A EP 97911715A EP 97911715 A EP97911715 A EP 97911715A EP 0932598 A1 EP0932598 A1 EP 0932598A1
Authority
EP
European Patent Office
Prior art keywords
oxo
pentanoic acid
acetoxy
phenyl
naphthalen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97911715A
Other languages
German (de)
French (fr)
Inventor
Hans P. Albrecht
Hamish John Allen
Kenneth Dale Brady
Bradley William Caprathe
John Lodge Gilmore
William Glen Harter
Sheryl Jeanne Hays
Catherine Rose Kostlan
Elizabeth Ann Lunney
Kimberly Suzanne Para
Anthony Jerome Thomas
Nigel Walker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Warner Lambert Co LLC
Original Assignee
BASF SE
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF SE, Warner Lambert Co LLC filed Critical BASF SE
Publication of EP0932598A1 publication Critical patent/EP0932598A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/51—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C07C275/16—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/02—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms
    • C07C317/04—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/20—Esters of monothiocarboxylic acids
    • C07C327/32—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D207/28—2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C07D233/36—One oxygen atom with hydrocarbon radicals, substituted by nitrogen atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/10—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms

Definitions

  • This invention relates to compounds that are inhibitors of interleukin-l ⁇ converting enzyme.
  • This invention also relates to a method of treatment of stroke, reperfusion injury, Alzheimer's disease, shigellosis, inflammatory diseases, and to a pharmaceutically acceptable composition that contains a compound that is an inhibitor of interleukin-l ⁇ converting enzyme.
  • the compounds of the present invention are inhibitors of interleukin- 1 ⁇ converting enzyme (ICE; Caspase-1) and are useful in treating diseases in which interleukin- 1 plays a role.
  • ICE interleukin- 1 ⁇ converting enzyme
  • ICE acts on pro-interleukin-l ⁇ (pro-IL-l ⁇ ) to produce interleukin-l ⁇ (IL-l ⁇ ), which is an inflammatory cytokine.
  • ICE (Caspase-1) regulates at least four cytokines.
  • diseases are associated with interleukin- 1 activity. Examples of diseases in which interleukin- 1 is involved include, but are not limited to, inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease, neuroinflammatory disorders such as stroke. Other diseases include septic shock, reperfusion injury, Alzheimer's disease, and shigellosis.
  • IL-l ⁇ activity has been shown to have beneficial in vivo effects.
  • compounds that are interleukin- 1 receptor antagonists have been shown to inhibit ischaemic and excitotoxic damage in rat brains. See, for example, Relton J.K., et al., Brain Research Bulletin.
  • the compounds of the present invention are also inhibitors of other cysteine proteases in the ICE family. Many of these proteases have only recently been described in the literature. While the nomenclature is still unresolved, the following proteases are representative members of this class of enzymes; Ich-2 (also called Tx or ICErel-II), ICErel-III, Ich-I (also called Nedd-2), CPP-32 (also called apopain and yama), Mch-2, Mch-3 (also called ICE-lap3, CMH-1), and Ced-3. See Henkart P.A., Immunity. 1996;4:195-201.
  • Caspase-4 can activate IL-l ⁇ and IL-18. It has been shown that a murine homolog of Caspase-4 can activate ICE. Thus, inhibition of Caspase-4 will act to inhibit ICE. See Thornberry N.A., et al., Perspectives in Drug Discovery and Design. 1994;2:389-399.
  • ICE In addition to its effects on IL-l ⁇ production, ICE has been shown to play a role in the production of the inflammatory mediator interferon- ⁇ (Ghayur, et al., Nature. 1997;386(6625):619-623). ICE processes the inactive proform of interferon- ⁇ inducing factor (IGIF; Interleukin- 18) to active IGIF, a protein which induces production of interferon- ⁇ by T-cells and natural killer cells. Interferon- ⁇ has been implicated in the pathogenesis of diseases such as inflammatory disorders and septic shock. Therefore, ICE inhibitors would be expected to have beneficial effects in such disease states by effects on interferon- ⁇ .
  • IGIF interferon- ⁇ inducing factor
  • cysteine proteases in the ICE family (also known as caspases with ICE being known as Caspase-1) has been further defined.
  • the following proteases are representative members of this class of enzymes using the nomenclature described in Alnemri, et al, Cell.
  • Caspase-2 also known as Ich-1
  • Caspase-3 also known as CPP32, Yama, and apopain
  • Caspase-4 also known as TX, Ich-2, and ICE rel-II
  • Caspase-5 also known as ICE rel-III
  • Caspase-6 also known as Mch2
  • Caspase-7 also known as Mch3
  • Caspase-8 also known as FLICE and Mch5
  • Caspase-9 also known as ICE-LAP6 and Mch6
  • Caspase-10 also known as Mch4
  • the present invention provides compounds of the Formula I
  • R 1 is R 3 OC-, R 3 CO-, R 3 SO 2 -, Ra
  • each R a is independently hydrogen, Ci -C6 alkyl, or -(CH2) n aryl;
  • R 2 is -(CRR) n -aryl, -(CRR) n -X-aryl,
  • each R is independently hydrogen, Ci -Cg alkyl, halogen or hydroxy
  • X is O or S
  • R 3 is Ci-Cs alkyl, aryl, heteroaryl,
  • each R' is independently Ci -C ⁇ alkyl
  • Ci -Cg alkylaryl, aryl, or hydrogen; each J is independently
  • each R b is independently hydrogen, Cj-Cg alkyl, aryl, substituted aryl; arylalkyl, heteroarylalkyl, substituted arylalkyl, or substituted heteroarylalkyl;
  • R4 is hydrogen
  • R 5 is C1-C6 alkyl-CO-, -(CH 2 ) n aryl,
  • Rl is phenyl-SO2-.
  • R 1 is CH3-OC-.
  • R 1 is phenyl-CH CH 2 -CO-.
  • R a is hydrogen
  • R 2 is -(CH2) n -phenyl.
  • R 2 is -(CH2) n -naphthyl.
  • R 2 is -(CH 2 ) n -O-phenyl.
  • R 2 is -(CH2) n -O-naphthyl.
  • R 2 is -(CH 2 ) n -S-phenyl.
  • R 2 is-(CH 2 )n-CH(phenyl) 2 .
  • R 2 is-(CH 2 )n-CH(phenyl) 2 .
  • R a is hydrogen; Ri is benzyloxycarbonyl; R 2 is aryl-X(CRR) n -, aryl-(CRR) n -, heteroaryl-(CRR) n -, or cycloalkyl-(CRR) n -; n is 1, 2, or 3; X is O or S; and R is hydrogen, methyl, or benzyl.
  • R a is hydrogen
  • Ri is benzyloxycarbonyl
  • R 2 is -(CH 2 ) n -naphthyl
  • R a is hydrogen; i is benzyloxycarbonyl; and
  • R 2 is -CH2-naphthyl.
  • R a is hydrogen; R 2 is benzyloxycarbonyl,
  • Also provided is a method of inhibiting interleukin-l ⁇ converting enzyme comprising administering to a patient in need of inhibition of interleukin-l ⁇ converting enzyme a therapeutically effective amount of a compound of Formula I.
  • the inflammatory disease is arthritis. In a preferred embodiment of the treatment of inflammatory diseases, the inflammatory disease inflammatory bowel disease.
  • Also provided is a method of treating reperfusion injury the method of comprising administering to a patient having reperfusion injury a therapeutically effective amount of a compound of Formula I.
  • composition that contains a compound of Formula I.
  • each n is independently 0 to 3, and the pharmaceutically acceptable, salts, esters, amides, and prodrugs thereof.
  • alkyl means a straight or branched chain hydrocarbon. Representative examples of alkyl groups are methyl, ethyl, propyl, isopropyl, isobutyl, butyl, tert-butyl, sec-butyl, pentyl, and hexyl.
  • alkoxy means an alkyl group attached to an oxygen atom. Representative examples of alkoxy groups include methoxy, ethoxy, tert-butoxy, propoxy, and isobutoxy.
  • halogen includes chlorine, fluorine, bromine and iodine.
  • aryl means an aromatic hydrocarbon. Representative examples of aryl groups include phenyl and naphthyl.
  • heteroatom includes oxygen, nitrogen, sulfur, and phosphorus.
  • heteroaryl means an aryl group wherein one or more carbon atom of the aromatic hydrocarbon has been replaced with a heteroatom. Examples of heteroaryl groups include furan, thiophene, pyrrole, thiazole, pyridine, pyrimidine, pyrazine, benzofuran, indole, coumarin, quinoline, isoquinoline, and naphthyridine.
  • the aryl or heteroaryl groups may be substituted with one or more substituents, which can be the same or different.
  • substituents include alkyl, alkoxy, thioalkoxy, hydroxy, halogen, trifluoromethyl, amino, alkylamino, dialkylamino, -NO 2 , -CN, -CO H, -CO 2 alkyl, -SO 3 H, -CHO,
  • n 1 to 5 and R is hydrogen or alkyl.
  • cycloalkyl means a cyclic alkyl group.
  • examples of cycloalkyl groups include cyclopropane, cyclobutane, cyclopentane, and cyclohexane.
  • heterocycle means a cycloalkyl group on which one or more carbon atom has been replaced with a heteroatom.
  • heterocycles include piperazine, morpholino, and piperidine.
  • aryl, heteroaryl, cycloalkyl, and heterocycle as used herein include substituted aryl, substituted heteroaryl, substituted cycloalkyl, and substituted heterocycle.
  • the compounds of Formula I can be administered to a patient either alone or as part of a pharmaceutically acceptable composition.
  • the compositions can be administered to patients such as humans and animals either orally, rectally, parenterally (intravenously, intramuscularly, or subcutaneously), intracisternally, intravaginally, intraperitoneally, intravesically, locally (powders, ointments, or drops), or as a buccal or nasal spray.
  • compositions suitable for parenteral injection may comprise physiologically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions.
  • suitable aqueous and nonaqueous carriers, diluents, solvents, or vehicles include water, ethanol, polyols (propyleneglycol, polyethyleneglycol, glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil), and injectable organic esters such as ethyl oleate.
  • Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants.
  • compositions may also contain adjuvants such as preserving, wetting, emulsifying, and dispensing agents.
  • adjuvants such as preserving, wetting, emulsifying, and dispensing agents.
  • Prevention of the action of microorganisms can be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like.
  • isotonic agents for example sugars, sodium chloride, and the like.
  • Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
  • the active compound is admixed with at least one inert customary excipient (or carrier) such as sodium citrate or dicalcium phosphate or, (a) fillers or extenders, as for example, starches, lactose, sucrose, glucose, mannitol, and silicic acid;
  • binders as for example, carboxymethylcellulose, alignates, gelatin, polyvinylpyrrolidone, sucrose, and acacia;
  • humectants as for example, glycerol
  • disintegrating agents as for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate;
  • absorption accelerators as for example, quaternary ammonium compounds
  • the dosage forms may also comprise buffering agents.
  • wetting agents as for example, cetyl alcohol, and glycerol monostearate
  • adsorbents as for example, kaolin and bentonite
  • lubricants as for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof.
  • the dosage forms may also comprise buffering agents.
  • compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethyleneglycols, and the like.
  • Solid dosage forms such as tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells, such as enteric coatings and others well known in the art. They may contain opacifying agents, and can also be of such composition that they release the active compound or compounds in a certain part of the intestinal tract in a delayed manner. Examples of embedding compositions which can be used are polymeric substances and waxes. The active compounds can also be in micro-encapsulated form, if appropriate, with one or more of the above-mentioned excipients.
  • Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs.
  • the liquid dosage forms may contain inert diluents commonly used in the art, such as water or other solvents, solubilizing agents and emulsifiers, as for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propyleneglycol, 1,3-butyleneglycol, dimethylformamide, oils, in particular, cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil, and sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethyleneglycols, and fatty acid esters of sorbitan or mixtures of these substances, and the like.
  • inert diluents commonly used in the art, such as water or other solvents, solub
  • the composition can also include adjuvants, such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
  • adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
  • Suspensions in addition to the active compounds, may contain suspending agents, as for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, macrocrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, or mixtures of these substances, and the like.
  • compositions for rectal administrations are preferably suppositories which can be prepared by mixing the compounds of the present invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethyleneglycol, or a suppository wax, which are solid at ordinary temperatures but liquid at body temperature and therefore, melt in the rectum or vaginal cavity and release the active component.
  • suitable non-irritating excipients or carriers such as cocoa butter, polyethyleneglycol, or a suppository wax, which are solid at ordinary temperatures but liquid at body temperature and therefore, melt in the rectum or vaginal cavity and release the active component.
  • Dosage forms for topical administration of a compound of this invention include ointments, powders, sprays, and inhalants.
  • the active component is admixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants as may be required. Ophthalmic formulations, eye ointments, powders, and solutions are also contemplated as being within the scope of this invention.
  • the compounds of the present invention can be administered to a patient at dosage levels in the range of about 0.1 to about 1,000 mg per day. For a normal human adult having a body weight of about 70 kg, a dosage in the range of about 0.01 to about 100 mg/kg of body weight per day is preferable.
  • the specific dosage used can vary. For example, the dosage can depend on a numbers of factors including the requirements of the patient, the severity of the condition being treated, and the pharmacological activity of the compound being used. The determination of optimum dosages for a particular patient is well known to those skilled in the art.
  • salts refers to those carboxylate salts, amino acid addition salts, esters, amides, and prodrugs of the compounds of the present invention which are, within the scope of sound medical judgement, suitable for use in contact with the tissues of patients without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the invention.
  • salts refers to the relatively non-toxic, inorganic and organic acid addition salts of compounds of the present invention.
  • salts can be prepared in situ during the final isolation and purification of the compounds or by separately reacting the purified compound in its free base form with a suitable organic or inorganic acid and isolating the salt thus formed.
  • Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate mesylate, glucoheptonate, lactobionate, and laurylsulphonate salts and the like.
  • alkali and alkaline earth metals such as sodium, lithium, potassium, calcium, magnesium, and the like
  • nontoxic ammonium, quaternary ammonium, and amine cations including, but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine and the like.
  • ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine and the like See, for example, Berge S.M., et al., "Pharmaceutical Salts.” J. Pharm. Sci.. 1977;66:1-19, which is incorporated herein by reference).
  • esters of the compounds of this invention examples include Ci -C6 alkyl esters wherein the alkyl group is a straight or branched chain. Acceptable esters also include C5-C7 cycloalkyl esters as well as arylalkyl esters such as, but not limited to benzyl. Ci -C4 alkyl esters are preferred. Esters of the compounds of the present invention may be prepared according to conventional methods.
  • Examples of pharmaceutically acceptable, non-toxic amides of the compounds of this invention include amides derived from ammonia, primary Cj-Cg alkyl amines and secondary Ci -C ⁇ dialkyl amines wherein the alkyl groups are straight or branched chain.
  • the amine may also be in the form of a 5- or 6-membered heterocycle containing one nitrogen atom.
  • Amides derived from ammonia, Ci -C3 alkyl primary amines and Ci -C2 dialkyl secondary amines are preferred. Amides of the compounds of the invention may be prepared according to conventional methods.
  • prodrug refers to compounds that are rapidly transformed in vivo to yield the parent compound of the above formulae, for example, by hydrolysis in blood.
  • a thorough discussion is provided in Higuchi T. and Stella V., "Pro-drugs as Novel Delivery Systems," Vol. 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated herein by reference.
  • the compounds of the present invention can exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of the present invention.
  • each asymmetric carbon can have either the R or S configuration. It is contemplated that all stereoisomeric forms of the compounds as well as mixtures thereof, including racemic mixtures, form part of this invention.
  • the compounds of the present invention are administered to a patient in need of ICE or Caspase-4 inhibition.
  • Caspase-4 inhibition are those patients having a disease or condition in which ICE or Caspase-4 plays a role.
  • diseases include, but are not limited to, inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease, neuroinflammatory disorders such as stroke, and septic shock.
  • Other diseases include reperfusion injury, Alzheimer's disease, and shigellosis.
  • a “therapeutically effective amount” is an amount of a compound of Formula I that when administered to a patient having a disease that can be treated with a compound of Formula I ameliorates a symptom of the disease.
  • a therapeutically effective amount of a compound of Formula I is readily determined by one skilled in the art by administering a compound of Formula I to a patient and observing the results.
  • 3-Benzyloxycarbonylamino-5-bromo-4-oxo-pentozoic acid tert-butyl ester also known as Z-Asp(OtBu)-bromomethyl ketone
  • Z-Asp(OtBu)-bromomethyl ketone can be purchased commercially or prepared according to the procedure of Dolle, et al., J. Med. Chem., 1994;37:563-564.
  • This methylbromo ketone is treated with an appropriately substituted carboxylic acid and a base such as potassium fluoride.
  • bases such as potassium carbonate, cesium carbonate, or potassium t-butoxide could be used.
  • the reagents should be mixed in dimethyl formamide (DMF), dimethylacetamide (DMA), dimethyl sulfoxide (DMSO), acetonitrile or other appropriate solvent and stirred at room temperature for 8 to 24 hours.
  • the t-butyl ester protecting group can be removed in acidic media ,preferably trifluoroacetic acid, to produce the carbobenzoxy aspartyl esters shown in Scheme 1.
  • a mixture of an appropriately substituted acyloxymethyl ketone of a carbobenzoxy aspartyl t-butyl ester was hydrogenated with an equivalent of hydrochloric or other acid in the presence of a catalyst such as palladium on carbon to yield the amine salt.
  • the salt can be acylated with an appropriately substituted isocyanate, sulfonyl chloride, chloroformate or phenylpropionyl chloride to afford the N-substituted derivatives.
  • isocyantes, sulfonyl chlorides, or chloro formates can be purchased commercially or synthesized by methods described in the chemical literature.
  • the t-butyl ester protecting group can be removed in the final step using acidic media, preferably trifluoroacetic acid, to produce the acyloxy methylketone derivatives shown in Scheme 2.
  • the amine salt of the acyloxymethyl ketone of Z-Asp(Ot-Bu)OH was synthesized and treated with an appropriately substituted carboxylic acid and coupling reagent.
  • the coupling agent may be, but is not limited to, such reagents as 1,3-dicyclohexylcarbodiimide (DCC), 1 -(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI), l, -carbonyldiimidazole (CDI), l, -carbonylbis(3-methylimidazolium) triflate (CBMIT), isobutylchloroformate, benzotriazol- 1 -yloxytris(dimethylamino)- phosphonium hexafluorophosphate (BOP), 2-(3,4-dihydro-4-oxo- 1,2,3- benzotriazin-3-yl)
  • DCC 1,
  • 1-Hydroxybenzotriazole hydrate should be added to the reaction to improve yield and limit isomerization and base, preferably an amine such as trimethyl amine or methyl morpholine should be added as an acid scavenger.
  • the resulting amide product was treated with acidic media, preferably trifluoroacetic acid, to remove the t-butyl ester and produce the final products as described in Scheme 3.
  • the amine salt of the acyloxymethyl ketone of Cbz-Asp(OtBu)OH was synthesized and treated with an appropriately substituted acid chloride or acid fluoride to generate an amide product.
  • the acid chlorides were purchased commercially or were prepared by treating carboxylic acids with agents such as thionyl chloride, phosphorous tribromide, or oxalyl chloide/DMF.
  • the acid fluorides were prepared by treating a carboxylic acid with cyanuric fluoride.
  • the penultimate amide product was treated with acidic media preferably trifluoroacetic acid to remove the t-butyl ester and afford the final products as described in Scheme 4.
  • Step B Step C Formation of the RCO 2 H, KF, 1 bromo methyl ketone DMF
  • the hydrochloride salt of H-Asp(OtBu)OMe was treated with an appropriately substituted carboxylic acid and coupling reagent.
  • the coupling agent may be but is not limited to such reagents described in Example 3.
  • 1-Hydroxybenzotriazole hydrate should be added to the reaction to improve yield and limit isomerization and base, preferably an amine such as trimethyl amine or methyl morpholine should be added as an acid scavenger.
  • the resulting amide product was treated with an alkaline reagent such as sodium hydroxide to hydrolyze the methyl ester to the carboxylic acid.
  • the hydrochloride salt of H-Asp(OtBu)OMe was treated with an appropriately protected amino acid and coupling reagent.
  • the coupling agent may be, but is not limited to, such reagents as described in Example 3.
  • 1-Hydroxybenzotriazole hydrate should be added to the reaction to improve yield and limit isomerization and base, preferably an amine such as trimethyl amine or methyl morpholine should be added as an acid scavenger.
  • the resulting amide product was treated with an alkaline reagent such as sodium hydroxide to hydrolyze the methyl ester to the carboxylic acid.
  • the Cbz-amine protecting group was removed using standard catalytic hydrogenation conditions and coupling of another protected amino acid can proceed as described above. This process was repeated until the peptide was the desired length.
  • the resulting peptide product was treated with an alkaline reagent such as sodium hydroxide to hydrolyze the methyl ester to the carboxylic acid.
  • the appropriately substituted acyloxymethyl ketone of a protected amino acid was synthesized as described in Example 7.
  • the Cbz-amine protecting group was removed using standard catalytic hydrogenation conditions, and the amine product was treated with an appropriately substituted carboxylic acid and a coupling reagent.
  • the coupling agent may be, but is not limited to, such reagents described in Example 3.
  • 1-Hydroxybenzotriazole hydrate should be added to the reaction to improve yield and limit isomerization and base, preferably an amine such as trimethyl amine or methyl morpholine should be added as an acid scavenger.
  • the penultimate amide product was treated with acidic media preferably trifluoroacetic acid to remove the t-butyl ester and afford the final products as described in Scheme 7.
  • Trans- 1 ,2-cyclohexanedicarboxylic anhydride was treated with the amine salt of an appropriately substituted acyloxymethyl ketone of aspartyl t-butyl ester in the presence of pyridine and 4-dimethylaminopyridine (DMAP) to yield the amide product.
  • the carboxylic acid can be functionalized with appropriately substituted amines or alcohols and standard coupling reagents as described in Example 3 to afford amide and ester products.
  • the penultimate product was treated with acidic media, preferably trifluoroacetic acid, to remove the t-butyl ester and afford the final products as described in Scheme 8.
  • Methyl methacrylate was treated with the anion of an appropriately substituted sulfide to afford the Michael adduct which was hydrolyzed in basic media such as sodium hydroxide to produce the carboxylic acid.
  • the amide intermediate is treated with an oxidizing agent which may be, but is not limited to, m-chloroperbenzoic acid, potassium monoperoxysulfate, or sodium perborate to obtain the desired oxidized product.
  • an oxidizing agent which may be, but is not limited to, m-chloroperbenzoic acid, potassium monoperoxysulfate, or sodium perborate.
  • the t-butyl ester of the penultimate intermediate was deprotected in acidic media, preferably trifluoroacetic acid, to afford the final compounds as described in Scheme 9.
  • a 4-substituted-2-oxazolidinone chiral auxiliary as described by Evans, et al., J. Org. Chem., 1985;50:1830 was mixed with a base, such as but not limited to, n-butyl lithium followed by treatment with an appropriately substituted acid chloride or other activated carboxylic acid to afford the N-acylated product.
  • a base such as, but not limited to, sodium bis(trimethylsilyl)amide and t-butyl bromoacetate to produce the alkylated chiral product.
  • the chiral auxiliary was removed using lithium hydroxide and hydrogen peroxide to obtain the chiral acid.
  • Treatment of the acid with the amine salt of H-Asp(OBz)O-allyl and a coupling reagent as described in Example 3 afforded the succinyl amide product.
  • the product can be elaborated in one of two ways.
  • the allyl ester was removed with phenylsilane and tetrakis(triphenyl-phosphine)palladium or other Pd(0) catalyst to obtain the carboxylic acid, and the acid was converted to the methylbromo ketone and subsequently to the acyloxymethyl ketone as described in Example 5.
  • the penultimate intermediate was subjected to catalytic hydrogenation to remove the benzyl ester and afford the final amide products as described in Scheme 10.
  • the allyl ester is removed using phenylsilane and tetrakistetrakis(triphenylphosphine)palladium or other Pd(0) catalyst to obtain the carboxylic acid.
  • This acid is converted to the methylbromo ketone and subsequently to the acyloxymethyl ketone as described in Example 5.
  • Removal of the t-butyl ester of the acyloxymethyl ketone with trifluoroacidic acid and subsequent conversion of the resulting carboxylic acid to the ester resulted in a new ester product.
  • the esterification can be accomplished using a variety of literature techniques which includes but is not limited to treatment of the carboxylic acid with an appropriately substituted alcohol in the presence of a coupling reagent.
  • the penultimate intermediate was subjected to catalytic hydrogenation to remove the benzyl ester and afford the final ester products as described in Scheme 10.
  • the appropriately substituted S-acetyl mercapto carboxylic acid was treated with benzyl bromide and l,8-diazobicyclo[5.4.0]undec-7-ene (DBU) to produce the benzyl ester which was subsequently reacted with chlorine gas to yield the sulfonyl chloride.
  • the sulfonyl chloride was treated with N,N-bis(p- methoxybenzyl)amine to afford the sulfonamide which was subjected to catalytic hydrogenation to obtain the intermediate carboxylic acid.
  • the acid was activated using cyuranic fluoride which was then mixed with the amine salt of H-Asp(Ot-
  • Z is carbobenzoxy, also known as cbz, Asp is aspartic acid and tBu is tert-butyl
  • Z is carbobenzoxy, also known as cbz, Asp is aspartic acid and tBu is tert-butyl
  • 1-naphthylacetic acid (1.00 g, 5.37 mmol
  • potassium fluoride (0.74 g, 12.74 mmol) in 10 mL of dimethylformamide (DMF) was stirred at room temperature for 12 hours.
  • DMF dimethylformamide
  • Step A A mixture of 3-benzyloxycarbonylamino-5-(naphthalen- 1 -yl-acetoxy)-4- oxo-pentanoic acid tert-butyl ester (1.495 g, 2.956 mmol, Example 1, Step A),
  • Example 2 In a process analogous to Example 2, using the appropriately substituted isocyantes, appropriately substituted sulfonyl chlorides, appropriately substituted chloroformates, or appropriately substituted acid chlorides with 3-amino- 5-(naphthalen-l-yl-acetoxy)-4-oxo-pentanoic acid, tert-butyl ester hydrochloride (Example 2, Step A), the corresponding compounds were prepared as follows: EXAMPLE 2a 3-Methoxycarbonylamino-5-(naphthalene- 1 -yl-acetoxy)-4-oxo-pentanoic acid, as off-white solid. Analysis calculated for C19H19HO7 (373.366): C, 61.12; H, 5.13; N, 3.75.
  • EXAMPLE 3a 5 -(Naphthalen- 1 -yl-acetoxy)- 4-oxo-3 - [(thiophene-3 -carbonvD-amino] -pentanoic acid, as a foamy off-white solid.
  • Diastereomer A or B was reacted with trifluoroacetic acid as described for Example 4 to yield 3-[(2-carbamoyl-cyclopentanecarbonyl)-amino]-5-(naphthalen- l-yl-acetoxy)-4-oxo-pentanoic acid 4b (diastereomer A), mp 171-185°C and 3 - [(2-carbamoyl-cyclopentanecarbonyl)-amino] -5 -(naphthalen- 1 -yl-acetoxy)-4- oxo-pentanoic acid 4c (diastereomer B), mp 208-210°C.
  • Example 2 (407 mg, 1.0 mmol) in a single portion. The mixture allowed to stir at room temperature for 16 hours. The solution was diluted with ethyl acetate and washed with saturated NaHCO3, saturated KHPO4 and brine solution, dried (MgSO4), filtered, and concentrated.
  • N-(l,2,3,4-tetrahydro-l-oxo-isoquinoline-2-yl)-acetyl aspartic acid 4-tert-butyl ester (2.8 g, 7.4 mMol) in tetrahydrofuran (40 mL) at -15°C was added N-methylmorpholine (0.75 mL, 8 mMol) followed by dropwise addition of ethyl chloroformate (0.79 mL, 8 mMol). After 15 minutes at -10°C 50 mL of a 0.2N solution of diazomethane in ether was added dropwise.
  • EXAMPLE 5z 3-[2-(3-Acetylamino-2-oxo-2H-pyridin-l-v ⁇ -acetylamino]-5-(3,3-diphenyl- propionyloxyV4-oxo-pentanoic acid as a course pink powder.
  • the starting acid was prepared as described in Bioorganic & Medicinal Chemistry Letters. 1997;7:1337-1342. Analysis calculated for C29H29N3O O.585 CF3CO2H (614.274):
  • EXAMPLE 5aa 3-[2-(3-Acetylamino-2-oxo-2H-pyridin-l-yl)-acetylamino]-5-(2-benzyl-3-phenyl- propionyloxy)-4-oxo-pentanoic acid as a fine brown powder.
  • the starting acid was prepared as described in Bioorganic & Medicinal Chemistry Letters. 1997;7:1337- 1342.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

The present invention relates to compounds that are inhibitors of interleukin-1β converting enzyme that have formula (I). This invention also relates to a method of treatment of stroke, inflammatory diseases, reperfusion injury, Alzheimer's disease, and shigellosis, and to a pharmaceutically acceptable composition that contains a compound that is an inhibitor of interleukin-1β converting enzyme.

Description

ASPARATE ESTER INHIBITORS OF INTERLEUKIN-lβ
CONVERTING ENZYME
FIELD OF THE INVENTION
This invention relates to compounds that are inhibitors of interleukin-lβ converting enzyme. This invention also relates to a method of treatment of stroke, reperfusion injury, Alzheimer's disease, shigellosis, inflammatory diseases, and to a pharmaceutically acceptable composition that contains a compound that is an inhibitor of interleukin-lβ converting enzyme.
BACKGROUND OF THE INVENTION
The compounds of the present invention are inhibitors of interleukin- 1 β converting enzyme (ICE; Caspase-1) and are useful in treating diseases in which interleukin- 1 plays a role.
ICE acts on pro-interleukin-lβ (pro-IL-lβ) to produce interleukin-lβ (IL-lβ), which is an inflammatory cytokine. In addition, ICE (Caspase-1) regulates at least four cytokines. ICE activates IL-β and IL-18 and indirectly regulates the production of IL-1 °= and IFNγ. Several diseases are associated with interleukin- 1 activity. Examples of diseases in which interleukin- 1 is involved include, but are not limited to, inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease, neuroinflammatory disorders such as stroke. Other diseases include septic shock, reperfusion injury, Alzheimer's disease, and shigellosis.
Agents that modulate IL-lβ activity have been shown to have beneficial in vivo effects. For example, compounds that are interleukin- 1 receptor antagonists have been shown to inhibit ischaemic and excitotoxic damage in rat brains. See, for example, Relton J.K., et al., Brain Research Bulletin.
1992;29:243-246. Additionally, ICE inhibitors were shown to reduce inflammation and pyrexia in rats. See Elford P.R., et al., British Journal of Pharmacology. 1995;115:601-606.
The compounds of the present invention are also inhibitors of other cysteine proteases in the ICE family. Many of these proteases have only recently been described in the literature. While the nomenclature is still unresolved, the following proteases are representative members of this class of enzymes; Ich-2 (also called Tx or ICErel-II), ICErel-III, Ich-I (also called Nedd-2), CPP-32 (also called apopain and yama), Mch-2, Mch-3 (also called ICE-lap3, CMH-1), and Ced-3. See Henkart P.A., Immunity. 1996;4:195-201. It is recognized that members of this enzyme family play key biological roles in both inflammation and apoptosis (programmed cell death). In particular, Caspase-4 can activate IL-lβ and IL-18. It has been shown that a murine homolog of Caspase-4 can activate ICE. Thus, inhibition of Caspase-4 will act to inhibit ICE. See Thornberry N.A., et al., Perspectives in Drug Discovery and Design. 1994;2:389-399.
In addition to its effects on IL-lβ production, ICE has been shown to play a role in the production of the inflammatory mediator interferon-γ (Ghayur, et al., Nature. 1997;386(6625):619-623). ICE processes the inactive proform of interferon-γ inducing factor (IGIF; Interleukin- 18) to active IGIF, a protein which induces production of interferon-γ by T-cells and natural killer cells. Interferon-γ has been implicated in the pathogenesis of diseases such as inflammatory disorders and septic shock. Therefore, ICE inhibitors would be expected to have beneficial effects in such disease states by effects on interferon-γ.
Recently, the nomenclature of those cysteine proteases in the ICE family (also known as caspases with ICE being known as Caspase-1) has been further defined. The following proteases are representative members of this class of enzymes using the nomenclature described in Alnemri, et al, Cell. 1996;87:171 : Caspase-2 (also known as Ich-1); Caspase-3 (also known as CPP32, Yama, and apopain); Caspase-4 (also known as TX, Ich-2, and ICE rel-II); Caspase-5 (also known as ICE rel-III); Caspase-6 (also known as Mch2 ); Caspase-7 (also known as Mch3); Caspase-8 (also known as FLICE and Mch5); Caspase-9 (also known as ICE-LAP6 and Mch6); Caspase-10 (also known as Mch4).
SUMMARY OF THE INVENTION
The present invention provides compounds of the Formula I
O
II wherein R1 is R3OC-, R3CO-, R3SO2-, Ra
I
R5NCHR6CO-,
each Ra is independently hydrogen, Ci -C6 alkyl, or -(CH2)n aryl; R2 is -(CRR)n-aryl, -(CRR)n-X-aryl,
-(CRR)n-heteroaryl,
-(CRR)n-X-heteroaryl,
-(CRR)n-(substituted-heteroaryl), -(CRR)n-(substituted-aryl),
-(CRR)n-X-(substituted-aryl),
-(CRR)n-aryl-aryl,
-(CRR)n-aryl-heteroaryl,
-(CRR)n-aryl-(CH2)n-aryl, -(CRR)n-CH(aryl)25
-(CRR)n-cycloalkyl,
-(CRR)n-X-cycloalkyl,
-(CRR)n-heterocycle,
-(CRR)n-X-heterocycle, -(CRR)n substituted heterocycle,
aryl
or substituted aryl]
or substituted aryl]
aryl
-(CRR)nCH
NHaryl
each R is independently hydrogen, Ci -Cg alkyl, halogen or hydroxy;
X is O or S;
R3 is Ci-Cs alkyl, aryl, heteroaryl,
-(CHR)n-aryl,
-(CHR)n-heteroaryl,
-(CHR)n-substituted heteroaryl,
-(CHR)n-substituted aryl,
O
II
-(CRR)nCORa,
-(CRR)nS(CH2)n-aryl, cycloalkyl, substituted cycloalkyl, heterocycle, substituted heterocycle, O
-(CRR)nCNR Ra, O
II
-(CRR)n-S-(CH2)n aryl,
II O
O alkyl,
R
I
J-CH2CH-,
O II
-CHR6C-heteroaryl,
O
II
-(CRR)nS(CH2)nCOR , O O
II II
-(CRR)nS(CH2)nCORa
O
-(CRR)nS(CH2)n -aryl,
O
II
-(CRR)nS(CH2)n -aryl,
II O
O
II
-(CRR)nSCC!-C6 alkyl,
O
II
-(CRR)nS(CH2)n aryl,
O
-(CRR)nS(CH2)nCO2Ra O O
— (CRR) — N JT— NHCCrC6alkyl
O
II
-(CH2)nNHOCι-C6 alkyl, O
II
-(CH2)nCNRbRb,
each R' is independently Ci -Cβ alkyl,
Ci -Cg alkylaryl, aryl, or hydrogen; each J is independently
-CO Rb,
-CONRbR ,
-SO2NRbRb, or
-SO2Rb; each Rb is independently hydrogen, Cj-Cg alkyl, aryl, substituted aryl; arylalkyl, heteroarylalkyl, substituted arylalkyl, or substituted heteroarylalkyl;
R4 is hydrogen,
Ci -C6 alkyl, O
II CH3OC-,
-phenyl, or
O I
C!-C6 alkyl C-;
R5 is C1-C6 alkyl-CO-, -(CH2)n aryl,
O I
Cι-C6-alkylOC-, C 1 -C6-alkyl-X-(CH2)nCO,
O
II C1-C6-alkyl-X-(CH2)nOC-, O
II
-C(CRR)naryl, O
II
-CNRaRa O
II
-SCι -C6 alkyl,
II O
O O
II II
-C(CH2)nCNR Ra O
II
-CO(CH2)n aryl, O
II -CO(CH2)n substituted aryl,
O O
II II
-C(CRR)nNHCO(CH2)n-aryl,
-(CH2)nX(CH2)n-aryl,
-C!-C6 alkyl X -Ci -C6 alkyl aryl, or
O 0 O
-C-CH-NHC-CH-NHCC γ -C6alkyl;
I I
(CH2)n CH2-heteroaryl
I CO2Ra R5a is
O
II
CCj-C6 alkyl, O
II
-COC!-C6 alkyl, O O
II II -C-CH-NHCC i -C6 alkyl,
I (CH2)n
I aryl or substituted aryl, O
II
CO(CH2)n aryl, O
II C(CH2)n aryl, or
O O
CCHNHCC!-C6 alkyl;
I
CH2 heteroaryl
Ry is hydrogen,
Ci-Cg alkyl, -(CH2)n aryl, -(CH2)nCO2Ra hydroxyl substituted
Cj-C6 alkyl, or imidazole substituted Ci -Cg alkyl; each n is independently 0 to 3, and the pharmaceutically acceptable, salts, esters, amides, and prodrugs thereof.
In a preferred embodiment of the compounds of Formula I, R^ is O
II phenyl-CH2-OC-.
In another preferred embodiment of the compounds of Formula I, Rl is phenyl-SO2-. In another preferred embodiment of the compounds of Formula I, O
II
R1 is CH3-OC-.
In another preferred embodiment of the compounds of Formula I, R1 is phenyl-CH CH2-CO-.
In another preferred embodiment of the compounds of Formula I,
In another preferred embodiment of the compounds of Formula I,
In another preferred embodiment of the compounds of Formula I, R1 is phenyl-CH2-CO-.
In another preferred embodiment of the compounds of Formula I,
In another preferred embodiment of the compounds of Formula I,
Ra is hydrogen.
In another preferred embodiment of the compounds of Formula I,
R2 is -(CH2)n-phenyl.
In another preferred embodiment of the compounds of Formula I, R2 is -(CH2)n-naphthyl.
In another preferred embodiment of the compounds of Formula I,
R2 is -(CH2)n-O-phenyl.
In another preferred embodiment of the compounds of Formula I, R2 is -(CH2)n-O-naphthyl. In another preferred embodiment of the compounds of Formula I,
R2 is -(CH2)n-S-phenyl.
In another preferred embodiment of the compounds of Formula I, R2 is-(CH2)n-CH(phenyl)2. In another preferred embodiment of the compounds of Formula I,
Ra is hydrogen; Ri is benzyloxycarbonyl; R2 is aryl-X(CRR)n-, aryl-(CRR)n-, heteroaryl-(CRR)n-, or cycloalkyl-(CRR)n-; n is 1, 2, or 3; X is O or S; and R is hydrogen, methyl, or benzyl.
In another preferred embodiment of the compounds of Formula I, Ra is hydrogen;
Ri is benzyloxycarbonyl; and
R2 is -(CH2)n-naphthyl,
-(CH2)n-phenyl,
-(CH2)n-cycloalkyl, -(CH2)nO(CH2)n-naphthyl,
-(CH2)nO(CH2)n-phenyl, or
-(CH2)nS(CH2)n-phenyl.
In another preferred embodiment of the compounds of Formula I, Ra is hydrogen; i is benzyloxycarbonyl; and
R2 is -CH2-naphthyl.
In another preferred embodiment of the compounds of Formula I, Ra is hydrogen; R2 is benzyloxycarbonyl,
,
O
II
C-CH-CH2-S-aryl, or
I CH3
O O
II II
-C-CHCH2-S-aryl.
I II
CH3 O
Also provided is a method of inhibiting interleukin-lβ converting enzyme, the method comprising administering to a patient in need of inhibition of interleukin-lβ converting enzyme a therapeutically effective amount of a compound of Formula I.
Also provided is a method of inhibiting Caspase-4, the method comprising administering to a patient in need of Caspase-4 inhibition a Caspase-4 inhibiting amount of a compound of Formula I .
Also provided is a method of treating stroke, the method comprising administering to a patient having a stroke or having had a stroke a therapeutically effective amount of a compound of Formula I.
Also provided is a method of treating inflammatory diseases, the method comprising administering to a patient having an inflammatory disease a therapeutically effective amount of a compound of Formula I.
In a preferred embodiment of the treatment of inflammatory diseases, the inflammatory disease is arthritis. In a preferred embodiment of the treatment of inflammatory diseases, the inflammatory disease inflammatory bowel disease.
Also provided is a method of treating reperfusion injury, the method of comprising administering to a patient having reperfusion injury a therapeutically effective amount of a compound of Formula I.
Also provided is a method of treating Alzheimer's disease, the method comprising administering to a patient having Alzheimer's disease a therapeutically effective amount of a compound of Formula I.
Also provided is a method of treating shigellosis, the method comprising administering to a patient having shigellosis a therapeutically effective amount of a compound of Formula I.
Also provided is a pharmaceutically acceptable composition that contains a compound of Formula I.
Also provided are the compounds: 3-Benzyloxycarbonylamino-5-(naphthalen-l -yl-acetoxy)-4-oxo-pentanoic acid;
3 -Benzyloxycarbonylamino-4-oxo-5 -(3 -phenyl-propionyloxy)-pentanoic acid;
3-Benzyloxycarbonylamino-5-(3-cyclohexyl-propionyloxy)-4-oxo- pentanoic acid;
3-Benzyloxycarbonylamino-5-[(naphthalene-l-yl-oxy)-acetoxy]-4-oxo- pentanoic acid;
3-Benzyloxycarbonylamino-4-oxo-5-phenoxyacetoxy-pentanoic acid; 3-Benzyloxycarbonylamino-4-oxo-5-phenylsulfanylacetoxy-pentanoic acid;
3-Benzyloxycarbonylamino-5-[(6-methoxy-naphthalene-l-yl)-acetoxy]-4- oxo-pentanoic acid;
3-Benzyloxycarbonylamino-5-(naphthalene-2-yl-acetoxy)-4-oxo-pentanoic acid; 3-Benzyloxycarbonylamino-5-(3-naphthalene-2-yl-propionyloxy)-4-oxo- pentanoic acid; 3-Benzyloxycarbonylamino-5-(3,3-diphenyl-propionyloxy)-4-oxo- pentanoic acid;
3-Benzyloxycarbonylamino-5-[(lH-indol-3-yl)-acetoxy]-4-oxo-pentanoic acid; 3-Benzyloxycarbonylamino-5-(indol-l-yl-acetoxy)-4-oxo-pentanoic acid;
3-Benzyloxycarbonylamino-5-(2-naphthalene-l-yl-propionyloxy)-4-oxo- pentanoic acid;
3 -Benzyloxycarbonylamino-4-oxo-5 - [(2-oxo-pyrrolidin- 1 -yl)-acetoxy] - pentanoic acid; 5-[(Acetyl-phenyl-amino)-acetoxy]-3-benzyloxycarbonyl-amino-4-oxo- pentanoic acid;
3-Benzyloxycarbonylamino-5-(2-benzyl-3-phenyl-propionyloxy)-4-oxo- pentanoic acid;
3-Benzyloxycarbonylamino-5-(hydroxy-naphthalene-l-yl-acetoxy)-4-oxo- pentanoic acid;
3 -Benzyloxycarbonylamino-4-oxo-5 - [(phenyl-amino)-acetoxy] -pentanoic acid;
3-Benzyloxycarbonylamino-5-[(6-hydroxy-naphthalene-l-yl)-acetoxy]-4- oxo-pentanoic acid; 3 -Benzyloxycarbonylamino-5 - [3 -(4-hydroxy-phenyl)-2-naphthalene- 1 -yl- propionyloxy)-4-oxo-pentanoic acid;
(S)-3-Benzyloxycarbonylamino-4-oxo-5-phenylacetoxy-pentanoic acid; (S)-3-Benzyloxycarbonylamino-4-oxo-5-(4-phenyl-butyryloxy)-pentanoic acid; 3-Benzyloxycarbonylamino-4-oxo-5-[(4-phenyl-naphthalen- 1 -yl)-acetoxy]- pentanoic acid;
3-Benzyloxycarbonylamino-5-[(4-methyl-naphthalen-l-yl)-acetoxy]-4- oxo-pentanoic acid;
3-Benzyloxycarbonylamino-4-oxo-5-[(4-thiophen-2-yl-naphthalen-l-yl)- acetoxy] -pentanoic acid;
3-Benzyloxycarbonylamino-5-[(4-fluoro-naphthalen-l-yl)-acetoxy]-4-oxo- pentanoic acid; 3-Benzyloxycarbonylamino-5-[(2-methyl-naphthalen-l-yl)-acetoxy]-4- oxo-pentanoic acid;
3-Benzyloxycarbonylamino-5-[(2-fluoro-naphthalen-l-yl)-acetoxy]-4-oxo- pentanoic acid; 5-(Benzofuran-4-yl-acetoxy)-3-benzyloxycarbonylamino-4-oxo-pentanoic acid;
5-(Benzo[b]thiophen-7-yl-acetoxy)-3-benzyloxycarbonylamino-4-oxo- pentanoic acid;
5-(Benzo[b]thiophen-4-yl-acetoxy)-3-benzyloxycarbonylamino-4-oxo- pentanoic acid;
5-[(4-Benzyl-naphthalen-l-yl)-acetoxy]-3-benzyloxycarbonylamino-4-oxo- pentanoic acid;
3-Benzyloxycarbonylamino-5-[(3 ,4-dihydro-naphthalen- 1 -yl)-acetoxy]-4- oxo-pentanoic acid; 3 -Benzyloxycarbonylamino-5- [(5 -bromo- 1 H-indol-3 -yl)-acetoxy] -4-oxo- pentanoic acid;
3-Benzyloxycarbonylamino-5-(3,4-diphenyl-butyryloxy)-4-oxo-pentanoic acid;
3 -Benzyloxycarbonylamino-4-oxo-5 -(3 -phenyl-3 -phenylamino- propionyloxy)-pentanoic acid;
3-Benzyloxycarbonylamino-4-oxo-5-[(l,2,3,4-tetrahydro-naphthalen-2-yl)- acetoxy] -pentanoic acid;
3-Benzyloxycarbonylamino-5-[(l-methanesulfonyl-piperidin-4-yl)- acetoxy]-4-oxo-pentanoic acid; 3-Benzyloxycarbonylamino-4-oxo-5-[(2,3,5,6-tetramethyl-phenyl)- acetoxy] -pentanoic acid;
5-(Benzothiazol-4-yl-acetoxy)-3-benzyloxycarbonylamino-4-oxo- pentanoic acid;
5-(Benzofuran-3-yl-acetoxy)-3-benzyloxycarbonylamino-4-oxo-pentanoic acid;
5 -(Benzo [b] thiophen-3 -yl-acetoxy)-3 -benzyloxycarbonylamino-4-oxo- pentanoic acid; 3-Benzyloxycarbonylamino-4-oxo-5-(3-phenyl-3-pyridin-2-yl- propionyloxy)-pentanoic acid;
3-Benzyloxycarbonylamino-5-[(2,3-dichloro-phenyl)-acetoxy]-4-oxo- pentanoic acid; 3-Benzyloxycarbonylamino-5-[(5-methyl-naphthalen-l-yl)-acetoxy]-4- oxo-pentanoic acid;
3-Benzyloxycarbonylamino-5-[(2-iodo-phenyl)-acetoxy]-4-oxo-pentanoic acid;
3-Benzyloxycarbonylamino-4-oxo-5-(3-pyridin-3-yl-propionyloxy)- pentanoic acid;
3 -Benzyloxycarbonylamino-5 - [(5 -methoxy-naphthalen- 1 -yl)-acetoxy] -4- oxo-pentanoic acid;
3-Benzyloxycarbonylamino-5-[(8-methyl-naphthalen-l-yl)-acetoxy]-4- oxo-pentanoic acid; 3-Benzyloxycarbonylamino-5-[(9H-fluoren-9-yl)-acetoxy]-4-oxo- pentanoic acid;
3 -Benzyloxycarbonylamino-5 -[(10,11 -dihydro-5H- dibenzo[a,d]cyclohepten-5-yl)-acetoxy]-4-oxo-pentanoic acid;
5-Oxo- 1 -(toluene-4-sulfonyl)-pyrrolidine-2-carboxylic acid 3-benzyloxycarbonylamino-4-carboxy-2-oxo-butyl ester;
5-Oxo-pyrrolidine-l,2-dicarboxylic acid 1 -benzyl ester 2-(3- benzyloxycarbonylamino-4-carboxy-2-oxo-butyl) ester; l-Benzoyl-pyrrolidine-2-carboxylic acid 3-benzyloxycarbonylamino-4- carboxy-2-oxo-butyl ester; Pyrrolidine-l,2-dicarboxylic acid 1 -benzyl ester 2-(3- benzyloxycarbonylamino-4-carboxy-2-oxo-butyl) ester;
3 -Benzyloxycarbonylamino-5-(2-benzyl-3 -phenyl -propionyloxy)-4-oxo- pentanoic acid;
3-Benzyloxycarbonylamino-5-[(5-cyano-naphthalen-l-yl)-acetoxy]-4-oxo- pentanoic acid;
3 -Benzyloxycarbonylamino-4-oxo-5 -(3 -phenyl-3 -pyridin-3 -yl- propionyloxy)-pentanoic acid; 3-Benzyloxycarbonylamino-4-oxo-5-(3-phenyl-3-pyridin-4-yl- propionyloxy)-pentanoic acid; and
3-Benzyloxycarbonylamino-4-oxo-5-[( 1 -oxo-3 ,4-dihydro- 1 H-isoquinolin- 2-yl)-acetoxy] -pentanoic acid. Also provided are the compounds:
3 -Benzenesulfonylamino-5 -(naphthalen- 1 -yl-acetoxy)-4-oxo-pentanoic acid;
3-Methoxycarbonylamino-5-(naphthalene-l-yl-acetoxy)-4-oxo-pentanoic acid; 5 -(Naphthalene- 1 -yl-acetoxy)-4-oxo-3 -(3 -phenyl-propionylamino)- pentanoic acid;
3-Methoxycarbonylamino-4-oxo-5-phenoxyacetoxy-pentanoic acid; and 3-(2-Methanesulfonyl- 1 -methyl-ethylsulfanylamino)-5-(naphthalen- 1 -yl- acetoxy)-4-oxo-pentanoic acid. Also provided are the compounds:
[S-(R*,R*)]-3-(2-Acetylamino-propionylamino)-5-(naphthalene-l-yl- acetoxy)-4-oxo-pentanoic acid;
5 -(Naphthalen- 1 -yl-acetoxy)-4-oxo-3 - [(thiophene-3 -carbonyl)-amino] - pentanoic acid; 3 - [(Furan-3 -carbonyl)-amino] -5 -(naphthalen- 1 -yl-acetoxy)-4-oxo- pentanoic acid;
5-(Naphthalen- 1 -yl-acetoxy)-4-oxo-3 - [2-(4-phenyl-butyrylamino)- propylamino] -pentanoic acid;
3 -(2-Methanesulfonylamino-propionylamino)-5-(naphthalen- 1 -yl-acetoxy)- 4-oxo-pentanoic acid;
3-[2-(2-Acetylamino-4-phenyl-butyrylamino)-propionylamino]-5- (naphthalen- 1 -yl-acetoxy)-4-oxo-pentanoic acid;
3-(2-Acetylamino-butyrylamino)-5-(naphthalen-l-yl-acetoxy)-4-oxo- pentanoic acid; 3-[2-(4-Carbamoyl-butyrylamino)-propionylamino]-5-(naphthalen- 1 -yl- acetoxy)-4-oxo-pentanoic acid; 3-(2-Benzyloxycarbonylamino-propionylamino)-5-(naphthalen- 1 -yl- acetoxy)-4-oxo-pentanoic acid;
5 -(Naphthalen- 1 -yl-acetoxy)-4-oxo-3-(2-ureido-propionylamino)- pentanoic acid; 3 -(2- Acetylamino-propionylamino)-5 -(naphthalen- 1 -yl-acetoxy)-4-oxo- pentanoic acid;
3 - [( 1 - Acetyl-pyrrolidine-2-carbonyl)-amino] -5 -(naphthalen- 1 -yl-acetoxy)- 4-oxo-pentanoic acid;
3-(2-Methyl-3-oxo-3-thiophen-2-yl-propionylamino)-5-(naphthalen-l-yl- acetoxy)-4-oxo-pentanoic acid;
3-(2-Acetylamino-acetylamino)-5-(naphthalen-l-yl-acetoxy)-4-oxo- pentanoic acid;
3-(2-Acetylamino-propionylamino)-5-(3,3-diphenyl-propionyloxy)-4-oxo- pentanoic acid; 3-[2-(2-Acetylamino-4-carboxy-butyrylamino)-propionylamino]-5-
(naphthalen-1 -yl-acetoxy)-4-oxo-pentanoic acid;
5 -(Naphthalen- 1 -yl-acetoxy)-4-oxo-3 - [2-(3 -phenyl-propionylamino)- propionylamino] -pentanoic acid;
3-[2-(3-Methyl-butyrylamino)-propionylamino]-5-(naphthalen-l-yl- acetoxy)-4-oxo-pentanoic acid;
3-[(l-Acetyl-4-benzyloxy-pyrrolidine-2-carbonyl)-amino]-5-(naphthalen- 1 -yl-acetoxy)-4-oxo-pentanoic acid;
3-(4-Carbamoyl-butyrylamino)-5-(naphthalen- 1 -yl-acetoxy)-4-oxo- pentanoic acid; and 3 -[2-(l -Methyl- 1 H-imidazol-4-yl)-acetylamino]-5-(naphthalen- 1 -yl- acetoxy)-4-oxo-pentanoic acid.
Also provided are the compounds:
(S)-5-(Naphthalene-l-yl-acetoxy)-4-oxo-3-phenylacetylamino-pentanoic acid; (S)-5-(Naphthalene-l-yl-acetoxy)-4-oxo-3-(2-thiophene-2-yl-acetylamino)- pentanoic acid; 3-[(2-Carbamoyl-cyclopentanecarbonyl)-amino]-5-(naphthalen- 1 -yl- acetoxy)-4-oxo-pentanoic acid;
3 - [(3 -Carbamoyl-bicyclo [2.2.1 ]heptane-2-carbonyl)-amino] -5 -(naphthalen- 1 -yl-acetoxy)-4-oxo-pentanoic acid; 3-(3-Methanesulfonyl-2-methyl-propionylamino)-5-(naphthalen-l-yl- acetoxy)-4-oxo-pentanoic acid;
3-(3-Benzenesulfonyl-2-methyl-propionylamino)-5-(naphthalen-l-yl- acetoxy)-4-oxo-pentanoic acid;
3-Butyrylamino-5-(naphthalen-2-yl-acetoxy)-4-oxo-pentanoic acid; 3-Acetylamino-5-(naphthalen-l-yl-acetoxy)-4-oxo-pentanoic acid;
3-(3-Methanesulfonyl-2-methyl-propionylamino)-5-(naphthalen-l-yl- acetoxy)-4-oxo-pentanoic acid;
3-(3-Methyl-butyrylamino)-5-(naphthalen-l-yl-acetoxy)-4-oxo-pentanoic acid; 3-(3-Carbamoyl-propionylamino)-5-(naphthalen-l-yl-acetoxy)-4-oxo- pentanoic acid;
[S-(R*,R*)]-3-(3-Acetylsulfanyl-2-methyl-propionylamino)-5-(naphthalen- l-yl-acetoxy)-4-oxo-pentanoic acid; and trans- - [(3 -Carbamoyl-cyclopentanecarbonyl)-amino] -5 -(naphthalen- 1 -yl- acetoxy)-4-oxo-pentanoic acid.
Also provided are the compounds:
3-(l,2,3,4-tetrahydro-l-oxo-isoquinoline-2-yl)-acetamino-5-(naphthalene- 1-yl acetoxy)-4-oxo-pentanoic acid;
3-(2-Methyl-3-phenethylcarbamoyl-propionylamino)-5-(naphthalen-l-yl- acetoxy)-4-oxo-pentanoic acid;
5-(Naphthalen-2-yl-acetoxy)-4-oxo-3-[2-(2-oxo-6-phenyl-piperidin-l-yl)- acetylamino] -pentanoic acid;
5 -(Naphthalen- 1 -yl-acetoxy)-4-oxo-3 - [2-(2-oxo-6-phenyl-piperidin- 1 -yl)- acetylamino] -pentanoic acid; 3 - [3 -Methyl-2-(3 -phenyl-propionylamino)-butyrylamino] -4-oxo-5- [( 1 -oxo-
1 ,2,3, 4-tetrahydro-naphthalen-2-yl)-acetoxy] -pentanoic acid; 3-(Naphthalen-2-yl-acetoxy)-4-oxo-3-[2-(l -oxo-3, 4-dihydro-l H- isoquinolin-2-yl)-acetylamino]-pentanoic acid;
5-(2-Benzyl-3-phenyl-propionyloxy)-4-oxo-3-[2-(l-oxo-3,4-dihydro-lH- isoquinolin-2-yl)-acetylamino]-pentanoic acid; 5-(2-Benzyl-3-phenyl-propionyloxy)-4-oxo-3-[2-(2-oxo-6-phenyl- piperidin- 1 -yl)-acetylamino] -pentanoic acid;
5 -(Naphthalen- 1 -yl-acetoxy)-4-oxo-3 - [2-( 1 -oxo- 1 ,2,3 ,4-tetrahydro- naphthalen-2-yl)-acetylamino]-pentanoic acid;
5 -(Naphthalen- 1 -yl-acetoxy)-4-oxo-3 - [2-( 1 -oxo-3 ,4-dihydro- 1 H- isoquinolin-2-yl)-propionylamino] -pentanoic acid;
5 -(Naphthalen-2-yl-acetoxy)-4-oxo-3 - [2-( 1 -oxo-3 ,4-dihydro- 1 H- isoquinolin-2-yl)-propionylamino]-pentanoic acid;
3 -[4-( 1 -Benzenesulfonyl- 1 H-pyrrol-2-yl)-4-oxo-butyrylamino] - 5-(naphthalen-l -yl-acetoxy)-4-oxo-pentanoic acid; 5-(2-Benzyl-3-phenyl-propionyloxy)-4-oxo-3-[2-(l-oxo-l,2,3,4-tetrahydro- naphthalen-2-yl)-acetylamino]-pentanoic acid;
5-(2-Benzyl-3-phenyl-propionyloxy)-4-oxo-3-[2-( 1 -oxo-3 ,4-dihydro- 1 H- isoquinolin-2-yl)-propionylamino]-pentanoic acid;
4-Oxo-3 - [2-( 1 -oxo-3 ,4-dihydro- 1 H-isoquinolin-2-yl)-propionylamino] - 5-[(l-oxo-l,2,3,4-tetrahydro-naphthalen-2-yl)-acetoxy]-pentanoic acid;
3-[4-( 1 -Benzenesulfonyl- 1 H-pyrrol-2-yl)-4-oxo-butyrylamino]- 5-(2-benzyl-3 -phenyl-propionyloxy)-4-oxo-pentanoic acid;
4-Oxo-5-[( 1 -oxo- 1 ,2,3 ,4-tetrahydro-naphthalen-2-yl)-acetoxy]- 3 - [2-( 1 -oxo- 1,2,3 ,4-tetrahydro-naphthalen-2-yl)-acetylamino] -pentanoic acid; 5-(Naphthalen- 1 -yl-acetoxy)-4-oxo-3-[2-(2-oxo-3-phenyl-imidazolidin-
1 -yl)-propionylamino] -pentanoic acid;
5-(Naphthalen-l-yl-acetoxy)-4-oxo-3-[2-(2-oxo-3-phenyl-tetrahydro- pyrimidin-1 -yl)-propionylamino] -pentanoic acid;
5-(Naphthalen-l-yl-acetoxy)-4-oxo-3-[2-(2-oxo-3-phenyl-tetrahydro- pyrimidin-l-yl)-acetylamino] -pentanoic acid;
3-(2-Acetylamino-3-methyl-butyrylamino)-5-(naphthalen-l-yl-acetoxy)- 4-oxo-pentanoic acid; 3-(2-Acetylamino-3-methyl-butyrylamino)-5-(2-benzyl-3-phenyl- propionyloxy)-4-oxo-pentanoic acid;
3-(2-Acetylamino-3-methyl-butyrylamino)-5-(3-benzyl-4-phenyl- butyryloxy)-4-oxo-pentanoic acid; 3 -(2- Acetylamino-3 -methyl-butyrylamino)-5 -(4-benzyl-5-phenyl- pentanoyloxy)-4-oxo-pentanoic acid;
3-(2-Acetylamino-3-methyl-butyrylamino)-4-oxo-5-[(l-oxo- 1 ,2,3,4-tetrahydro-naphthalen-2-yl)-acetoxy]-pentanoic acid;
5-(3-Benzyl-4-phenyl-butyryloxy)-3-[3-methyl-2-(3-phenyl- propionylamino)-butyrylamino]-4-oxo-pentanoic acid;
3-[2-(3-Acetylamino-2-oxo-2H-pyridin-l-yl)-acetylamino]-5-(3,3- diphenyl-propionyloxy)-4-oxo-pentanoic acid; and
3-[2-(3-Acetylamino-2-oxo-2H-pyridin-l-yl)-acetylamino]-5-(2-benzyl-3- phenyl-propionyloxy)-4-oxo-pentanoic acid. Also provided are the compounds:
3-[2-(2-Benzyloxycarbonylamino-4-carboxy-butyrylamino)-3-methyl- butyrylamino] -5 -(naphthalen- 1 -yl-acetoxy)-4-oxo-pentanoic acid; 3-[2-(2-Benzyloxycarbonylamino-3-methyl-butyrylamino)- propionylamino]-5-(naphthalen- 1 -yl-acetoxy)-4-oxo-pentanoic acid; 3-(2-Acetylamino-3-methyl-butyrylamino)-5-(naphthalen-l-yl-acetoxy)-
4-oxo-pentanoic acid;
3-[2-(2-Benzyloxycarbonylamino-3-methyl-butyrylamino)- propionylamino]-5-(3,3-diphenyl-propionyloxy)-4-oxo-pentanoic acid; 3 - [2-(2-Benzyloxycarbonylamino-3 -methyl-butyrylamino)- propionylamino]-5-(2-benzyl-3-phenyl-propionyloxy)-4-oxo-pentanoic acid;
3-[2-(2-Benzyloxycarbonylamino-3-methyl-butyrylamino)- propionylamino]-5-(naphthalen- 1 -yl-acetoxy)-4-oxo-pentanoic acid;
5-(2-Benzyl-3-phenyl-propionyloxy)-3-{2-[4-carboxy-2-(3-phenyl- propionylamino)-butyrylamino]-3-methyl-butyrylamino}-4-oxo-pentanoic acid; 3-(2-Benzyloxycarbonylamino-3-methyl-butyrylamino)-5-(3,3-diphenyl- propionyloxy)-4-oxo-pentanoic acid; 3-(2-Acetylamino-3-hydroxy-butyrylamino)-5-(naphthalen-l-yl-acetoxy)- 4-oxo-pentanoic acid;
3-(2-Acetylamino-3-hydroxy-butyrylamino)-5-(3,3-diphenyl- propionyloxy)-4-oxo-pentanoic acid; 3-(2-{2- [2- Acetylamino-3 -(1 H-indol-3 -yl)-propionylamino] -4-carboxy- butyrylamino}-3-methyl-butyrylamino)-5-(2-benzyl-3-phenyl-propionyloxy)- 4-oxo-pentanoic acid; and
5-(3 ,3 -Diphenyl-propionyloxy)-4-oxo-3 - [2-(4-phenyl-butyrylamino)- propionylamino] -pentanoic acid. Also provided are the compounds:
3-(2-{2-[2-Acetylamino-3-(lH-indol-3-yl)-propionylamino]-4-carboxy- butyrylamino}-3-methyl-butyrylamino)-5-(naphthalen-l-yl-acetoxy)-4-oxo- pentanoic acid; and
3 -(2- { 2- [2- Acetylamino-3 -(4-hydroxy-phenyl)-propionylamino] - 4-carboxy-butyrylamino} -3-methyl-butyrylamino)-5-(naphthalen- 1 -yl-acetoxy)-
4-oxo-pentanoic acid.
Also provided are the compounds:
3-[(2-Carboxy-cyclohexanecarbonyl)-amino]-5-(naphthalen-l-yl-acetoxy)- 4-oxo-pentanoic acid; 3-[(2-Methoxycarbonyl-cyclohexanecarbonyl)-amino]-5-(naphthalen- 1 -yl- acetoxy)-4-oxo-pentanoic acid; and
3-[(2-Carbamoyl-cyclohexanecarbonyl)-amino]-5-(naphthalen-l-yl- acetoxy)-4-oxo-pentanoic acid.
Also provided are the compounds: 3-(3-Benzylsulfanyl-2-methyl-propionylamino)-5-(naphthalen-l-yl- acetoxy)-4-oxo-pentanoic acid;
3-(2-Methyl-3-phenylmethanesulfonyl-propionylamino)-5-(naphthalen- 1 -yl-acetoxy)-4-oxo-pentanoic acid;
3-[3-(2-Carboxy-ethanesulfanyl)-2-methyl-propionylamino]- 5-(naphthalen-l-yl-acetoxy)-4-oxo-pentanoic acid;
5-(2-Benzyl-3-phenyl-propionyloxy)-3-[3-(2-carboxy-ethanesulfonyl)- 2-methyl-propionylamino]-4-oxo-pentanoic acid; 5-(2-Benzyl-3-phenyl-propionyloxy)-3-[3-(3-carboxy-propane-l-sulfιnyl)- 2-methyl-propionylamino]-4-oxo-pentanoic acid;
5-(Naphthalen-l-yl-acetoxy)-4-oxo-3-(2-phenylmethanesulfanyl- propionylamino)-pentanoic acid; 3-(2-Methyl-3-phenylsulfanyl-propionylamino)-5-(naphthalen-l-yl- acetoxy)-4-oxo-pentanoic acid;
5 -(2-Benzyl-3 -phenyl-propionyloxy)-3 -(2-methyl-3 -phenylsulfanyl- propionylamino)-4-oxo-pentanoic acid;
3-(2-Methyl-3-phenethylsulfanyl-propionylamino)-5-(naphthalen-l-yl- acetoxy)-4-oxo-pentanoic acid;
5-(2-Benzyl-3-phenyl-propionyloxy)-3-(2-methyl-3-phenethylsulfanyl- propionylamino)-4-oxo-pentanoic acid;
5-(2-Benzyl-3-phenyl-propionyloxy)-3-(3-benzylsulfanyl-2-methyl- propionylamino)-4-oxo-pentanoic acid; 5-(2-Benzyl-3-phenyl-propionyloxy)-3-(2-benzylsulfanyl- propionylamino)-4-oxo-pentanoic acid;
3-[2-Methyl-3-(3-phenyl-propylsulfanyl)-propionylamino]-5-(naphthalen- 1 -yl-acetoxy)-4-oxo-pentanoic acid;
3-(3-Benzenesulfonyl-2-methyl-propionylamino)-5-(naphthalen-l-yl- acetoxy)-4-oxo-pentanoic acid;
3-(3-Benzenesulfonyl-2-methyl-propionylamino)-5-(2-benzyl-3-phenyl- propionyloxy)-4-oxo-pentanoic acid;
5-(2-Benzyl-3-phenyl-propionyloxy)-3-[2-methyl-3-(2-phenyl- ethanesulfonyl)-propionylamino]-4-oxo-pentanoic acid; 3-[2-Methyl-3-(2-phenyl-ethanesulfonyl)-propionylamino]-5-(naphthalen-
1 -yl-acetoxy)-4-oxo-pentanoic acid;
5-(Naphthalen- 1 -yl-acetoxy)-4-oxo-3-(2-phenylmethanesulfonyl- propionylamino)-pentanoic acid;
5-(2-Benzyl-3-phenyl-propionyloxy)-3-(2-methyl- 3-phenylmethanesulfonyl-propionylamino)-4-oxo-pentanoic acid;
5-(2-Benzyl-3-phenyl-propionyloxy)-4-oxo-3-(2-phenylmethanesulfonyl- propionylamino)-pentanoic acid; 3 - [2-Methyl-3 -(3 -phenyl-propane- 1 -sulfonyl)-propionylamino] - 5 -(naphthalen- 1 -yl-acetoxy)-4-oxo-pentanoic acid;
5-(2-Benzyl-3-phenyl-propionyloxy)-3-[2-methyl-3-(3-phenyl-propane- 1 -sulfonyl)-propionylamino]-4-oxo-pentanoic acid; 5-(2-Benzyl-3-phenyl-propionyloxy)-3-[3-(2-carboxy-ethylsulfanyl)-
2-methyl-propionylamino]-4-oxo-pentanoic acid;
3-[3-(3-Carboxy-propylsulfanyl)-2-methyl-propionylamino]- 5 -(naphthalen- 1 -yl-acetoxy)-4-oxo-pentanoic acid;
5 -(2-Benzyl-3 -phenyl-propionyloxy)-3 - [3 -(3 -carboxy-propylsulfanyl)- 2-methyl-propionylamino]-4-oxo-pentanoic acid;
3-(3-Carboxymethylsulfanyl-2-methyl-propionylamino)-5-(naphthalen- 1 -yl-acetoxy)-4-oxo-pentanoic acid;
5 -(2-Benzyl-3 -phenyl-propionyloxy)-3 -(3 -carboxymethylsulfanyl- 2-methyl-propionylamino)-4-oxo-pentanoic acid; 3-[3-(2-Carboxy-ethanesulfonyl)-2-methyl-propionylamino]-
5 -(naphthalen- 1 -yl-acetoxy)-4-oxo-pentanoic acid;
3 - [3 -(3 -Carboxy-propane- 1 -sulfonyl)-2-methyl-propionylamino] - 5 -(naphthalen- 1 -yl-acetoxy)-4-oxo-pentanoic acid;
3-(3-Carboxymethanesulfonyl-2-methyl-propionylamino)-5-(naphthalen- l-yl-acetoxy)-4-oxo-pentanoic acid;
5-(2-Benzyl-3-phenyl-propionyloxy)-3-[3-(3-carboxy-propane-l-sulfonyl)- 2-methyl-propionylamino] -4-oxo-pentanoic acid;
5-(2-Benzyl-3-phenyl-propionyloxy)-3-(3-carboxymethanesulfonyl- 2-methyl-propionylamino)-4-oxo-pentanoic acid; 3-[3-(3 -Carboxy-propane- 1 -sulfιnyl)-2-methyl-propionylamino] -
5 -(naphthalen- 1 -yl-acetoxy)-4-oxo-pentanoic acid;
3 - [2-Methyl-3 -(3 -phenyl-propane- 1 -sulfinyl)-propionylamino] - 5-(naphthalen-l-yl-acetoxy)-4-oxo-pentanoic acid; and
5-(2-Benzyl-3-phenyl-propionyloxy)-3-[2-methyl-3-(3-phenyl-propane- l-sulfmyl)-propionylamino] -4-oxo-pentanoic acid.
Also provided are the compounds: 3 - [3 -Methyl-2-(phenethylcarbamoyl-methyl)-butyrylamino] -5 -(naphthalen- 1 -yl-acetoxy)-4-oxo-pentanoic acid; and
3-(3-Carboxy-2-methyl-propionylamino)-5-(naphthalen-l-yl-acetoxy)-4- oxo-pentanoic acid. Also provided is the compound:
3-(2-Methyl-3-sulfamoyl-propionylamino)-5-(naphthalen-l-yl-acetoxy)-4- oxo-pentanoic acid.
Also provided are the compounds:
3-(3-Carbamoyl-2-methyl-propionylamino)-5-(naphthalen-l-yl-acetoxy)-4- oxo-pentanoic acid;
3-(2-Benzyloxycarbonylamino-3-methyl-naphthalen-l-yl-acetoxy)-4-oxo- pentanoic acid;
3-[(2-Carbamoyl-cyclopentanecarbonyl)-amino]-5-(naphthalen-l-yl- acetoxy)-4-oxo-pentanoic acid; 3 - [( 1 -Carbamoyl-pyrrolidine-2-carbonyl)-amino]-5 -(naphthalen- 1 -yl- acetoxy)-4-oxo-pentanoic acid;
3-(2-{2-[2-Acetylamino-3-(4-hydroxy-phenyl)-propionylamino]- 4-carboxy-butyrylamino } -3 -methyl-butyrylamino)-5 -(2-benzyl-3 -phenyl- propionyloxy)-4-oxo-pentanoic acid; 3-(3-Carbamoyl-2-methyl-propionylamino)-5-(naphthalen-l-yl-acetoxy)-4- oxo-pentanoic acid;
3-(2-Carbamoylmethyl-3-methyl-butyrylamino)-5-(naphthalen- 1 -yl- acetoxy)-4-oxo-pentanoic acid;
3-(3-Benzyloxy-2-ureido-propionylamino)-5-(naphthalen-l-yl-acetoxy)-4- oxo-pentanoic acid;
3-[2-(2-Benzyloxycarbonylamino-4-carboxy-butyrylamino)-3-methyl- butyrylamino]-5-(2-benzyl-3-phenyl-propionyloxy)-4-oxo-pentanoic acid;
3-{2-[4-Carboxy-2-(3-phenyl-propionylamino)-butyrylamino]-3-methyl- butyrylamino}-5-(naphthalen-l-yl-acetoxy)-4-oxo-pentanoic acid; and 3-[2-(2-Acetylamino-4-carboxy-butyrylamino)-3-methyl-butyrylamino]-
5-(naphthalen- 1 -yl-acetoxy)-4-oxo-pentanoic acid. Also provided are compounds of the Formula I
wherein R is O
-COCH2 phenyl, O
II
-S-phenyl,
O O
II -COCH3, O
II
CCH2CH2 phenyl, O O
II II C-CHNHCCH3,
I CH3
O
II -CCH thienyl,
O
II
-CCι-C6 alkyl, -(CH2)3 phenyl, OCH2phenyl,
O O
II II
-CCH-NHS-CH3,
I II
CH3 O
0 0 o
II II II
-C-CH-NH-C-CH-NHCCH3,
I I
CH3 (CH2)2
I phenyl O O
II II
-C-CH-NHCCH3,
CH2
I CH3
O O O
II II II
-CCHNHC(CH2)3CNH2,
I CH3
O O
II II
-C-CHCH2S-phenyl,
CH3 O
O
II
-C-furyl,
phenyl
-C-CH-NHCNH2,
I CH3
O O
II Ii -CCH-C-thienyl,
I CH3
O O
II II -C-CHCH2-S-CH3,
I II CH3 o
O O
II II -C(CH2)2CNH2,
O O
II II
-C(CH2)3CNH2, O O
-CCHCH2CNH2, I
CH3
O O
-S(CH2)nSCH3,
O O O O
-CCHCH2SCH35
CH3 O
OCH2phenyl
O O O
C-CH-NHC-CHNHCCH3, I I
CH3 (CH2)2
CO2H
O
O
— C— CH— N Λ N-phenyl
I __j ■
CH,
O
-CCH-SCH2 phenyl,
CH3
OCH2phenyl
CO2H O O — CH-NHCCHNHCCH,
O
O O
II II
•C-CH-NHC(CH2)2 phenyl,
CH3
O II NHCCH,
O O
II II
-CCHCH2CNH(CH2)2 phenyl,
I CH O HCCH.
O
II
-CCH-CH2-S-phenyl,
I
CH3 O O
II II
-CCHCH2-S-phenyl,
I II
CH3 O
O
II
-C-CHCH -S-(CH2)2 phenyl,
I CH3
O O
II II
-C-CH-CH2-S(CH2)2 phenyl,
I II
CH3 O
O
II
-C-CHCH2SCH phenyl,
I CH3
O O
II II
-C-CH-CH2-S(CH2)2 phenyl,
I II
CH3 O O O
II II
-C-CH — SCH2 phenyl,
CH3 O
CH2CH2phenyl ,
O O
-S-CHCH SCH3,
II I II
O CH3 O O O
II II
-CCHCH2SCCH3,
I CH3
O
II
-CCHCH2CO2H,
I CH3 O
-CCHCH2S-(CH2)3-phenyl,
I CH3
O O
II II
-C-CH-CH2S-(CH2)3 phenyl,
I II
CH3 O
O
II
-C-CH-CH2S(CH2)2 CO2H,
I
CH3 O O
II II
-C-CHCH2S(CH2)2CO H, or
I II
CH3 O
O
II
-CCHCH2S-(CH2)2CO2H; and
I II
CH3 O
R2 is
-CH2CH phenyl, -CH2 naphthyl, -CH2CH2 cyclohexyl,
-CH2O naphthyl, -CH2O phenyl, -CH S-phenyl, -CH2-substituted naphthyl, -CH CH(phenyl)2, -CH2-imidazole, -(CH2)3-phenyl,
-CH-naphthyl,
I CH3
CH3^c.O
— CH2— N — phenyl
-CH[CH2phenyl]2, -CH-naphthyl,
OH
-CH2-NH phenyl, CH2substituted phenyl
- CH -CH^ naphthyl -CH2-naphthyl-phenyl,
-CH2-fluorenyl,
-CH2 naphthyl-thienyl,
-CH2-benzofuranyl, -CH2-benzothienyl,
-CH2-naρhthyl-CH2 phenyl,
-CH2-substituted phenyl,
-CH2-substituted indolyl,
H2phenyl
phenyl
/
- CH?— CH
NHphenyl
/ pyridyl - CH2-CH phenyl
each n is independently 0 to 3, and the pharmaceutically acceptable, salts, esters, amides, and prodrugs thereof.
DETAILED DESCRIPTION OF THE INVENTION
The term "alkyl" means a straight or branched chain hydrocarbon. Representative examples of alkyl groups are methyl, ethyl, propyl, isopropyl, isobutyl, butyl, tert-butyl, sec-butyl, pentyl, and hexyl.
The term "alkoxy" means an alkyl group attached to an oxygen atom. Representative examples of alkoxy groups include methoxy, ethoxy, tert-butoxy, propoxy, and isobutoxy. The term "halogen" includes chlorine, fluorine, bromine and iodine.
The term "aryl" means an aromatic hydrocarbon. Representative examples of aryl groups include phenyl and naphthyl. The term "heteroatom" includes oxygen, nitrogen, sulfur, and phosphorus. The term "heteroaryl" means an aryl group wherein one or more carbon atom of the aromatic hydrocarbon has been replaced with a heteroatom. Examples of heteroaryl groups include furan, thiophene, pyrrole, thiazole, pyridine, pyrimidine, pyrazine, benzofuran, indole, coumarin, quinoline, isoquinoline, and naphthyridine.
The aryl or heteroaryl groups may be substituted with one or more substituents, which can be the same or different. Examples of suitable substituents include alkyl, alkoxy, thioalkoxy, hydroxy, halogen, trifluoromethyl, amino, alkylamino, dialkylamino, -NO2, -CN, -CO H, -CO2alkyl, -SO3H, -CHO,
-COalkyl, -CONH2, -CONH-alkyl, -CONHR , -CON(alkyl)2, -(CH2)n-NH2,
-(CH2)nOH, -(CH2)n-NH-alkyl, -NHR , or -NHCOR1, where n is 1 to 5 and R is hydrogen or alkyl.
The term "cycloalkyl" means a cyclic alkyl group. Examples of cycloalkyl groups include cyclopropane, cyclobutane, cyclopentane, and cyclohexane.
The term "heterocycle" means a cycloalkyl group on which one or more carbon atom has been replaced with a heteroatom. Examples of heterocycles include piperazine, morpholino, and piperidine.
The terms aryl, heteroaryl, cycloalkyl, and heterocycle as used herein include substituted aryl, substituted heteroaryl, substituted cycloalkyl, and substituted heterocycle.
The symbol " — " means a bond.
The compounds of Formula I can be administered to a patient either alone or as part of a pharmaceutically acceptable composition. The compositions can be administered to patients such as humans and animals either orally, rectally, parenterally (intravenously, intramuscularly, or subcutaneously), intracisternally, intravaginally, intraperitoneally, intravesically, locally (powders, ointments, or drops), or as a buccal or nasal spray.
Compositions suitable for parenteral injection may comprise physiologically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents, or vehicles include water, ethanol, polyols (propyleneglycol, polyethyleneglycol, glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil), and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants.
These compositions may also contain adjuvants such as preserving, wetting, emulsifying, and dispensing agents. Prevention of the action of microorganisms can be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, for example sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin.
Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is admixed with at least one inert customary excipient (or carrier) such as sodium citrate or dicalcium phosphate or, (a) fillers or extenders, as for example, starches, lactose, sucrose, glucose, mannitol, and silicic acid;
(b) binders, as for example, carboxymethylcellulose, alignates, gelatin, polyvinylpyrrolidone, sucrose, and acacia;
(c) humectants, as for example, glycerol; (d) disintegrating agents, as for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate;
(e) solution retarders, as for example paraffin;
(f) absorption accelerators, as for example, quaternary ammonium compounds;
(g) wetting agents, as for example, cetyl alcohol, and glycerol monostearate; (h) adsorbents, as for example, kaolin and bentonite; and (i) lubricants, as for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In the case of capsules, tablets, and pills, the dosage forms may also comprise buffering agents.
Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethyleneglycols, and the like.
Solid dosage forms such as tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells, such as enteric coatings and others well known in the art. They may contain opacifying agents, and can also be of such composition that they release the active compound or compounds in a certain part of the intestinal tract in a delayed manner. Examples of embedding compositions which can be used are polymeric substances and waxes. The active compounds can also be in micro-encapsulated form, if appropriate, with one or more of the above-mentioned excipients.
Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art, such as water or other solvents, solubilizing agents and emulsifiers, as for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propyleneglycol, 1,3-butyleneglycol, dimethylformamide, oils, in particular, cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil, and sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethyleneglycols, and fatty acid esters of sorbitan or mixtures of these substances, and the like.
Besides such inert diluents, the composition can also include adjuvants, such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents. Suspensions, in addition to the active compounds, may contain suspending agents, as for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, macrocrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, or mixtures of these substances, and the like. Compositions for rectal administrations are preferably suppositories which can be prepared by mixing the compounds of the present invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethyleneglycol, or a suppository wax, which are solid at ordinary temperatures but liquid at body temperature and therefore, melt in the rectum or vaginal cavity and release the active component.
Dosage forms for topical administration of a compound of this invention include ointments, powders, sprays, and inhalants. The active component is admixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants as may be required. Ophthalmic formulations, eye ointments, powders, and solutions are also contemplated as being within the scope of this invention. The compounds of the present invention can be administered to a patient at dosage levels in the range of about 0.1 to about 1,000 mg per day. For a normal human adult having a body weight of about 70 kg, a dosage in the range of about 0.01 to about 100 mg/kg of body weight per day is preferable. The specific dosage used, however, can vary. For example, the dosage can depend on a numbers of factors including the requirements of the patient, the severity of the condition being treated, and the pharmacological activity of the compound being used. The determination of optimum dosages for a particular patient is well known to those skilled in the art.
The term "pharmaceutically acceptable salts, esters, amides, and prodrugs" as used herein refers to those carboxylate salts, amino acid addition salts, esters, amides, and prodrugs of the compounds of the present invention which are, within the scope of sound medical judgement, suitable for use in contact with the tissues of patients without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the invention. The term "salts" refers to the relatively non-toxic, inorganic and organic acid addition salts of compounds of the present invention. These salts can be prepared in situ during the final isolation and purification of the compounds or by separately reacting the purified compound in its free base form with a suitable organic or inorganic acid and isolating the salt thus formed. Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate mesylate, glucoheptonate, lactobionate, and laurylsulphonate salts and the like. These may include cations based on the alkali and alkaline earth metals, such as sodium, lithium, potassium, calcium, magnesium, and the like, as well as nontoxic ammonium, quaternary ammonium, and amine cations including, but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine and the like. (See, for example, Berge S.M., et al., "Pharmaceutical Salts." J. Pharm. Sci.. 1977;66:1-19, which is incorporated herein by reference). Examples of pharmaceutically acceptable, non-toxic esters of the compounds of this invention include Ci -C6 alkyl esters wherein the alkyl group is a straight or branched chain. Acceptable esters also include C5-C7 cycloalkyl esters as well as arylalkyl esters such as, but not limited to benzyl. Ci -C4 alkyl esters are preferred. Esters of the compounds of the present invention may be prepared according to conventional methods.
Examples of pharmaceutically acceptable, non-toxic amides of the compounds of this invention include amides derived from ammonia, primary Cj-Cg alkyl amines and secondary Ci -Cβ dialkyl amines wherein the alkyl groups are straight or branched chain. In the case of secondary amines the amine may also be in the form of a 5- or 6-membered heterocycle containing one nitrogen atom.
Amides derived from ammonia, Ci -C3 alkyl primary amines and Ci -C2 dialkyl secondary amines are preferred. Amides of the compounds of the invention may be prepared according to conventional methods.
The term "prodrug" refers to compounds that are rapidly transformed in vivo to yield the parent compound of the above formulae, for example, by hydrolysis in blood. A thorough discussion is provided in Higuchi T. and Stella V., "Pro-drugs as Novel Delivery Systems," Vol. 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated herein by reference. In addition, the compounds of the present invention can exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of the present invention.
The compounds of the present invention can exist in different stereoisomeric forms by virtue of the presence of asymmetric centers in the compounds; ie, each asymmetric carbon can have either the R or S configuration. It is contemplated that all stereoisomeric forms of the compounds as well as mixtures thereof, including racemic mixtures, form part of this invention.
The compounds of the present invention are administered to a patient in need of ICE or Caspase-4 inhibition. In general, patients in need of ICE or
Caspase-4 inhibition are those patients having a disease or condition in which ICE or Caspase-4 plays a role. Examples of such diseases include, but are not limited to, inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease, neuroinflammatory disorders such as stroke, and septic shock. Other diseases include reperfusion injury, Alzheimer's disease, and shigellosis.
A "therapeutically effective amount" is an amount of a compound of Formula I that when administered to a patient having a disease that can be treated with a compound of Formula I ameliorates a symptom of the disease. A therapeutically effective amount of a compound of Formula I is readily determined by one skilled in the art by administering a compound of Formula I to a patient and observing the results.
The following examples illustrate particular embodiments of the invention and are not intended to limit the scope of the specification and claims in any manner. EXAMPLES
The following Schemes 1 through 11 show generally how compounds of the present invention can be made.
Scheme 1
3-Benzyloxycarbonylamino-5-bromo-4-oxo-pentozoic acid tert-butyl ester, also known as Z-Asp(OtBu)-bromomethyl ketone, can be purchased commercially or prepared according to the procedure of Dolle, et al., J. Med. Chem., 1994;37:563-564. This methylbromo ketone is treated with an appropriately substituted carboxylic acid and a base such as potassium fluoride. Alternately, other bases such as potassium carbonate, cesium carbonate, or potassium t-butoxide could be used. The reagents should be mixed in dimethyl formamide (DMF), dimethylacetamide (DMA), dimethyl sulfoxide (DMSO), acetonitrile or other appropriate solvent and stirred at room temperature for 8 to 24 hours. The t-butyl ester protecting group can be removed in acidic media ,preferably trifluoroacetic acid, to produce the carbobenzoxy aspartyl esters shown in Scheme 1. Scheme 2
or ROCOC1
A mixture of an appropriately substituted acyloxymethyl ketone of a carbobenzoxy aspartyl t-butyl ester was hydrogenated with an equivalent of hydrochloric or other acid in the presence of a catalyst such as palladium on carbon to yield the amine salt. The salt can be acylated with an appropriately substituted isocyanate, sulfonyl chloride, chloroformate or phenylpropionyl chloride to afford the N-substituted derivatives. These isocyantes, sulfonyl chlorides, or chloro formates can be purchased commercially or synthesized by methods described in the chemical literature. The t-butyl ester protecting group can be removed in the final step using acidic media, preferably trifluoroacetic acid, to produce the acyloxy methylketone derivatives shown in Scheme 2.
Scheme 3
Step A
In a manner similar to Example 2, the amine salt of the acyloxymethyl ketone of Z-Asp(Ot-Bu)OH was synthesized and treated with an appropriately substituted carboxylic acid and coupling reagent. The coupling agent may be, but is not limited to, such reagents as 1,3-dicyclohexylcarbodiimide (DCC), 1 -(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI), l, -carbonyldiimidazole (CDI), l, -carbonylbis(3-methylimidazolium) triflate (CBMIT), isobutylchloroformate, benzotriazol- 1 -yloxytris(dimethylamino)- phosphonium hexafluorophosphate (BOP), 2-(3,4-dihydro-4-oxo- 1,2,3- benzotriazin-3-yl)-l,l,3,3-tetramethyluronium tetrafluoroborate (TDBTU), and 2-( 1 H-benzotriazol- 1 -yl)- 1 , 1 ,3 ,3-tetramethyluronium hexafluorophosphate (HBTU). 1-Hydroxybenzotriazole hydrate should be added to the reaction to improve yield and limit isomerization and base, preferably an amine such as trimethyl amine or methyl morpholine should be added as an acid scavenger. The resulting amide product was treated with acidic media, preferably trifluoroacetic acid, to remove the t-butyl ester and produce the final products as described in Scheme 3. Scheme 4
Step A
In a manner similar to Example 2, the amine salt of the acyloxymethyl ketone of Cbz-Asp(OtBu)OH was synthesized and treated with an appropriately substituted acid chloride or acid fluoride to generate an amide product. The acid chlorides were purchased commercially or were prepared by treating carboxylic acids with agents such as thionyl chloride, phosphorous tribromide, or oxalyl chloide/DMF. The acid fluorides were prepared by treating a carboxylic acid with cyanuric fluoride. The penultimate amide product was treated with acidic media preferably trifluoroacetic acid to remove the t-butyl ester and afford the final products as described in Scheme 4.
Scheme 5
Step A
HC1
Step B Step C Formation of the RCO2H, KF, 1 bromo methyl ketone DMF
The hydrochloride salt of H-Asp(OtBu)OMe was treated with an appropriately substituted carboxylic acid and coupling reagent. The coupling agent may be but is not limited to such reagents described in Example 3. 1-Hydroxybenzotriazole hydrate should be added to the reaction to improve yield and limit isomerization and base, preferably an amine such as trimethyl amine or methyl morpholine should be added as an acid scavenger. The resulting amide product was treated with an alkaline reagent such as sodium hydroxide to hydrolyze the methyl ester to the carboxylic acid. The resulting acid was treated with a chloroformate such as isobutylchloroformate, followed by diazomethane and then hydrobromic acid to afford the methyl bromo ketone. Treatment of the methylbromo ketone with an appropriately substituted carboxylic acid and a base such as potassium fluoride (as described in Example 1) produced the desired acyloxymethyl ketones which were deprotected as described previously with trifluoroacetic acid to afford the final compounds as described in Scheme 5. Scheme 6
Steps A-D Step E
Formation of the bromo
HC1 methyl ketone
The hydrochloride salt of H-Asp(OtBu)OMe was treated with an appropriately protected amino acid and coupling reagent. The coupling agent may be, but is not limited to, such reagents as described in Example 3.
1-Hydroxybenzotriazole hydrate should be added to the reaction to improve yield and limit isomerization and base, preferably an amine such as trimethyl amine or methyl morpholine should be added as an acid scavenger. The resulting amide product was treated with an alkaline reagent such as sodium hydroxide to hydrolyze the methyl ester to the carboxylic acid. The Cbz-amine protecting group was removed using standard catalytic hydrogenation conditions and coupling of another protected amino acid can proceed as described above. This process was repeated until the peptide was the desired length. The resulting peptide product was treated with an alkaline reagent such as sodium hydroxide to hydrolyze the methyl ester to the carboxylic acid. The resulting acid was subsequently treated with a chloroformate such as isobutylchloroformate, followed by diazomethane and then hydrobromic acid to afford the methylbromo ketone. Treatment of the methylbromo ketone with an appropriately substituted carboxylic acid and a base such as potassium fluoride (as described in Example 1) produced the desired acyloxymethyl ketones which were deprotected as described previously with trifluoroacetic acid to afford the final compounds as described in Scheme 6. Scheme 7
The appropriately substituted acyloxymethyl ketone of a protected amino acid was synthesized as described in Example 7. The Cbz-amine protecting group was removed using standard catalytic hydrogenation conditions, and the amine product was treated with an appropriately substituted carboxylic acid and a coupling reagent. The coupling agent may be, but is not limited to, such reagents described in Example 3. 1-Hydroxybenzotriazole hydrate should be added to the reaction to improve yield and limit isomerization and base, preferably an amine such as trimethyl amine or methyl morpholine should be added as an acid scavenger. The penultimate amide product was treated with acidic media preferably trifluoroacetic acid to remove the t-butyl ester and afford the final products as described in Scheme 7. Scheme 8
pyridine, DMAP
Trans- 1 ,2-cyclohexanedicarboxylic anhydride was treated with the amine salt of an appropriately substituted acyloxymethyl ketone of aspartyl t-butyl ester in the presence of pyridine and 4-dimethylaminopyridine (DMAP) to yield the amide product. The carboxylic acid can be functionalized with appropriately substituted amines or alcohols and standard coupling reagents as described in Example 3 to afford amide and ester products. The penultimate product was treated with acidic media, preferably trifluoroacetic acid, to remove the t-butyl ester and afford the final products as described in Scheme 8. Scheme 9
Methyl methacrylate was treated with the anion of an appropriately substituted sulfide to afford the Michael adduct which was hydrolyzed in basic media such as sodium hydroxide to produce the carboxylic acid. This acid was combined with the amine salt of the acyloxymethyl ketone of aspartyl t-butyl ester and a coupling reagent such as those described in Example 3 to obtain the amide product. If the sulfide (where n= 0) is the desired product, no oxidation step is employed, and the amide t-butyl ester is deprotected in acidic media, preferably trifluoroacetic acid, to afford the final product. Alternately, if the sulfoxide (n = 1) or sulfone (n = 2) is the final product, the amide intermediate is treated with an oxidizing agent which may be, but is not limited to, m-chloroperbenzoic acid, potassium monoperoxysulfate, or sodium perborate to obtain the desired oxidized product. The t-butyl ester of the penultimate intermediate was deprotected in acidic media, preferably trifluoroacetic acid, to afford the final compounds as described in Scheme 9. Scheme 10
i.NaN(SiMe3)2,-78°C ii. BrCH2C02 tBu
Coupling reagent
o
A 4-substituted-2-oxazolidinone chiral auxiliary as described by Evans, et al., J. Org. Chem., 1985;50:1830 was mixed with a base, such as but not limited to, n-butyl lithium followed by treatment with an appropriately substituted acid chloride or other activated carboxylic acid to afford the N-acylated product. This product was subsequently treated with a base such as, but not limited to, sodium bis(trimethylsilyl)amide and t-butyl bromoacetate to produce the alkylated chiral product. The chiral auxiliary was removed using lithium hydroxide and hydrogen peroxide to obtain the chiral acid. Treatment of the acid with the amine salt of H-Asp(OBz)O-allyl and a coupling reagent as described in Example 3 afforded the succinyl amide product.
At this stage of the process, the product can be elaborated in one of two ways. First the t-butyl ester was removed in acidic media, preferably trifluoroacetic acid, and the resulting acid was coupled with an appropriately substituted amine in the presence of a coupling reagent as described in Example 3 to form a new amide product. The allyl ester was removed with phenylsilane and tetrakis(triphenyl-phosphine)palladium or other Pd(0) catalyst to obtain the carboxylic acid, and the acid was converted to the methylbromo ketone and subsequently to the acyloxymethyl ketone as described in Example 5. The penultimate intermediate was subjected to catalytic hydrogenation to remove the benzyl ester and afford the final amide products as described in Scheme 10.
Alternatively, in a second route to the final products, the allyl ester is removed using phenylsilane and tetrakistetrakis(triphenylphosphine)palladium or other Pd(0) catalyst to obtain the carboxylic acid. This acid is converted to the methylbromo ketone and subsequently to the acyloxymethyl ketone as described in Example 5. Removal of the t-butyl ester of the acyloxymethyl ketone with trifluoroacidic acid and subsequent conversion of the resulting carboxylic acid to the ester resulted in a new ester product. The esterification can be accomplished using a variety of literature techniques which includes but is not limited to treatment of the carboxylic acid with an appropriately substituted alcohol in the presence of a coupling reagent. The penultimate intermediate was subjected to catalytic hydrogenation to remove the benzyl ester and afford the final ester products as described in Scheme 10. Scheme 11
EtOH:CCl4 (l:9)
The appropriately substituted S-acetyl mercapto carboxylic acid was treated with benzyl bromide and l,8-diazobicyclo[5.4.0]undec-7-ene (DBU) to produce the benzyl ester which was subsequently reacted with chlorine gas to yield the sulfonyl chloride. The sulfonyl chloride was treated with N,N-bis(p- methoxybenzyl)amine to afford the sulfonamide which was subjected to catalytic hydrogenation to obtain the intermediate carboxylic acid. The acid was activated using cyuranic fluoride which was then mixed with the amine salt of H-Asp(Ot-
Bu)OMe to produce the amide product. The methyl ester was hydrolyzed with sodium hydroxide, and the carboxylic acid was elaborated to the acyloxymethyl ketone by chemistry previously described for Example 5. The p-methyoxybenzyl protecting groups of the sulfonamide were removed using oxidizing conditions preferably, but not limited to eerie ammonium nitrate, and the t-butyl ester protecting group was removed in acidic media preferably with trifluoroacetic acid to afford the desired sulfonamide products as described in Scheme 11.
EXAMPLE 1 3-Benzyloxycarbonylamino-5-(naphthalene- 1 -yl-acetoxy)-4-oxo-pentanoic acid Step A
A mixture of Z-Asp(OtBu)-bromomethylketone (Z is carbobenzoxy, also known as cbz, Asp is aspartic acid and tBu is tert-butyl) (2.03 g, 5.07 mmol, purchased from BACHEM Bioscience Inc. or prepared according to the procedure of Dolle R.E., et al., U. Med. Chem., 1994;37:563-564]), 1-naphthylacetic acid (1.00 g, 5.37 mmol) and potassium fluoride (0.74 g, 12.74 mmol) in 10 mL of dimethylformamide (DMF) was stirred at room temperature for 12 hours. The mixture was partitioned between ethyl acetate and saturated NaHCO3 solution.
The ethyl acetate extract was washed with saturated KH2PO4 and brine solutions, dried (MgSO4), filtered, and concentrated. Medium pressure chromatography
(silica gel, 75% hexanes-25% ethyl acetate) of the crude oil afforded 3-benzyloxycarbonylamino-5-(naphthalene- 1 -yl-acetoxy)-4-oxo-pentanoic acid tert-butyl ester as a colorless oil.
Step B
A solution of 3-benzyloxycarbonylamino-5-(naphthalene-l-yl-acetoxy)- 4-oxo-pentanoic acid tert-butyl ester (0.500 g, 0.989 mmol, Example 1, Step A) and trifluoroacetic acid (10 mL, 0.13 mol) in 20 mL of dichloromethane was stirred at room temperature for 2 hours. The solution was concentrated to give the title compound as a foamy white solid. Analysis calculated for C25H23NO7O.7OH2O (462.075):
C, 64.98; H, 5.32; N, 3.03. Found: C, 64.94; H, 5.01 ; N, 3.01.
In a process analogous to Example 1, the corresponding compounds were prepared: EXAMPLE la 3-Benzyloxycarbonylamino-4-oxo-5-(3-phenyl-propionyloxy)-pentanoic acid. as white solid. Analysis calculated for C22H23NO7.O.25H2O (417.935): C, 63.23; H, 5.67, N, 3.35.
Found: C, 63.19; H, 5.55; N, 3.27.
EXAMPLE lb 3-Benzyloxycarbonylamino-5-(3-cvclohexyl-propionyloxy)-4-oxo-pentanoic acid. as white foamy solid. Analysis calculated for C22H29NO7.O.67H2O (431.489):
C, 61.24; H, 7.09; N, 3.25. Found: C, 61.25; H, 6.85; N, 3.21.
EXAMPLE lc 3-Benzyloxycarbonylamino-5-[(naphthalene-l-yl-oxy)-acetoxy]-4-oxo-pentanoic acid, as white foamy solid.
Analysis calculated for C25H 3NO8.0.40H2O (472.670):
C, 63.53; H, 5.08; N, 2.96. Found: C, 63.55; H, 4.87; N, 2.77.
EXAMPLE Id 3-Benzyloxycarbonylamino-4-oxo-5-phenoxyacetoxy-pentanoic acid, as foamy white solid. Analysis calculated for C2i H2ιNOg.0.67H2θ (427.414):
C, 59.01; H, 5.27; N, 3.28. Found: C, 58.99; H, 4.91; N. 3.15. EXAMPLE le 3-Benzyloxycarbonylamino-4-oxo-5-phenylsulfanylacetoxy-pentanoic acid, as white solid. Analysis calculated for C21H21NO7S (431.468): C, 58.46; H, 4.91; N, 3.25.
Found: C, 58.08; H, 4.83; N, 3.14.
EXAMPLE If 3-Benzyloxycarbonylamino-5-[(6-methoxy-naphthalene-l-yl)-acetoxy]-4-oxo- pentanoic acid, as off-white solid. Analysis calculated for C26H25NO8«H2O (497.506):
C, 62.77; H, 5.47; N, 2.82. Found: C, 62.73; H, 5.24; N, 2.61.
EXAMPLE lg 3-Benzyloxycarbonylamino-5-(naphthalene-2-yl-acetoxy)-4-oxo-pentanoic acid. as off-white solid.
Analysis calculated for C25H23NO7.O.8OH2O (463.877):
C, 64.73; H, 5.34; N, 3.02. Found: C, 64.64; H, 4.94; N, 2.88.
EXAMPLE lh 3-Benzyloxycarbonylamino-5-(3-naphthalene-2-yl-propionyloxy)-4-oxo-pentanoic acid, as white solid. Analysis calculated for C26H25NO7 (463.492):
C, 67.38; H, 5.44; N, 3.02. Found: C, 64.39; H, 5.10; N, 2.76.
EXAMPLE li
3-Benzyloxycarbonylamino-5-(3.3-diphenyl-propionyloxyV4-oxo-pentanoic acid, as foamy tan solid. Analysis calculated for C28H27NO7 (489.530):
C, 68.70; H, 5.56; N, 2.86. Found: C, 66.68; H, 5.72; N, 3.07.
EXAMPLE lj 3-Benzyloxycarbonylamino-5-r(lH-indol-3-yl)-acetoxy1-4-oxo-pentanoic acid. as off-white solid. Analysis calculated for C23H22N2O7O.9OH2O (454.655):
C, 60.76; H, 5.28; N, 6.16. Found: C, 60.76; H, 4.88; N, 5.65.
EXAMPLE Ik
3-Benzyloxycarbonylamino-5-(indol-l-yl-acetoxy)-4-oxo-pentanoic acid. as light purple solid.
Analysis calculated for C23H22N2O7O.75H2O (451.952):
C, 61.12; H, 5.24; N, 6.20. Found: C, 61.20; H, 5.11; N, 5.90.
EXAMPLE 11 3 -Benzyloxycarbonylamino-5-(2-naphthalene- 1 -yl-propionyloxy)-4-oxo-pentanoic acid, as white solid. Analysis calculated for C26H25NO7.O.2OH2O (467.095): C, 66.86; H, 5.48; N, 3.00.
Found: C, 66.87; H, 5.61; N, 2.71.
EXAMPLE lm 3-Benzyloxycarbonylamino-4-oxo-5- (2-oxo-pyrrolidin-l-yl)-acetoxy1-pentanoic acid, as white solid. Analysis calculated for Ci 9H22N2O8O.5OH2O (415.403):
C, 54.94; H, 5.58; N, 6.74. Found: C, 55.18; H, 5.72; N, 6.36. EXAMPLE In 5-[(Acetyl-phenyl-aminoVacetoxyl-3-benzyloxycarbonyl-amino-4-oxo-pentanoic acid, as off-white solid. Analysis calculated for C23H24N2θ8«0.70NaHCθ3(515.264): C, 55.25; H, 4.83; N, 5.44.
Found: C, 55.03; H, 4.86; N, 5.41.
EXAMPLE lo 3-Benzyloxycarbonylamino-5-(2-benzyl-3-phenyl-propionyloxy -4-oxo-pentanoic acid, potassium salt as hygroscopic white solid. Analysis calculated for C29H28NO7.K.O.9OH2O (557.865):
C, 62.44; H, 5.38; N, 2.51. Found: C, 62.40; H, 5.19; N, 2.17.
EXAMPLE lp 3-Benzyloxycarbonylamino-5-('hvdroxy-naphthalene-l-yl-acetoxy)-4-oxo- pentanoic acid, as white solid.
Analysis calculated for C25H23NO8O.3OH2O (470.869):
C, 63.77; H, 5.05; N, 2.98. Found: C, 63.73; H, 4.87; N, 2.93.
EXAMPLE lq 3-Benzyloxycarbonylamino-4-oxo-5-[(phenyl-amino)-acetoxy1-pentanoic acid, trifluoroacetic acid salt, as brown solid. Analysis calculated for C21H22N2O7.O.5OCF3CO2H (471.431):
C, 56.05; H, 4.81; N, 5.94. Found: C, 55.72; H, 4.98; N, 5.78.
EXAMPLE lr
3-Benzyloxycarbonylamino-5-[(6-hvdroxy-naphthalene-l-yl)-acetoxy]-4-oxo- pentanoic acid, as white solid. Analysis calculated for C25H23NO8O.4OH2O (472.670):
C, 63.53; H, 5.08; N, 2.96. Found: C, 63.53; H, 5.25; N, 2.83.
EXAMPLE Is 3-Benzyloxycarbonylamino-5-[3-(4-hvdroxy-phenyl)-2-naphthalene-l-yl- propionyloxy)-4-oxo-pentanoic acid, as white solid. Analysis calculated for C32H29NO8O.5OH2O (564.598):
C, 68.08; H, 5.36; N, 2.48. Found: C, 67.98; H, 5.40; N, 2.34.
EXAMPLE It
(S -3-Benzyloxycarbonylamino-4-oxo-5-phenylacetoxy-pentanoic acid
IH NMR (400 MHz, d6DMSO) 7.31 (m, 10H), 5.05 (s, 2H), 4.92 (m, 2H),
4.45 (m, IH), 3.75 (s, 2H), 2.71 (dd, IH), 2.52 (dd, IH)
EXAMPLE lu (S)-3-Benzyloxycarbonylamino-4-oxo-5-(4-phenyl-butyryloxy)-pentanoic acid
!H NMR (400 MHz, d6DMSO) 7.86 (bs, IH), 7.27 (m, 10H), 5.05 (s, 2H),
4.91 (m, 2H), 4.46 (m, IH), 2.72 (dd, IH), 2.61 (t, 2H), 2.52 (dd, IH), 2.36 (t, 2H), 1.83 (m, 2H)
EXAMPLE lv 3-Benzyloxycarbonylamino-4-oxo-5-r(4-phenyl-naphthalen-l-yl)-acetoxy]- pentanoic acid, as a white solid, mp 111-119°C, dec. Analysis calculated for C31H27NO7 (525.563):
C, 70.85; H, 5.18; N, 2.67. Found: C, 70.60; H, 5.11; N, 2.64. EXAMPLE lw 3-Benzyloxycarbonylamino-5-r(4-methyl-naphthalen-l-yl)-acetoxy]-4-oxo- pentanoic acid, as a white solid, mp 94-100°C, dec. Analysis calculated for C26H25NO7O.I5 H O (466.194): C, 66.99; H, 5.47; N, 3.00.
Found: C, 66.95; H, 5.32; N, 2.94.
EXAMPLE lx 3-Benzyloxycarbonylamino-4-oxo-5-r(4-thiophen-2-yl-naphthalen-l-yl)-acetoxy]- pentanoic acid, as an off-white solid, mp 63-68°C, dec. Analysis calculated for C29H25NO7S (531.589):
C, 65.52; H, 4.74; N, 2.63. Found: C, 65.32; H, 5.08; N, 2.47.
EXAMPLE ly 3-Benzyloxycarbonylamino-5-[(4-fluoro-naphthalen-l-yl)-acetoxyl-4-oxo- pentanoic acid, as a white solid, mp 100-103°C, dec.
Analysis calculated for C25H22FNO7 (467.455):
C, 64.24; H, 4.74; N, 3.00. Found: C, 63.98; H, 4.52; N, 2.89.
EXAMPLE lz 3 -Benzyloxycarbonylamino-5 - [(2-methyl-naphthalen- 1 -ylVacetoxy] -4-oxo- pentanoic acid, as a white solid, mp 139-144°C. Analysis calculated for C26H25NO7 (463.492):
C, 67.38; H, 5.44; N, 3.02. Found: C, 67.09; H, 5.44; N, 2.84.
EXAMPLE laa
3-Benzyloxycarbonylamino-5-[(2-fluoro-naphthalen-l-yl)-acetoxy -4-oxo- pentanoic acid, as a white solid, mp 98-102°C. Analysis calculated for C25H22FNO7 (467.455):
C, 64.24; H, 4.74; N, 3.00. Found: C, 63.57; H, 4.47; N, 2.85.
EXAMPLE lbb 5 -(Benzofuran-4-yl-acetoxy)-3 -benzyloxycarbonylamino-4-oxo-pentanoic acid, as light yellow oil. Analysis calculated for C23H21NO8O.65 H O (451.136):
C, 61.24; H, 4.98; N, 3.10. Found: C, 61.22; H, 4.80; N, 2.98.
EXAMPLE lcc
5-(Benzo[b1thiophen-7-yl-acetoxy)-3-benzyloxycarbonylamino-4-oxo-pentanoic acid, as light yellow oil.
Analysis calculated for C23H iNO7S'1.5 H2O (482.513):
C, 57.25; H, 5.01; N, 2.90. Found: C, 57.35; H, 4.82; N, 2.76.
EXAMPLE ldd 5-(Benzorblthiophen-4-yl-acetoxy)-3-benzyloxycarbonylamino-4-oxo-pentanoic acid, as a foamy off-white solid. Analysis calculated for C23H21NO7S (455.490): C, 60.65; H, 4.65; N, 3.08.
Found: C, 60.90; H, 4.90; N, 2.92.
EXAMPLE lee 5-[(4-Benzyl-naphthalen-l-yl)-acetoxy]-3-benzyloxycarbonylamino-4-oxo- pentanoic acid, as a white solid, mp 66-77°C, dec. Analysis calculated for C32H29NO7»0.30 H O (544.995):
C, 70.52; H, 5.48; N, 2.57. Found: C, 70.55; H, 5.35; N, 2.49. EXAMPLE Iff 3-Benzyloxycarbonylamino-5-r(3.4-dihydro-naphthalen-l-yl)-acetoxyl-4-oxo- pentanoic acid, as a foamy light yellow solid. Analysis calculated for C25H25NO7O.2O H2O (455.084): C, 65.98; H, 5.63; N, 3.08.
Found: C, 66.06; H, 5.74; N, 3.04.
EXAMPLE lgg 3 -Benzyloxycarbonylamino-5 - \(5 -bromo- 1 H-indol-3 -vD-acetoxy] -4-oxo- pentanoic acid, as a tan solid, mp 122-129°C, dec. Analysis calculated for C23H2iBrN2θ7 (517.342):
C, 53.40; H, 4.09; N, 5.41. Found: C, 53.77; H, 3.94; N, 5.25.
EXAMPLE lhh 3-Benzyloxycarbonylamino-5-(3.4-diphenyl-buτyryloxy)-4-oxo-pentanoic acid, as a hygroscopic white solid.
Analysis calculated for C29H29NO7 »0.30 H2O (508.962):
C, 68.44; H, 5.86; N, 2.75. Found: C, 68.41; H, 5.92; N, 2.56.
EXAMPLE lii 3-Benzyloxycarbonylamino-4-oxo-5-(3-phenyl-3-phenylamino-propionyloxy)- pentanoic acid as a hygroscopic light green solid. Analysis calculated for C28H28N2O7O.5O H2O (513.552):
C, 65.49; H, 5.69; N, 5.46. Found: C, 65.58; H, 5.62; N, 5.19.
EXAMPLE ljj
3-Benzyloxycarbonylamino-4-oxo-5-[(1.2.3.4-tetrahydro-naphthalen-2-yl)- acetoxy] -pentanoic acid, as a white solid, mp 75-83°C, dec. Analysis calculated for C25H27NO7 (453.496):
C, 66.21; H, 6.00; N, 3.09. Found: C, 66.02; H, 5.89; N, 2.96.
EXAMPLE lkk 3-Benzyloxycarbonylamino-5-[(l-methanesulfonyl-piperidin-4-yl)-acetoxy]-4- oxo-pentanoic acid as a yellow amorphous solid. Analysis calculated for C21 H28N2O9SO.25 EtOAc (506.556):
C, 52.16; H, 5.97; N, 5.53. Found: C, 51.96; H, 6.09; N, 5.22.
EXAMPLE 111
3-Benzyloxycarbonylamino-4-oxo-5-r(2.3,5,6-tetramethyl-phenyl)-acetoxy]- pentanoic acid, mp 139-145°C. Analysis calculated for C25H29NO7:
C, 65.92; H, 6.42; N, 3.07. Found: C, 65.66; H, 6.30; N, 2.97.
EXAMPLE 1mm 5-(Benzothiazol-4-yl-acetoxy)-3-benzyloxycarbonylamino-4-oxo-pentanoic acid, as a white solid. Analysis calculated for C22H20 2O7SO.I5 CF3CO H (473.582): C, 56.56; H, 4.29; N, 5.92.
Found: C, 56.52; H, 4.09; N, 6.02.
EXAMPLE Inn 5-(Benzofuran-3-yl-acetoxy -3-benzyloxycarbonylamino-4-oxo-pentanoic acid as a foamy white solid. Analysis calculated for C23H2iNO8'0.14 CF3CO2H (455.389):
C, 61.40; H, 4.68; N, 3.08. Found: C, 61.49; H, 4.86; N, 3.13. EXAMPLE loo 5-(Benzo[b]thiophen-3-yl-acetoxy)-3-benzyloxycarbonylamino-4-oxo-pentanoic acid. m l lO-l l l°C. Analysis calculated for C23H21NO7S: C, 60.65; H, 4.65; N, 3.08; S, 7.04.
Found: C, 60.45; H, 4.67; N, 3.02; S, 7.07.
EXAMPLE lpp 3-Benzyloxycarbonylamino-4-oxo-5-(3-phenyl-3-pyridin-2-yl-propionyloxyV pentanoic acid, as an amorphous white solid. Analysis calculated for C27H26 2θ7»CF3CO2H (604.542):
C, 57.62; H, 4.50; N, 4.63. Found: C, 57.32; H, 4.65 ; N, 4.46.
EXAMPLE lqq 3-Benzyloxycarbonylamino-5-[(2.3-dichloro-phenyl)-acetoxy]-4-oxo-pentanoic acid, as a white solid.
Analysis calculated for C2lHi9Cl2NO7*0.18 CF3CO2H (488.818):
C, 52.48; H, 3.96; N, 2.86. Found: C, 52.46; H, 4.03; N, 2.80.
EXAMPLE lrr 3 -Benzyloxycarbonylamino-5 - [(5 -methyl-naphthalen- 1 -vP-acetoxyl -4-oxo- pentanoic acid, as a gray solid. Analysis calculated for C26H25NO7.O.2O CF3CO2H (486.296):
C, 65.21; H, 5.22; N, 2.88. Found: C, 65.21 ; H, 5.30; N, 2.88.
EXAMPLE lss
3-Benzyloxycarbonylamino-5-[(2-iodo-phenyl)-acetoxy]-4-oxo-pentanoic acid. as an off-white hygroscopic solid. Analysis calculated for C21H20INO7 (525.300):
C, 48.02; H, 3.84; N, 2.67. Found: C, 48.33; H, 3.88; N, 2.66.
EXAMPLE ltt 3-Benzyloxycarbonylamino-4-oxo-5-(3-pyridin-3-yl-propionyloxy)-pentanoic acid, trifluoroacetic acid salt as an off-white solid. Analysis calculated for C2lH22N2O7*CF3CO2H (528.443):
C, 52.28; H, 4.39; N, 5.30. Found: C, 52.26; H, 4.36; N, 5.19.
EXAMPLE luu
3-Benzyloxycarbonylamino-5-[(5-methoxy-naphthalen-l-yl)-acetoxy]-4-oxo- pentanoic acid, as a white solid.
Analysis calculated for C26H25NO8O.O3 CF3CO2H (482.912):
C, 64.82; H, 5.22; N, 2.90. Found: C, 64.86; H, 5.22; N, 2.92.
EXAMPLE lw 3-Benzyloxycarbonylamino-5- ('8-methyl-naphthalen-l-yl)-acetoxy]-4-oxo- pentanoic acid, as a tan solid. Analysis calculated for C26H25NO7O.2 CF3CO2H (486.297): C, 65.21; H, 5.22; N, 2.88.
Found: C, 65.16; H, 5.38; N, 2.73.
EXAMPLE lww 3-Benzyloxycarbonylamino-5-r(9H-fluoren-9-yl -acetoxy]-4-oxo-pentanoic acid MS (APCI) m/z 488.4 (M+l)
EXAMPLE lxx
3 -Benzyloxycarbonylamino-5- rC 10.11 -dihydro-5H-dibenzora.d1cyclohepten-5-yl)- acetoxy] -4-oxo-pentanoic acid MS (APCI) m/z 515.8 (M+l)
EXAMPLE lyy 5-Oxo-l-(toluene-4-sulfonyl)-pyrrolidine-2-carboxylic acid 3- benzyloxycarbonylamino-4-carboxy-2-oxo-butyl ester MS (APCI) m/z 547.3 (M+l)
EXAMPLE lzz 5-Oxo-pyrrolidine-l,2-dicarboxylic acid 1 -benzyl ester 2-(3-benzyloxycarbonyl- amino-4-carboxy-2-oxo-butyl) ester MS (APCI) m/z 527.3 (M+l)
EXAMPLE laaa
1 -Benzoyl-pyrrolidine-2-carboxylic acid 3-benzyloxycarbonylamino-4-carboxy-2- oxo-butyl ester
MS (APCI) m/z 483.0 (M+l)
EXAMPLE lbbb Pyrrolidine-1.2-dicarboxylic acid 1 -benzyl ester 2-(3-benzyloxycarbonylamino-4- carboxy-2-oxo-butyl) ester MS (APCI) m/z 469.1 (M-43)
EXAMPLE lccc 3-Benzyloxycarbonylamino-5-(2-benzyl-3-phenyl-propionyloxy)-4-oxo-pentanoic acid
MS (ESI) m/z 502.4 (M-H)
EXAMPLE lddd 3-Benzyloxycarbonylamino-5-[(5-cvano-naphthalen-l-yl)-acetoxyl-4-oxo- pentanoic acid, as a tan solid. Analysis for C26H22 2O7O.O7 CF3CO2H (482.456)
C, 65.08; H, 4.61; N, 5.81. Found: C, 65.03; H, 4.79; N, 5.64.
EXAMPLE 1 eee 3-Benzyloxycarbonylamino-4-oxo-5-(3-phenyl-3-pyridin-3-yl-propionyloxy)- pentanoic acid as an orange solid. Analysis calculated for C27H 6N2O7 »1.02 CF3CO2H (606.822):
C, 57.48; H, 4.49; N, 4.62. Found: C, 57.45; H, 4.69; N, 4.29.
EXAMPLE lfff
3-Benzyloxycarbonylamino-4-oxo-5-(3-phenyl-3-pyridin-4-yl-propionyloxy')- pentanoic acid, as a tan solid.
Analysis calculated for C27H26 2°7'1-23 CF3CO2H (630.767): C, 56.10; H, 4.35; N, 4.44. Found: C, 56.10; H, 4.50; N, 4.25.
EXAMPLE lggg
3 -Benzyloxycarbonylamino-4-oxo-5-[( 1 -oxo-3.4-dihydro- 1 H-isoquinolin-2-vP- acetoxy] -pentanoic acid
MS (ESI) m/z 469.1 (M+l). (1 -Oxo-3, 4-dihydro- lH-isoquinolin-2-yl)-acetic acid was prepared according to the procedure of W. K. Anderson, et al., J. Med. Chem..
1988;31:2097.
EXAMPLE 2
3-Benzenesulfonylamino-5-(naphthalen- 1 -yl-acetoxy)-4-oxo-pentanoic acid
Step A A mixture of 3-benzyloxycarbonylamino-5-(naphthalen- 1 -yl-acetoxy)-4- oxo-pentanoic acid tert-butyl ester (1.495 g, 2.956 mmol, Example 1, Step A),
20% Pd C (0.50 g) and concentrated hydrochloric acid (1.00 mL, 12.1 mmol) in
25 mL of ethanol was hydrogenated under balloon pressure at room temperature for 2 hours. The mixture was filtered through a pad of Celite, and the filtrate was concentrated to give 3-amino-5-(naphthalen-l-yl-acetoxy)-4-oxo-pentanoic acid, tert-butyl ester hydrochloride as a foamy off-white solid.
Step B
To a solution at 0°C under nitrogen of 3-amino-5 (naphthalen- 1-yl- acetoxy)-4-oxo-pentanoic acid, tert-butyl ester hydrochloride (0.239 g,
0.587 mmol, Example 2, Step A) in 10 mL of acetonitrile was added dropwise (via syringe) benzenesulfonyl chloride (0.075 mL, 0.588 mmol), followed by dropwise addition of 4-methylmorpholine (0.20 mL, 1.819 mmol). The solution was allowed to slowly warm to room temperature overnight. The solution was concentrated, redissolved into ethyl acetate and washed with saturated NaHCO3, saturated KH2PO4 and brine solutions. The ethyl acetate extract was dried
(MgSO4), filtered, concentrated and chromatographed (silica gel, 80% hexanes-
20% ethyl acetate) to give 3-benzenesulfonylamino-5-(naphthalen-l-yl-acetoxy)- 4-oxo-pentanoic acid, tert-butyl ester as a light yellow oil.
Step C
A solution of 3-benzenesulfonylamino-5-(naphthalen-l-yl acetoxy)-4-oxo- pentanoic acid, tert-butyl ester (0.136 g, 0.266 mmol, Example 2, Step B) and 10 mL of trifluoroacetic acid in 20 mL of dichloromethane was stirred at room temperature for 1 hour. The solution was concentrated to give the titled compound as a foamy off-white solid.
Analysis calculated for C23H21NO7S.O.75H2O (469.002):
C, 58.90; H, 4.84; N, 2.99. Found: C, 58.94; H, 4.73; N, 3.02.
In a process analogous to Example 2, using the appropriately substituted isocyantes, appropriately substituted sulfonyl chlorides, appropriately substituted chloroformates, or appropriately substituted acid chlorides with 3-amino- 5-(naphthalen-l-yl-acetoxy)-4-oxo-pentanoic acid, tert-butyl ester hydrochloride (Example 2, Step A), the corresponding compounds were prepared as follows: EXAMPLE 2a 3-Methoxycarbonylamino-5-(naphthalene- 1 -yl-acetoxy)-4-oxo-pentanoic acid, as off-white solid. Analysis calculated for C19H19HO7 (373.366): C, 61.12; H, 5.13; N, 3.75.
Found: C, 60.85; H, 5.25; N, 3.58.
EXAMPLE 2b 5 -(Naphthalene- 1 -yl-acetoxy)-4-oxo-3 -("3 -phenyl-propionylaminoVpentanoic acid, as white solid. Analysis calculated for C 6H25NO6.0.25H2O (451.996):
C, 69.09; H, 5.69; N, 3.10. Found: C, 69.06; H, 5.45; N, 2.91.
EXAMPLE 2c 3 -Methoxycarbonylamino-4-oxo-5 -phenoxyacetoxy-pentanoic acid, as foamy off- white solid.
Analysis calculated for Ci5Hi7NO8O.80NaHCO3 (406.510):
C, 46.68; H, 4.41; N, 3.45. Found: C, 46.89; H, 4.44; N, 3.43.
EXAMPLE 2d 3-(2-Methanesulfonyl-ethanesulfonylamino)-5-(naphthalen-l-yl-acetoxyV4-oxo- pentanoic acid, as a solid, mp 131-135°C. Analysis calculated for C20H23NO9S2 (485.536):
C, 49.48; H, 4.78; N, 2.88. Found: C, 49.26; H, 4.60; N, 2.88. EXAMPLE 2e 3-(2-MethanesulfonyI-l-methyl-ethylsulfanylamino)-5-(naphthalen-l-yl-acetoxy)- 4-oxo-pentanoic acid Analysis calculated for C2iH25NO9S2*1.0 H O (517.578): C, 48.73; H, 5.26; N, 2.71.
Found: C, 48.90; H, 5.60; N, 2.78.
EXAMPLE 3 S-(R*,R*)1-3-(2-Acetylamino-propionylamino)-5-(naphthalene-l-yl-acetoxy> 4-oxo-pentanoic acid Step A
To a solution at 0°C under nitrogen of N-acetyl alanine (0.176 g, 1.34 mmol), 3-amino-5-(naphthalene-l-yl-acetoxy)-4-oxo-pentanoic acid, tert- butyl ester, hydrochloride (0.500 g, 1.22 mmol, Example 2, Step A), 2-(lH- benzotriazole-l-yl)-l,l,3,3-tetramethyluronium tetrafluoroborate (0.431 g, 1.34 mmol), 1-hydroxybenzotriazole (0.214 g, 1.58 mmol) in 15 mL of dichloromethane was added dropwise (via syringe) N,N-diisopropylethylamine (0.531 mL, 3.05 mmol). The solution was allowed to slowly warm to room temperature overnight. The solution was then dissolved in ethyl acetate and washed with 2x 5% citric acid solution, 2x saturated NaHCO3, and lx brine. The ethyl acetate extract was dried (MgSO4), filtered, concentrated, and chromatographed (silica gel, 30% tetrahydrofuran-70% dichloromethane) to give [S-(R*,R*)]-3-(2-Acetylamino-propionylamino)-5-(naphthalene-l-yl-acetoxy)- 4-oxo-pentanoic acid, tert-butyl ester as a light yellow thick oil.
Step B A solution of [S-(R*,R*)]-3-(2-Acetylamino-propionylamino)-
5 -(naphthalene- 1 -yl-acetoxy)-4-oxo-pentanoic acid, tert-butyl ester (0.467 g, 0.96 mmol), and 7.5 mL of trifluoroacetic acid in 7.5 mL of dichloromethane was stirred at room temperature for 2 hours. The solution was concentrated and chromatographed (silica gel, 94% dichloromethane-5% methanol- 1% acetic acid) to give the title compound as an oily foam. The title compound was then lyophilized to a solid from acetonitrile and water.
IH NMR (400 MHz, d6DMSO), 12.43 (bs, IH), 8.44 (d, IH), 7.95 (m, 2H),
7.87 (m, IH), 7.51 (m, 4H), 4.87 (m, 2H), 4.56 (m, IH), 4.23 (s, 2H), 4.18 (m, IH), 2.72 (dd, IH), 2.54 (dd, IH), 1.81 (s, 3H), 1.17 (d, 3H)
In a process analogous to Example 3, the corresponding compounds were prepared:
EXAMPLE 3a 5 -(Naphthalen- 1 -yl-acetoxy)- 4-oxo-3 - [(thiophene-3 -carbonvD-amino] -pentanoic acid, as a foamy off-white solid.
Analysis calculated for C22Hi9NO6S*0.45 H2O (433.571):
C, 60.95; H, 4.63; N, 3.23. Found: C, 60.98; H, 4.81; N, 3.29.
EXAMPLE 3b 3 - IYFuran-3 -carbonvD-amino] -5 -(naphthalen- 1 -yl-acetoxy)-4-oxo-pentanoic acid, as a white solid. Analysis calculated for C22Hi9NO7»0.25 H2O (413.903):
C, 63.84; H, 4.75; N, 3.38. Found: C, 63.86; H, 4.50; N, 3.39.
EXAMPLE 3c
5-(Naphthalen-l-yl-acetoxy)-4-oxo-3-[2-(4-phenyl-butyrylamino)-propylamino]- pentanoic acid MS(CI) m/z 533 (M+l)
EXAMPLE 3d 3-(2-Methanesulfonylamino-propionylamino)-5-(naphthalen-l-yl-acetoxy)-4-oxo- pentanoic acid MS(APCI) m/z 465 (M+l) EXAMPLE 3e 3-r2-(2-Acetylamino-4-phenyl-butyrylamino)-propionylaminol-5-(naphthalen-l- yl-acetoxy)-4-oxo-pentanoic acid MS (APCI) m/z 590.4 (M+l)
EXAMPLE 3f
3-(2-Acetylamino-butyrylamino)-5-(naphthalen-l-yl-acetoxy)-4-oxo-pentanoic acid
MS (APCI) m/z 443.5 (M+l)
EXAMPLE 3g 3-r2-(4-Carbamoyl-butyrylamino)-propionylamino]-5-(naphthalen-l-yl-acetoxy)-
4-oxo-pentanoic acid MS (APCI) m/z 500.5 (M+l)
EXAMPLE 3h 3-(2-Benzyloxycarbonylamino-propionylamino)-5-(naphthalen-l-yl-acetoxy)-4- oxo-pentanoic acid
MS (APCI) m/z 521.4 (M+l)
EXAMPLE 3i 5-(Naphthalen-l-yl-acetoxy)-4-oxo-3-(2-ureido-propionylamino)-pentanoic acid MS (APCI) m/z 430.5 (M+l)
EXAMPLE 3j
3-(2-Acetylamino-propionylamino)-5-(naphthalen-l-yl-acetoxy)-4-oxo-pentanoic acid
MS (APCI) m/z 429.5 (M+l)
EXAMPLE 3k 3-r(l-Acetyl-pyrrolidine-2-carbonyl)-amino1-5-(naphthalen-l-yl-acetoxy -4-oxo- pentanoic acid MS (APCI) m/z 455.5 (M+l)
EXAMPLE 31 3-(2-Methyl-3-oxo-3-thiophen-2-yl-propionylamino)-5-(naphthalen-l-yl-acetoxy)- 4-oxo-pentanoic acid MS (APCI) m/z 482.4 (M+l)
EXAMPLE 3m 3-(2-Acetylamino-acetylamino)-5-(naphthalen- 1 -yl-acetoxy)-4-oxo-pentanoic acid MS (APCI) m/z 415.5 (M+l)
EXAMPLE 3n 3-(2-Acerylamino-propionylamino)-5-(3.3-diphenyl-propionyloxy)-4-oxo- pentanoic acid MS (APCI) m/z 469.2 (M+l)
EXAMPLE 3o 3-[2-(2-Acetylamino-4-carboxy-butyrylamino)-propionylamino]-5-(naphthalen-l- yl-acetoxy -4-oxo-pentanoic acid
MS (APCI) m/z 596.1 (M-l)
Example 3p 5-(Naphthalen-l-yl-acetoxy)-4-oxo-3-[2-(3-phenyl-propionylamino)- propionylamino]-pentanoic acid MS (APCI) m/z 518.8 (M+l)
EXAMPLE 3q 3-[2-(3-Methyl-butyrylamino)-propionylamino1-5-(naphthalen-l-yl-acetoxy)-4- oxo-pentanoic acid MS (APCI) m/z 470.8 (M+l) EXAMPLE 3r 3-[(l-Carbamoyl-pyrrolidine-2-carbonylVamino1-5-(naphthalen-l-yl-acetoxy -4- oxo-pentanoic acid
EXAMPLE 3s 3-(3-Benzyloxy-2-ureido-propionylamino)-5-(naphthalen-l-yl-acetoxy -4-oxo- pentanoic acid
EXAMPLE 3t 3 - [( 1 - Acetyl-4-benzyloxy-pyrrolidine-2-carbonyl)-amino] -5 -(naphthalen- 1 -yl- acetoxy -4-oxo-pentanoic acid
EXAMPLE 3u
3-(4-Carbamoyl-butyrylaminoV5-(naphthalen- 1 -yl-acetoxy)-4-oxo-pentanoic acid
EXAMPLE 3v 3 -(3 -Carbamoyl-2-methyl-propionylamino)-5-(naphthalen- 1 -yl-acetoxy -4-oxo- pentanoic acid
EXAMPLE 3 w
3-[2-(l-Methyl-lH-imidazol-4-yl)-acetylamino1-5-(naphthalen-l-yl-acetoxy)-4- oxo-pentanoic acid
EXAMPLE 4 (S -5-(Naphthalene- 1 -yl-acetoxy)-4-oxo-3-phenylacetylamino-pentanoic acid Step A
To a solution at room temperature under nitrogen of phenylacetyl chloride (0.160 mL, 1.22 mmol), 3 -amino-5 -(naphthalene- l-yl-acetoxy)-4-oxo-pentanoic acid, tert-butyl ester, hydrochloride (0.500 g, 1.22 mmol, example 2, Step A), 4-dimethylaminopyridine (catalytic) in 25 mL of acetonitrile was added dropwise (via syringe) N,N-diisopropylethylamine (0.471 mL, 2.69 mmol). The solution was stirred overnight. The solution was then dissolved in ethyl acetate and washed with 2x 5% citric acid solution, 2x saturated NaHCO3, and lx brine. The ethyl acetate extract was dried (MgSO4), filtered, concentrated, and chromatographed
(silica gel, 40% ethyl acetate-60% hexanes) to give (S)-5-(naphthalene-l-yl- acetoxy)-4-oxo-3-phenylacetylamino-pentanoic acid, tert-butyl ester as a thick oil.
Step B
(S)-5-(Naphthalene-l-yl-acetoxy)-4-oxo-3-phenylacetylamino-pentanoic acid, tert-butyl ester (0.300 g, 0.61 mmol, Example 4, Step A) and 7.5 mL of trifluoroacetic acid in 7.5 mL of dichloromethane was stirred at room temperature for 2 hours. The solution was concentrated and chromatographed (silica gel, 40% ethylacetate-59% hexanes- 1% acetic acid) to give the title compound as an oily foam. The title compound was then lyophilized to a solid from acetonitrile and water.
!H NMR (400 MHz, d6DMSO), 12.49 (bs, IH), 8.64 (bs, IH), 7.94 (m, 2H),
7.84 (m, IH), 7.49 (m, 4H), 7.27 (m, 5H), 4.85 (bs, 2H), 4.62 (m, IH), 4.21 (s, 2H), 3.47 (s, 2H), 2.69 (dd, IH), 2.59 (dd, IH)
In a process analogous to Example 4, the corresponding compounds were prepared:
EXAMPLE 4a (S)-5-(Naphthalene-l-yl-acetoxy -4-oxo-3-(2-thiophene-2-yl-acetylamino)- pentanoic acid
!H NMR (400 MHz, d6DMSO), 12.52 (bs, IH), 8.67 (bs, IH), 7.89 (m,
3H), 7.49 (m, 4H), 7.34 (m, IH), 6.93 (m, 2H), 4.88 (bs, 2H), 4.62 (m, IH), 4.22 (s, 2H), 3.71 (s, 2H), 2.69 (dd, IH), 2.60 (dd, IH)
EXAMPLE 4b and 4c 3-r(2-Carbamoyl-cvclopentanecarbonyl)-amino]-5-(naphthalen-l-yl-acetoxy)-4- oxo-pentanoic acid, diastereomer A and B Step A
To a solution of trans-2-carbamoyl-cyclopentanecarboxylic acid (130 mg, 0.83 mmol) and pyridine (65 mg, 0.83 mmol) in acetonitrile (100 mL) was added cyanuric fluoride (110 mg, 0.83 mmol) and the reaction mixture was stirred at room temperature for 3 hours. Ice water (10 mL) was added and the reaction mixture was stirred for 5 minutes. It was extracted with methylene chloride (75 mL) and the organic layer was evaporated to give the crude intermediate acid fluoride (50 mg). A solution of the acid fluoride in 1 : 1 methylene chloride: acetonitrile (20 mL) was treated with the hydrochloride salt of 3 amino-5- (naphthalene- 1 -yl-acetoxy) 4-oxo-pentanoic acid tert- butyl ester (100 mg,
0.25 mmol, Example 2, Step A) and N-methylmorpholine (0.5 mmol). The reaction mixture was stirred at room temperature for 2 hours followed by evaporation of the solvent. Purification by flash chromatography (silica gel, ethyl acetate) gave two diastereomers of 3-[(2-carbamoyl-cyclopentanecarbonyl)- amino]-5-(naphthalen-l-yl-acetoxy)-4-oxo-pentanoic acid tert-butyl ester
[diastereomer A (high Rf) MS (AP+): 510.9 and diastereomer B(low Rf)] MS (APCI) m/z 510.9 (M+l).
Step B
Diastereomer A or B was reacted with trifluoroacetic acid as described for Example 4 to yield 3-[(2-carbamoyl-cyclopentanecarbonyl)-amino]-5-(naphthalen- l-yl-acetoxy)-4-oxo-pentanoic acid 4b (diastereomer A), mp 171-185°C and 3 - [(2-carbamoyl-cyclopentanecarbonyl)-amino] -5 -(naphthalen- 1 -yl-acetoxy)-4- oxo-pentanoic acid 4c (diastereomer B), mp 208-210°C.
EXAMPLE 4d 3-[(3-Carbamoyl-bicvclor2.2.11heptane-2-carbonyl)-amino]-5-(naphthalen-l-yl- acetoxy)-4-oxo-pentanoic acid
3 - [(3 -Carbamoyl-bicyclo [2.2.1 ]heptane-2-carbonyl)-amino] -5 -(naphthalen- 1 -yl-acetoxy)-4-oxo-pentanoic acid tert-butyl ester was prepared by the method of Example 4b and 4c in 47% yield from (IR, 2S, 3S, 4S)-3-carbamoyl-2- carboxybicyclo[2.2.1]heptane (Ohtani, et al., JOC. 1991;562:122-2127). EXAMPLE 4e 3-(3-Carbamoyl-2-methyl-propionylamino)-5-(naphthalen-l-yl-acetoxy -4-oxo- pentanoic acid Step A To a solution of (S)-(-)-2-methylsuccinamic acid (0.160 g, 1.22 mmol, prepared according to the procedure in Chem. Pharm. Bull., 1991;39(10):2706- 2708) in 25 mL of dichloromethane and 25 mL of tetrahydrofuran at -78°C was added N-methylpiperidine (0.163 mL, 1.34 mmol) followed by dropwise addition of isobutyl chloroformate (0.166 mL, 1.26 mmol). The reaction mixture was stirred for 1 hour at -78°C. A solution of 3-amino-5-(naphthalene-l-yl-acetoxy)-
4-oxo-pentanoic acid tert-butyl ester, hydrochloride (0.500 g, 1.22 mmol, Example 2, Step A) in dichloromethane (25 mL) and tetrahydrofuran (25 mL) was added dropwise while simultaneously adding N-methylpiperidine (0.163 mL, 1.34 mmol) dropwise with a second addition funnel. The reaction mixture was allowed to slowly warm to room temperature and was stirred overnight. The reaction mixture was diluted with ethyl acetate was washed sequentially with 5% citric acid, saturated sodium bicarbonate, and finally with saturated sodium chloride. The organic layer was dried over magnesium sulfate, filtered and concentrated in vacuo. The resulting solid was suspended in diethyl ether, collected by filtration, washed with diethyl ether and dried under reduced pressure to yield 294 mg (49%) of the intermediate 3-(3-carbamoyl-2-methyl-propionylamino)-5-(naphthalen-l-yl- acetoxy)-4-oxo-pentanoic acid tert-butyl ester.
Step B
A solution of 3-(3-carbamoyl-2-methyl-propionylamino)-5-(naphthalen-l- yl-acetoxy)-4-oxo-pentanoic acid tert- butyl ester (0.150 g, 0.309 mmol, Example
4e, Step A) in 10 mL of 4N hydrochloric acid/dioxane was stirred at room temperature for 2 hours. The solution was concentrated and the product purified by reverse phase HPLC. Lyophilization from acetonitrile and water gave 3-(3- carbamoyl-2-methyl-propionylamino)-5-(naphthalen-l-yl-acetoxy)-4-oxo- pentanoic acid as a solid. 1HNMR(400MHz, DMSO) 12.38 (bs,lH), 8.49 (d,lH), 7.88 (m,lH), 7.54(m,4H), 7.28 (s,lH), 6.76 (s,lH), 4.89 (s,2H), 4.46 (m,lH), 4.22 (s,2H), 2.71 (m,2H), 2.74 (m,lH), 2.32 (dd, IH), 2.08 (dd, IH), 0.98 (d,3H). MS (APCI) m/z 429.1 (M+H).
EXAMPLE 4f 3-(3-Methanesulfonyl-2-methyl-propionylamino -5-(naphthalen-l-yl-acetoxyV4- oxo-pentanoic acid Part A
A solution of 2(S)-methyl -3-methylsulfonyl) propionic acid (250 mg, 1.5 mmol, prepared according to the procedure of Vazquez, M. L. , et al., [WO 94/10136]) in 10 mL of thionyl chloride was allowed to stirred at 55°C under
N2 for 2 hours. The solvent was removed under reduced pressure, washed with benzene and reconcentrated to give an off-white solid. The resultant solid was dissolved in 40 mL THF and N-methylmorpholine (300 mg, 3.0 mmol) and 4-dimethylaminopyridine (120 mg, 1.0 mmol.) added followed by 3 amino-5- (naphthalene- 1 -yl-acetoxy) 4-oxo-pentanoic acid tert butyl ester, hydrochloride
(Example 2, Step A) (407 mg, 1.0 mmol) in a single portion. The mixture allowed to stir at room temperature for 16 hours. The solution was diluted with ethyl acetate and washed with saturated NaHCO3, saturated KHPO4 and brine solution, dried (MgSO4), filtered, and concentrated. Medium pressure chromatography (silica gel, 75% hexanes-25% ethyl acetate to 60% hexanes-40% ethyl acetate) of the crude oil afforded [S-(R*,R*)]-3-(3-methanesulfonyl-2-methyl- propionylamino)-5-(naphthalen-l-yl-acetoxy)-4-oxo-pentanoic acid tert butyl ester.
Part B A solution of [S-(R* ,R*)]-3-(3-methanesulfonyl-2-methyl- propionylamino)-5-(naphthalen-l-yl-acetoxy)-4-oxo-pentanoic acid tert butyl ester (232 mg, 0.45 mmol.)and trifluoroacetic acid (5 mL, 0.065 mol) in 5 mL of dichloromethane was stirred at room temperature for 2 hours. The solution was concentrated in vacuo and suspended in water to give the title compound as a off- white solid. Analysis calculated for C22H25NO S*H2O (481.51):
C, 54.87; H, 5.65; N, 2.91. Found: C, 54.78; H, 5.42; N, 2.78.
EXAMPLE 4g 3-(3-Benzenesulfonyl-2-methyl-propionylamino)-5-(naphthalen-l-yl-acetoxy)-4- oxo-pentanoic acid Part A
To a solution of 2-methyl-3-(thiobenzene) propionic acid methyl ester (4 g, 19 mmol., prepared according to the procedure J. Org. Chem.. 1981;46:235-9) in 100 mL of acetic acid was added sodium perborate (7.33 g, 47.6 mmol) and the mixture heated to 55°C for 17 hours. The reaction was poured into water, extracted with methylene chloride, washed with aqueous sodium bicarbonate, dried (MgSO4) and concentrated to give of 2-methyl-3 -(benzenesulfonyl) propionic acid methyl ester as a colorless oil.
Part B
To a solution of 2-methyl-3-(benzenesulfonyl) propionic acid methyl ester (4.47 g, 18.5 mmol) in 60 mL of THF was added a solution of lithium hydroxide (0.93 g, 22.2 mmol.) in water (30 mL). The solution was allowed to stir at room temperature for 16 hours and then acidified to pH 1 with IN KHSO and the solution extracted with ethyl acetate 3 times. The combined organic solution was dried (MgSO4) and concentrated to give a colorless oil which solidified upon standing to give 2-methyl-3 -(benzenesulfonyl) propionic acid. Part C
A solution of 2-methyl-3 -(benzenesulfonyl) propionic acid (300 mg, 1.3 mmol) in 10 mL of thionyl chloride was allowed to stir at 55°C under N2 for
16 hours. The solvent was removed under reduced pressure washed with benzene and reconcentrated to give yellow oil. The resultant oil was dissolved in 40 mL THF and N-methylmorpholine (300 mg, 3.0 mmol) and 4-dimethylaminopyridine (120 mg, 1.0 mmol.) added followed by 3 amino-5 -(naphthalene- 1-yl-acetoxy) 4-oxo-pentanoic acid, tert-butyl ester, hydrochloride (407 mg, 1.0 mmol, Example 2, Step A) in a single portion. The mixture allowed to stir at room temperature for 36 hours. The solution was diluted with ethyl acetate and washed with saturated NaHCO3, saturated KHPO4 and brine solution, dried (MgSO4), filtered, and concentrated. Medium pressure chromatography (silica gel, 75% hexanes-25% ethyl acetate to 60% hexanes-40% ethyl acetate) of the crude oil afforded 3-(3- benzenesulfonyl-2-methyl-propionylamino)-5 -(naphthalen- 1 -yl-acetoxy)-4-oxo- pentanoic acid tert butyl ester.
Part D
A solution of 3-(3-benzenesulfonyl-2-methyl-propionylamino)-5- (naphthalen- 1 -yl-acetoxy)-4-oxo-pentanoic acid tert butyl ester (216 mg, mmol) and trifluoroacetic acid (5 mL, 0.065 mol) in 5 mL of dichloromethane was stirred at room temperature for 2 hours. The solution was concentrated in vacuo and suspended in ethyl ether to give the title compound as a off-white solid. Analysis calculated for C27H27NO S-C2HF3O2 (611.10) C, 56.01; H, 4.58; N, 2.29.
Found: C, 56.12; H, 4.86; N, 2.40.
In a process analogous to Example 4, the corresponding compounds were prepared:
EXAMPLE 4h 3-Butyrylamino-5-(naphthalen-2-yl-acetoxy)-4-oxo-pentanoic acid
MS (CI) m/z 386 (M+l)
EXAMPLE 4i 3-Acetylamino-5-(naphthalen- 1 -yl-acetoxy)-4-oxo-pentanoic acid as a foamy off-white solid. Analysis calculated for C19H19NO6Η2O (375.382):
C, 60.80; H, 5.64; N, 3.73. Found: C, 61.07; H, 5.70; N, 3.57. EXAMPLE 4j 3-(3-Methanesulfonyl-2-methyl-propionylamino)-5-(naphthalen-l-yl-acetoxy)-4- oxo-pentanoic acid Analysis calculated for C22H25NO8S«1.0 H2O (481.526): C, 54.88; H, 5.65; N, 2.91.
Found: C, 54.78; H, 5.42; N, 2.78.
EXAMPLE 4k 3-(3-Methyl-butyrylamino)-5-(naphthalen-l-yl-acetoxy)-4-oxo-pentanoic acid MS (APCI) m/z 399.8 (M+l)
EXAMPLE 41
3-(3-Carbamoyl-propionylamino)-5-(naphthalen-l-yl-acetoxy)-4-oxo-pentanoic acid
!H NMR (400 Mhz, DMSO) 12.38 (bs,lH), 8.44 (d,lH), 7.93 (m,3H), 7.50(m,4H), 7.28 (s,lH), 6.75 (s,lH), 4.92 (dd,2H), 4.56 (m,lH), 4.23 (s,2H), 2.68 (dd,lH), 2.52 (dd,lH), 2.49 (m, 4H).
MS (APCI) m/z 415.5 (M+H)
EXAMPLE 4m [S-(R*.R*)l-3-(3-Acetylsulfanyl-2-methyl-propionylamino)-5-(naphthalen-l-yl- acetoxy)-4-oxo-pentanoic acid Analysis calculated for C23H25NO7SO.1 CF CO2H (470.925):
C, 59.17; H, 5.37; N, 2.97. Found: C, 59.39; H, 5.59; N, 3.01.
EXAMPLE 4n trα -3-[(3-Carbamoyl-cvclopentanecarbonyl)-amino1-5-(naphthalen-l-yl- acetoxy)-4-oxo-pentanoic acid Analysis calculated for C24H26N2θ7*1.5 H2O:
C, 59.86; H, 6.07; N, 5.82. Found: C, 59.74; H, 5.80; N, 5.48.
EXAMPLE 5 3-(1.2,3,4-tetrahvdro-l-oxo-isoquinoline-2-ylVacetamino-5-(naphthalene-
1-yl acetoxy)-4-oxo-pentanoic acid Step A
To a solution of (1,2,3, 4-tetrahydro-l-oxo-isoquinoline-2-yl)acetic acid (2.7 g, 13.0 mMol) prepared according to the procedure of Anderson W.K., et al., J. Med. Chem. 1988;31:2097 and H-Asp (OtBu)OMe-HCl (2.9 g, 12.0 mMol) in dimethylformamide (40 mL) was added at 0°C l-ethyl-3-(3'-dimethylamino- propyl) carbodiimide x HC1 (2.5 g, 13.0 mMol) and triethylamine (4.05 g, 40 mMol). The mixture was stirred at room temperature for 16 hours. Most of the solvent was removed under reduced pressure, the residue was dissolved in ethyl acetate. The organic phase was washed successively with aqueous sodium hydrogen carbonate and water, dried over sodium sulfate, and concentrated to give 4.5 g of an amorphous residue.
The residue was dissolved in 40 mL of dioxane/water (1 :1) and hydrolyzed in the presence of thymolphthalein by dropwise addition of IN NaOH (12.0 mL). After evaporation of most of the dioxane and dilution with water the aqueous solution was extracted with ether, acidified with dilute HC1 to pH 2-3, and the product extracted into ethyl acetate. The organic phase was washed with water, dried over sodium sulfate, and concentrated under reduced pressure to give 3.4 g of crystalline N-(l,2,3,4-tetrahydro-l-oxo-isoquinoline-2-yl)-acetyl aspartic acid, 4-tert-butyl ester.
Step B
To a solution of N-(l,2,3,4-tetrahydro-l-oxo-isoquinoline-2-yl)-acetyl aspartic acid, 4-tert-butyl ester (2.8 g, 7.4 mMol) in tetrahydrofuran (40 mL) at -15°C was added N-methylmorpholine (0.75 mL, 8 mMol) followed by dropwise addition of ethyl chloroformate (0.79 mL, 8 mMol). After 15 minutes at -10°C 50 mL of a 0.2N solution of diazomethane in ether was added dropwise. The reaction was kept for 2 hours at room temperature then 15 mL of a solution of 48% HBr in glacial acetic acid (1:1) was added dropwise at 0°C. After stirring for 15 minutes the reaction mixture was poured into ethyl acetate. The organic phase was washed successively with saturated aqueous sodium hydrogen carbonate and water, dried over sodium sulfate, and concentrated under reduced pressure to give 3 -( 1 ,2,3 ,4-tetrahydro- 1 -oxo-isoquinoline-2-yl)-acetamino-5-bromo-4-oxo- pentanoic acid, tert-butyl ester (3.1 g).
Step C
To a mixture of 3-(l,2,3,4-tetrahydro-l-oxo-isoquinoline-2-yl)- acetamino-5-bromo-4-oxo-pentanoic acid, tert-butyl ester (0.7 g, 1.5 mMol) and potassium fluoride (0.26 g, 4.5 mMol) in dimethylformamide (30 mL) was added 1-naphthylacetic acid (0.28 g, 1.5 mMol). The mixture was stirred at room temperature for 16 hours. Most of the solvent was evaporated under reduced pressure, the residue was partitioned between ethyl acetate and water. The organic phase was washed successively with aqueous sodium hydrogen carbonate and water, dried over sodium sulfate. Evaporation under reduced pressure followed by chromatography over silica (elution with dichloromethane/acetone 20:1) gave 0.31 g of 3-(l,2,3,4-tetrahydro-l-oxo-isoquinoline-2-yl)-acetamino-
5-(naphthalene-l-yl acetoxy)-4-oxo-pentanoic acid, tert-butyl ester.
Step D
3-(l,2,3,4-tetrahydro-l-oxo-isoquinoline-2-yl)-acetamino-5-(naphthalene- 1-yl acetoxy)-4-oxo-pentanoic acid, tert-butyl ester (0.28 g, 0.5 mMol) in 20 mL of a 1 : 1 mixture of dichloromethane/trifiuoroacetic acid was stirred at room temperature for 45 minutes. Evaporation under reduced pressure followed by crystallization from dichloromethane/ether/hexane gave 3-(l,2,3,4-tetrahydro- 1 -oxo-isoquinoline-2-yl)-acetamino-5-(naphthalene- 1 -yl acetoxy)-4-oxo-pentanoic acid (0.19 g). m. p. 117°C-124°C; NMR (d6-DMSO, ppm): 12.5 (bs, IH), 8.5 (d, IH),
8.1-7.8 (M, 4H), 7.6-7.4 (m, 5H), 7.4-7.2 (m, 2H), 5.0 (m, 2H), 4.65 (dd, IH), 4.25 (s, 2H), 4.18 (dd, 2H), 3.6 (m, 2H), 3.0 (m, 2H), 2.75-2.5 (2m, 2H).
EXAMPLE 5a 3-(2-Methyl-3-phenethylcarbamoyl-propionylamino)-5-(naphthalen-l-yl-acetoxy)-
4-oxo-pentanoic acid Step A
A solution of itaconic anhydride (5.00g, 44.6 mmol) and phenethylamine (5.95 g, 49.1 mmol) in 100 mL of acetonitrile was stirred at room temperature under nitrogen for 72 hours. The mixture (solid had formed) was concentrated, then partitioned between EtOAc and IN HC1. The organic extract was washed with brine, dried (MgSO4), concentrated and the residue was crystallized from diethyl ether to give 5.24 g (50%) of 2-(phenethylcarbamoyl-methyl)-acrylic acid as a white solid: mp 133-140°C. Analysis calculated for C13H15NO3 (233.269):
C, 66.94; H, 6.48; N, 6.00. Found: C, 66.74; H, 6.56; N, 6.00.
Step B
A solution of 2-(phenethylcarbamoyl-methyl)-acrylic acid ( 2.76 g, 11.8 mmol, Step A) in 100 mL of THF was treated with 5% Pd/C (0.2 g) and hydrogenated at room temperature and 52 psi of hydrogen for 2.5 hours. The mixture was filtered and concentrated to give 2.39 g (86%) of 2-(phenethylcarbamoyl-methyl)-propionic acid as an off-white solid. Analysis calculated for Ci 3H17NO3 (235.285): C, 66.36; H, 7.28; N, 5.95.
Found: C, 65.31 ; H, 7.05; N, 5.80. Step C
A mixture of 2-(phenethylcarbamoyl-methyl)-propionic acid (1.63 g, 6.93 mmol, Step B), H-Asp(OtBu)-OMe»HCl (1.83 g, 7.64 mmol, purchased from Bachem Bioscience Inc.), 1-hydroxybenzotriazole hydrate (1.17 g, 7.64 mmol), N-ethyl-N'-(3-dimethylaminopropyl)-carbodiimide hydrochloride (1.46 g,
7.62 mmol) and 4-methylmorpholine (0.95 mL, 8.64 mmol) in 100 mL of dichloromethane was stirred at room temperature for 24 hours. The mixture was concentrated, then partitioned between EtOAc and saturated NaHCO3 solution.
The organic extract was washed with saturated KH2PO4 and brine solutions, dried (MgSO4), filtered, concentrated, and chromatographed (silica gel, 25% hexanes-
75% EtOAc) to give 2.54 g (87%) of 2-(2-methyl-3-phenethylcarbamoyl- propionylamino)-succinic acid, 4-tert-butyl ester 1 -methyl ester as a waxy white solid.
Analysis calculated for C22H32N2O6 (420.510): C, 62.84; H, 7.67; N, 6.66.
Found: C, 62.68; H, 7.69; N, 6.54.
Step D
A solution of 2-(2-methyl-3-phenethylcarbamoyl-propionylamino)- succinic acid, 4-tert-butyl ester 1 -methyl ester (2.11 g, 5.01 mmol, Step C) and 0.1N sodium hydroxide solution (60.1 mL, 6.01 mmol) in 60 mL of ethanol was stirred at room temperature for 12 hours. The solution was concentrated, acidified with saturated KH2PO4 solution to a pH ~5 and extracted with chloroform
(2 x 100 mL). The combined chloroform extract was dried (MgSO4), filtered and concentrated to give 2.23 g (-100%) of 2-(2-methyl-3-phenethylcarbamoyl- propionylamino)-succinic acid, 4-tert-butyl ester as a colorless oil, which was used without further purification.
A solution of 2-(2-methyl-3-phenethylcarbamoyl-propionylamino)- succinic acid, 4-tert-butyl ester (2.23 g, 5.49 mmol) and 4-methylmorpholine
(0.61 mL, 5.73 mmol) in 50 mL of THF in a Clear-Seal joint 250-mL round- bottom flask was cooled to ca. -45°C (Dry Ice-acetonitrile slurry) and treated with isobutyl chloroformate (0.75 mL, 5.78 mmol). Solid immediately formed, the mixture was stirred for 15 minutes, then treated with a 0.5 M diazomethane in ether solution (55 mL, 27.5 mmol, generated from Diazald). The cooling bath was removed, the light yellow solution was stirred at room temperature for 2 hours, cooled to 0°C and treated dropwise with a solution of 48% hydrobromic acid
(10 mL, 184 mmol) in 10 mL of acetic acid. The colorless solution was stirred at room temperature for 30 minutes, then partitioned between EtOAc and water (~200 mL of each). The organic extract was washed with water, saturated NaHCO3 and brine solutions, dried (MgSO4), filtered, and concentrated to give 1.40 g (53%) of 2-(2-methyl-3-phenethylcarbamoyl-propionylamino)-5-bromo-
4-oxo-pentanoic acid, tert-butyl ester as a light yellow solid.
Step E
A mixture of 2-(2-methyl-3-phenethylcarbamoyl-propionylamino)- 5-bromo-4-oxo-pentanoic acid, tert-butyl ester (0.70 g, 1.45 mmol, Step D), 1-naphthylacetic acid (0.34 g, 1.81 mmol) and potassium fluoride (0.21 g,
3.61 mmol) in 2.5 mL of DMF was stirred at room temperature for 12 hours. The sample was partitioned between EtOAc and saturated NaHCO3 solution. The organic extract was washed with saturated KH2PO4 and brine solutions, dried (MgSO4), filtered, and concentrated. The residue was chromatographed (silica gel, 25% hexanes-75% EtOAc) to give 0.65 g (77%) of 3-(2-methyl-
3-phenethylcarbamoyl-propionylamino)-5-(naphthalen-l-yl-acetoxy)-4-oxo- pentanoic acid, tert-butyl ester.
Step F
A solution of 3-(2-methyl-3-phenethylcarbamoyl-propionylamino)- 5-(naphthalen-l -yl-acetoxy)-4-oxo-pentanoic acid, tert- butyl ester (0.62 g,
1.06 mmol, Step E) and trifluoroacetic acid (5 mL) in 20 mL of dichloromethane was stirred at room temperature for 1 hour, then concentrated to a yellow oil. The sample was partitioned between EtOAc and saturated KH2PO4 solution. The organic extract was washed with brine, dried (MgSO4), filtered, and concentrated to 0.51 g (91%) of 3-(2-methyl-3-phenethylcarbamoyl-propionylamino)- 5-(naphthalen-l-yl-acetoxy)-4-oxo-pentanoic acid as a white solid. Analysis calculated for C3øH32N2θ7'l/3 H2O (538.604):
C, 66.90; H, 6.11; N, 5.20. Found: C, 66.90; H, 6.14; N, 5.10.
In a process analogous to Example 5, the corresponding compounds were prepared:
EXAMPLE 5b 5-(Naphthalen-2-yl-acetoxy)-4-oxo-3-r2-(2-oxo-6-phenyl-piperidin-l-vπ- acetylamino]-pentanoic acid (as a mixture of diastereomers):
1H NMR (d6-DMSO): 612.5 (IH, s), 8.38 (IH, 2d), 7.90-7.75 (4H, m),
7.50-7.10 (8H, m), 4.90 (2H, dd), 4.70-4.50 (2H, m), 4.40 (IH, m), 3.90 (2H, s), 3.0 (IH, dd), 2.7 (IH, m), 2.40-2.30 (2H, m), 2.20 (IH, m) 1.8-1.5 (4H, m). The starting acid, 6-phenyl-piperidine-2-one, was prepared according to the procedure of L.D. Desaubry, C.G. Wermuth and J.J. Bourguignon, Tetrahedron Lett..
1995 ;36:4249, then alkylation with ethyl bromoacetate (NaH/toluene; 1 hour at 110°C) followed by alkaline hydrolysis.
EXAMPLE 5c 5 -(Naphthalen- 1 -yl-acetoxyV4-oxo-3- 2-(2-oxo-6-phenyl-piperidin- 1 -yl)- acetylamino]-pentanoic acid (as a mixture of diastereomers): lH NMR (d6-DMSO): 513.0-12.0 (IH, bs), 8.4 (IH, m), 8.1-7.8 (3H, m),
7.6-7.0 (9H, m), 5.05-4.8 (2H, m), 4.70-4.50 (2H, m), 4.45-4.35 (IH, m), 4.25 (2H, s), 3.0 (IH, m), 2.7 (IH, m), 2.5 (DMSO + IH, m), 2.40 (2H, m), 2.10 (IH, m) 1.8-1.5 (3H, m). The starting acid, 6-phenyl-piperidine-2-one, was prepared as described for Example 5b. EXAMPLE 5d 3-r3-Methyl-2-(3-phenyl-propionylamino)-butyrylamino]-4-oxo-5-[(l-oxo- 1 ,2,3,4-tetrahvdro-naphthalen-2-yl)-acetoxy1-pentanoic acid MS (ESI) m/z 565.2 (M+l)
EXAMPLE 5e
5 -(Naphthalen-2-yl-acetoxy)-4-oxo-3 - [2-( 1 -oxo-3.4-dihydro- 1 H-isoquinolin-2-yl)- acetylamino -pentanoic acid
!H NMR (d6-DMSO): 512.5 (IH, m) 8.6 (IH, d), 8.0-7.8 (5H, m), 7.55-7.25 (6H,
2m), 4.95 (2H, dd), 4.65 (IH, dd), 4.15 (2H, s), 3.95 (2H, s), 3.55 (2H, dd), 3.0 (2H, m), 2.75 (IH, dd), 2.6 (IH, m). The starting acid, 1 -oxo-3 ,4-dihydro- 1H- isoquinolin-2-yl)-acetic acid, was prepared as described for Example 5.
EXAMPLE 5f 5-(2-Benzyl-3 -phenyl -propionyloxy)-4-oxo-3 - [2-( 1 -oxo-3 ,4-dihydro- 1 H- isoquinolin-2-yl)-acetylamino]-pentanoic acid MS (ESI) m/z 557.2 (M+l)
The starting acid, (1 -oxo-3 ,4-dihydro- lH-isoquinolin-2-yl)-acetic acid, was prepared as described for Example 5.
EXAMPLE 5g 5-(2-Benzyl-3-phenyl-propionyloxy)-4-oxo-3-[2-(2-oxo-6-phenyl-piperidin-l-yl)- acetylamino] -pentanoic acid (as a mixture of diastreomers)
!H NMR (d6-DMSO): 612.5 (IH, bs), 8.35 (IH, 2d), 7.4-7.1 (15H, m), 4.75 (2H, dd), 4.6 (2H, m), 4.40 (IH, m), 3.1-2.5 (8H, m), 2.35 (2H, m), 2.10 (IH, m) 1.8-1.5 (3H, m). The starting acid, 6-phenyl-piperidine-2-one, was prepared as described for Example 5b.
EXAMPLE 5h
5-(Naphthalen-l-yl-acetoxy)-4-oxo-3-[2-(l-oxo-1.2,3,4-tetrahydro-naphthalen- 2-yl -acetylaminol-pentanoic acid MS (ESI) m/z 483.5 (M-H O). The starting acid, ( 1 -oxo-3 ,4-dihydro- 1H- isoquinolin-2-yl)-acetic acid, was prepared as for Example 5.
EXAMPLE 5i 5-(Naphthalen- 1 -yl-acetoxy -4-oxo-3-[2-( 1 -oxo-3 ,4-dihydro- 1 H-isoquinolin-2-yl)- propionylamino] -pentanoic acid
MS (ESI) m/z 517.4 (M+l). The starting acid, 2-(l -oxo-3 ,4-dihydro- 1H- isoquinolin-2-yl)-propionic acid, was prepared in analogy to the literature procedure of Example 5, starting from ethyl 2-bromopropionate.
EXAMPLE 5j 5-(Naphthalen-2-yl-acetoxy)-4-oxo-3-[2-(l-oxo-3.4-dihvdro-lH-isoquinolin-2-yl)- propionylamino]-pentanoic acid
MS (ESI) m/z 517.3 (M+l). The starting acid, 2-(l -oxo-3 ,4-dihydro- 1H- isoquinolin-2-yl)-propionic acid, was prepared as described for Example 5i.
EXAMPLE 5k 3-[4-(l-Benzenesulfonyl-lH-pyrrol-2-yl)-4-oxo-butyrylamino]-5-(naphthalen-
1 -yl-acetoxy -4-oxo-pentanoic acid
MS (ESI) m/z 605.4 (M+l). The starting acid, 4-(l -benzenesulfonyl- lH-pyrrol- 2-yl)-4-oxo-butyric acid, was prepared as described according to the procedure of M. Kakushima,et al., J. Org. Chem.. 1983;48: 3214.
EXAMPLE 51
5-(2-Benzyl-3-phenyl-propionyloxy)-4-oxo-3-[2-(l-oxo-1.2,3,4-tetrahvdro- naphthalen-2-yl)-acetylamino]-pentanoic acid
MS (ESI) m/z 556.4 (M+l). The starting acid, (1 -oxo-3 ,4-dihydro- lH-isoquinolin- 2-yl)-acetic acid, was prepared as described for Example 5.
EXAMPLE 5m
5-(2-Benzyl-3-phenyl-propionyloxy)-4-oxo-3-[2-(l-oxo-3.4-dihvdro-lH- isoquinolin-2-ylVpropionylamino] -pentanoic acid (as a mixture of diastreomers): ]H NMR (d6-DMSO): 512.5 (IH, m), 8.5 (IH, m), 7.9 (IH, m), 7.45-7.10 (13H, m), 5.2 (IH, m), 4.8 (2H, m), 4.65 (2H, m), 3.55 (2H, m), 3.1-2.65 (9H, m), 1.3 (3H, d). The starting acid, 2-(l -oxo-3 ,4-dihydro- lH-isoquinolin-2-yl)- propionic acid, was prepared as described as described for Example 5i.
EXAMPLE 5n
4-Oxo-3 - [2-( 1 -oxo-3 ,4-dihvdro- 1 H-isoquinolin-2-yl)-propionylamino]-5- [( 1 -oxo- 1 ,2,3,4-tetrahydro-naphthaIen-2-yl)-acetoxy1-pentanoic acid (as a mixture of diastreomers): iH NMR (d6-DMSO): 512.5 (IH, s), 8.6-8.5 (IH, 2d), 7.9 (2H, m), 7.6-7.2 (6H, m), 5.3-5.1 (IH, m), 4.9 (2H, s), 4.7 (IH, m), 3.45 (2H, m), 3.2-2.5 (9H, m),
2.2 (IH, m), 1.95 (IH, m), 1.3 (3H, d). The starting acid, 2-(l -oxo-3, 4-dihydro- lH-isoquinolin-2-yl)-propionic acid, was prepared as described for Example 5i.
EXAMPLE 5o 3-[4-(l-Benzenesulfonyl-lH-pyrrol-2-yl)-4-oxo-butyrylaminol-5-(2-benzyl- 3-phenyl-propionyloxy)-4-oxo-pentanoic acid
MS (ESI) m/z 659.4 (M+l). The starting acid, 4-(l -benzenesulfonyl- lH-pyrrol- 2-yl)-4-oxo-butyric acid, was prepared as described for Example 5k.
EXAMPLE 5p 4-Oxo-5- (l-oxo-l,2,3,4-tetrahvdro-naphthalen-2-yl)-acetoxyl-3-r2-(l-oxo- 1 ,2, 3 ,4-tetrahvdro-naphthalen-2-yl)-acetylamino1 -pentanoic acid
MS (ESI) m/z 520.2 (M+l). The starting acid, (1 -oxo-3, 4-dihydro- lH-isoquinolin- 2-yl)-acetic acid, was prepared as described for Example 5.
EXAMPLE 5q 5-(Naphthalen-l-yl-acetoxy)-4-oxo-3-[2-(2-oxo-3-phenyl-imidazolidin-l-yl)- propionylamino]-pentanoic acid
MS (ESI) m/z 518.2 (M+l). The starting acid, 2-(2-oxo-3-phenyl-imidazolidin- l-yl)-propionic acid, was prepared according to the procedure of Basha (see Example 5 s) followed by alkylation and subsequent alkaline hydrolysis. EXAMPLE 5r 5-(Naphthalen-l-yl-acetoxy)-4-oxo-3-r2-(2-oxo-3-phenyl-tetrahydro-pyrimidin- 1 -ylVpropionylamino] -pentanoic acid
MS (ESI) m/z 546.3 (M+l). The starting acid, 2-(2-oxo-3-phenyl-tetrahydro- pyrimidin-l-yl)-propionic acid was prepared from 2-oxo-3-phenyl-tetrahydro pyrimidine (see Basha, Example 5s) followed by alkylation with ethyl 2-bromo- propionate and subsequent alkaline hydrolysis.
EXAMPLE 5s 5-(Naphthalen-l-yl-acetoxy)-4-oxo-3-[2-(2-oxo-3-phenyl-tetrahvdro-pyrimidin- 1 -ylVacetylaminol -pentanoic acid
MS (ESI) m/z 532.3 (M+l). l-Phenyl-tetrahydropyrimidine-2-one was prepared according to the procedure of A. Basha, Tetrahedron Lett.. 1988;29:2525 followed by alkylation with ethyl bromoacetate (NaH/DMF; 16 hours at room temp.) and subsequent alkaline hydrolysis.
EXAMPLE 5t
3-(2-Acetylamino-3-methyl-butyrylamino)-5-(naphthalen-l-yl-acetoxy)-4-oxo- pentanoic acid
MS (ESI)m/z 455.3 (M-H).
EXAMPLE 5u 3-(2-Acetylamino-3-methyl-butyrylamino)-5-(2-benzyl-3-phenyl-propionyloxy)-
4-oxo-pentanoic acid MS (ESI) m/z 511.3 (M+l).
EXAMPLE 5v 3 -(2- Acetylamino-3 -methyl-butyrylamino)- 5 -(3 -benzyl-4-phenyl-butyryloxy)- 4-oxo-pentanoic acid
MS (ESI) m/z 525.3 (M+l). EXAMPLE 5w 3-(2-Acetylamino-3-methyl-butyrylamino)-5-(4-benzyl-5-phenyl-pentanoyloxy)- 4-oxo-pentanoic acid MS (ESI) m/z 537.3 (M-l).
EXAMPLE 5x
3-(2-Acetylamino-3-methyl-butyrylamino)-4-oxo-5-[(l-oxo-1.2.3.4-tetrahvdro- naphthalen-2-yl -acetoxy] -pentanoic acid MS (ESI) m/z 475.3 (M+l).
EXAMPLE 5y 5-(3-Benzyl-4-phenyl-butyryloxy)-3-r3-methyl-2-(3-phenyl-propionylamino)- butyrylamino] -4-oxo-pentanoic acid MS (ESI) m/z 601.3 (M+l).
EXAMPLE 5z 3-[2-(3-Acetylamino-2-oxo-2H-pyridin-l-vπ-acetylamino]-5-(3,3-diphenyl- propionyloxyV4-oxo-pentanoic acid as a course pink powder. The starting acid was prepared as described in Bioorganic & Medicinal Chemistry Letters. 1997;7:1337-1342. Analysis calculated for C29H29N3O O.585 CF3CO2H (614.274):
C, 58.99; H, 4.86; N, 6.84. Found: C, 59.38; H, 5.16; N, 6.20.
EXAMPLE 5aa 3-[2-(3-Acetylamino-2-oxo-2H-pyridin-l-yl)-acetylamino]-5-(2-benzyl-3-phenyl- propionyloxy)-4-oxo-pentanoic acid as a fine brown powder. The starting acid was prepared as described in Bioorganic & Medicinal Chemistry Letters. 1997;7:1337- 1342.
Analysis calculated for C3oH3iN3O O.468 CF3CO2H (614.960):
C, 60.42; H, 5.16; N, 6.83. Found: C, 60.82; H, 5.39; N, 6.42. EXAMPLE 6 3-[2-(2-Benzyloxycarbonylamino-4-carboxy-butyrylamino)-3-methyl- butyrylamino]-5-(naphthalen- 1 -yl-acetoxy)-4-oxo-pentanoic acid Step A A mixture of HC1«H-Asp (OtBu)-OMe (13.1 g, 54.6 mmol), Z-Val-OH
(15.1 g, 60.1 mmol), HOBT«H2O (9.2 g, 60.0 mmol), l-ethyl-3-(3'- dimethylaminopropyl)carbodiimide hydrochloride (EDCIΗC1, 11.5 g, 60.0 mmol) and 4-methylmorpholine (7.5 mL, 68.2 mmol) in 500 mL of dichloromethane was stirred at room temperature under nitrogen for 12 hours. The mixture was concentrated, then partitioned between ethyl acetate and sat. NaHCO3 solution.
The organic extract was washed with sat. KH2PO4 and brine solutions, dried
(MgSO4), filtered and concentrated to give 23.9 g (-100%) of 2-(2-benzyloxy- carbonylamino-3-methyl-butyrylamino)-succinic acid 4-tert-butyl ester 1 -methyl ester as a white solid. MS (APCI) m/z (rel intensity) 436.9 (M+, 100), 380.9 (M-56, 94).
Step B
A solution of 2-(2-benzyloxycarbonylamino-3-methyl-butyrylamino)- succinic acid 4-tert-butyl ester 1 -methyl ester (23.8 g, 54.5 mmol, Example 6, Step A) and concentrated hydrochloric acid (5.0 mL, 60.5 mmol) in 600 mL of EtOH:THF (5:1) was treated with 20% Pd/C (2.0 g) and hydrogenated at room temperature, 50 psig H2 for 1.2 hours. The sample was filtered and concentrated.
The resultant oily solid was washed with diethyl ether, filtered and vacuum dried to give 16.5 g of 2-(2-amino-3 -methyl -butyrylamino)-succinic acid 4-tert-butyl ester 1 -methyl ester, hydrochloride as a white solid, mp 166-167°C. MS(APCI) m/z (rel intensity) 302.1 (M, 20), 301.1 (M-l, 100).
Analysis calculated for Cι4H26N2θ5«HCl (338.835):
C, 49.63; H, 8.03; N, 8.27. Found: C, 49.62; H, 8.19; N, 8.21. Step C
A mixture of HCl*H-ValAsp (OtBu)-OMe (2-(2-amino-3-methyl- butyrylamino)-succinic acid 4-tert-butyl ester 1 -methyl ester, hydrochloride, 15.4 g, 45.6 mmol, Example 6, Step B), Z-Glu(OtBu)-OH (15.8 g, 46.9 mmol), HOBT'H2O (7.7 g, 50.1 mmol), EDCI-HC1 (9.6 g, 50.1 mmol) and
4-methylmorpholine (6.3 mL, 57.3 mmol) in 500 mL of dichloromethane was stirred at room temperature under nitrogen for 12 hours. The mixture was concentrated, then partitioned between ethyl acetate and sat. NaHCO3 solution.
The organic extract was washed with sat. KH2PO4 and brine solutions, dried (MgSO4), filtered and concentrated to give 26.3 g (93%) of
Z-Glu(OtBu)Val Asp(OtBu)-OMe [2- [2-(2-benzyloxycarbonylamino-4-tert- butoxycarbonyl-butyrylamino)-3-methyl-butyrylamino]-succinic acid 4-tert-butyl ester 1 -methyl ester] as a white solid. MS(APCI) m/z (rel intensity) 622.0 (M, 100), 565.9 (M-56, 68). Analysis calculated for C31H47N3O10 (621.734):
C, 59.89; H, 7.62; N, 6.76. Found: C, 59.88; H, 7.63; N, 6.70.
Step D
A solution of Z-Glu(OtBu)ValAsp(OtBu)-OMe (17.2 g, 27.6 mmol, Example 6, Step C) and 0.1N sodium hydroxide (330 mL, 33.0 mmol) in 300 mL of ethanol was stirred at room temperature under nitrogen for 1 hour. The slightly cloudy solution was concentrated (to remove most of the ethanol), acidified with saturated KH2PO4 solution to a pH -5 and extracted twice with 500 mL of chloroform:methanol (9:1). The combined organic extract was dried (MgSO4), filtered, and concentrated to give 15.0 g (89%) of Z-Glu(OtBu)ValAsp(OtBu)-OH as a foamy white solid. Analysis calculated for C30H45N3O1 Q (607.707):
C, 59.29; H, 7.46; N, 6.91. Found: C, 59.26; H, 7.57; N, 6.54. Step E
A solution of Z-Glu(OtBu)ValAsp(OtBu)-OH (14.9 g, 24.6 mmol) and
4-methylmorpholine (2.7 mL, 24.6 mmol) in 200 mL of THF at ca. -40 °C (Dry Ice- CH3CN bath) was treated with iso-butyl chloroformate (3.2 mL, 24.6 mmol). Solid immediately formed. The sample was stirred for 15 minutes, then treated with cold diazomethane (300 mL of an ether solution, freshly prepared for Diazald). The sample was stirred at room temperature for 2 hours, cooled to 0°C and quenched by dropwise addition of a 48% hydrobromic acid-acetic acid solution (35 mL of each). The ice-bath was removed, the sample was stirred at room temperature for 30 minutes, then extracted with ethyl acetate- water (500 mL of each). The organic extract was washed with water, sat. NaHCO3 and brine solutions, dried (MgSO4), filtered, and concentrated. The residue was crystallized from dichloromethane-hexanes to give 10.5 g (63%) of 3-[2-(2- benzyloxycarbonylamino-4-tert-butoxycarbonyl-butyrylamino)-3-methyl- butyrylamino]-5-bromo-4-oxo-pentanoic acid tert-butyl ester
(Z-Glu(OtBu)ValAsp(OtBu)CH2Br) as a white solid.
Analysis calculated for C3ιH46BrN3θ9 (684.636):
C, 54.39; H, 6.77; N, 6.14. Found: C, 54.24; H, 6.63; N, 6.08.
Step F
A mixture of Z-Glu(OtBu)ValAsp(OtBu)CH2Br (9.4 g, 13.8 mmol,
Example 6, Step E), 1-naphthylacetic acid (3.2 g, 17.2 mmol) and potassium fluoride (2.0 g, 34.4 mmol) in 20 mL of DMF was stirred at room temperature for 12 hours. The mixture was partitioned between ethyl acetate and saturated NaHCO3 solution. The organic extract was washed with sat. KH2PO4 and brine solutions, dried (MgSO4), filtered and concentrated to give 3-[2-(2-benzyloxy- carbonylamino-4-tert-butoxycarbonyl-butyrylamino)-3-methyl-butyrylamino]- 5-(naphthalen-l-yl-acetoxy)-4-oxo-pentanoic acid tert-butyl ester as a white solid, mp 92-105°C. Analysis calculated for C43H55N3O11 (789.931):
C, 65.38; H, 7.02; N, 5.32. Found: C, 65.13; H, 7.20; N, 5.36.
Step G A solution of 3-[2-(2-benzyloxycarbonylamino-4-tert-butoxycarbonyl- butyrylamino)-3-methyl-butyrylamino]-5-(naphthalen-l-yl-acetoxy)-4-oxo- pentanoic acid tert-butyl ester (1.0 g, 1.27 mmol, Example 6, Step F) and 10 mL of trifluoroacetic acid in 20 mL of dichloromethane was stirred at room temperature for 1 hour. The solution was concentrated to a light yellow oil. Ether (-50 mL) was added and the oil slowly solidified. The mixture was filtered and vacuum dried to give 0.81 g (95%) of 3-[2-(2-benzyloxycarbonylamino- 4-carboxy-butyrylamino)-3-methyl-butyrylamino]-5-(naphthalen-l-yl-acetoxy)- 4-oxo-pentanoic acid as a white solid. Analysis calculated for C35H39N3O11«0.70 H O (690.325): C, 60.90; H, 5.90; N, 6.09.
Found: C, 60.90; H, 5.90; N, 6.30.
In a process analogous to Example 6, the corresponding compounds were prepared:
EXAMPLE 6a 3-f2-(2-Benzyloxycarbonylamino-3-methyl-butyrylamino)-propionylamino]-
5 -(naphthalen- 1 -yl-acetoxy -4-oxo-pentanoic acid as a white solid, mp 160-163 °C. Analysis calculated for C33H37N3O9»0.50 H2O (628.685):
C, 63.05; H, 6.09; N, 6.68. Found: C, 63.13; H, 5.96; N, 6.68. EXAMPLE 6b 3-(2-Acetylamino-3-methyl-butyrylamino)-5-(naphthalen-l-yl-acetoxy)-4-oxo- pentanoic acid MS (APCI) m/z 457.5 (M+l)
EXAMPLE 6c
3-[2-(2-Benzyloxycarbonylamino-3-methyl-butyrylamino)-propionylamino]-
5-(3.3-diphenyl-propionyloxy -4-oxo-pentanoic acid as a white solid, mp 99-104°C.
Analysis calculated for C36H41N3O9 (659.743): C, 65.54; H, 6.26; N, 6.37.
Found: C, 65.25; H, 6.23; N, 6.25.
EXAMPLE 6d 3-(2-Benzyloxycarbonylamino-3-methyl-naphthalen-l-yl-acetoxy)-4-oxo- pentanoic acid MS (APCI) m/z 549.0 (M+l)
EXAMPLE 6e 3-[2-(2-Benzyloxycarbonylamino-4-carboxy-buryrylamino)-3-methyl- butyrylamino]-5-(2-benzyl-3-phenyl-propionyloxy)-4-oxo-pentanoic acid as white solid. Analysis calculated for C39H45N3O11«0.50 H2O (740.815):
C, 63.23; H, 6.26; N, 5.67. Found: C, 63.14; N, 6.16; N, 5.55. EXAMPLE 6f 3- 2-(2-Benzyloxycarbonylamino-3-methyl-butyrylamino)-propionylamino]- 5-(2-benzyl-3-phenyl-propionyloxy)-4-oxo-pentanoic acid as a white solid. Analysis calculated for C37H43N3O9»0.13 CF3CO2H (688.593): C, 64.99; H, 6.31; N, 6.10.
Found: C, 64.98; H, 6.50; N, 6.10.
EXAMPLE 6g 3-[2-(2-Benzyloxycarbonylamino-3-methyl-butyrylamino)-propionylamino]- 5 -(naphthalen- 1 -yl-acetoxy -4-oxo-pentanoic acid as a white solid. Analysis calculated for C33H37N3θ9'0.25 CF3CO2H (648.184):
C, 62.08; H, 5.79; N, 6.48. Found: C, 62.07; H, 5.85; N, 6.68.
EXAMPLE 6h 3 -(2- { 2- [2-Acetylamino-3 -(4-hvdroxy-phenyl)-propionylamino -4-carboxy- butyrylaminol-3-methyl-butyrylamino -5-(2-benzyl-3-phenyl-propionyloxy')-
4-oxo-pentanoic acid as a white solid, mp 156-168°C, dec. Analysis calculated for C42H50N4O12Η2O (820.902):
C, 61.45; H, 6.38; N, 6.82. Found: C, 61.43 ; H, 6.27; N, 6.76.
EXAMPLE 6i
5-(2-Benzyl-3 -phenyl-propionyloxy)-3 - { 2- [4-carboxy-2-(3 -phenyl- propionylamino)-butyrylamino] -3 -methyl-butyrylamino > -4-oxo-pentanoic acid as a white solid. Analysis calculated for C4oH47N3θ1o'0.13 CF3CO2H (744.658): C, 64.94; H, 6.38; N, 5.64.
Found: C, 64.93; H, 6.63; N, 5.61. EXAMPLE 6j 3-{2-[4-Carboxy-2-(3-phenyl-propionylamino -butyrylamino]-3-methyl- butyrylamino j-5-(naphthalen-l -yl-acetoxy)-4-oxo-pentanoic acid as a white solid. Analysis calculated for C36H41N3Oιo*0.44 CF3CO2H (725.913): C, 61.02; H, 5.75; N, 5.79.
Found: C, 61.04; H, 6.04; N, 6.19.
EXAMPLE 6k 3-(2-Benzyloxycarbonylamino-3-methyl-butyrylaminoV5-(3,3-diphenyl- propionyloxy)-4-oxo-pentanoic acid MS (APCI) m/z 588.9 (M+l)
EXAMPLE 61 3-(2-Acetylamino-3-hvdroxy-butyrylamino)-5-(naphthalen-l-yl-acetoxy -4-oxo- pentanoic acid MS (APCI) m/z 456.9 (M-l)
EXAMPLE 6m
3-(2-Acetylamino-3-hvdroxy-butyrylamino)-5-(3,3-diphenyl-propionyloxy)-4-oxo- pentanoic acid
MS (APCI) m/z 496.9 (M-l)
EXAMPLE 6n 3-(2-{2-[2-Acetylamino-3-(lH-indol-3-yl)-propionylaminol-4-carboxy- butyrylamino}-3-methyl-butyrylamino)-5-(2-benzyl-3-phenyl-propionyloxyV
4-oxo-pentanoic acid as an orange solid.
Analysis calculated for C44H51N5O1 l.33 H2O (849.944):
C, 62.18; H, 6.36; N, 8.24. Found: C, 62.16; H, 6.24; N, 8.18. EXAMPLE 6o 5-(3.3-Diphenyl-propionyloxy -4-oxo-3-[2-(4-phenyl-butyrylamino - propionylamino]-pentanoic acid MS (APCI) m/z 573.2 (M+l)
EXAMPLE 7
3-(2-{2-[2-Acetylamino-3-(lH-indol-3-yl)-propionylaminol-4-carboxy- butyrylamino) -3-methyl-butyrylamino)-5-(naphthalen- 1 -yl-acetoxyV4-oxo- pentanoic acid Step A A solution of 3-[2-(2-benzyloxycarbonylamino-4-tert-butoxycarbonyl- butyrylamino)-3-methyl-butyrylamino]-5-(naphthalen-l-yl-acetoxy)-4-oxo- pentanoic acid tert-butyl ester (5.3 g, 6.7 mmol, Example 6, Step F) in 300 mL of ethanohTHF (2:1) was treated with 0.6 g of 20% Pd/C and hydrogenated at room temperature, balloon pressure for 3 hours. The sample was filtered and concentrated to 5.0 g (>100%) of 3-[2-(2-amino-4-tert-butoxycarbonyl- butyrylamino)-3-methyl-butyrylamino]-5-(naphthalen-l-yl-acetoxy)-4-oxo- pentanoic acid tert-butyl ester as yellow oil.
Step B
A mixture of 3-[2-(2-amino-4-tert-butoxycarbonyl-butyrylamino)- 3-methyl-butyrylamino]-5-(naphthalen-l-yl-acetoxy)-4-oxo-pentanoic acid tert- butyl ester (1.25 g, 1.91 mmol, Example 7, Step A), AcTrp-OH (0.52 g, 2.10 mmol), HOBT«H2O (0.32 g, 2.10 mmol), EDCI'HCl (0.40 g, 2.10 mmol) and 4-methylmorpholine (0.26 mL, 2.36 mmol) in 25 mL of dichloromethane was stirred at room temperature for 12 hours. The sample was concentrated, then partitioned between ethyl acetate and sat. NaHCO3 solution. The organic extract was washed with sat. KH2PO4 and brine solutions, dried (MgSO4), filtered and concentrated. The residue was chromatographed (MPLC, silica gel, 25% hexanes- 75% ethyl acetate) to give 0.95 g (56%) of 3-(2-{2-[2-acetylamino-3-(lH-indol- 3 -yl)-propionylamino] -4-tert-butoxycarbonyl-butyrylamino } -3 -methyl- butyrylamino)-5-(naphthalen-l-yl-acetoxy)-4-oxo-pentanoic acid, tert-butyl ester as a white solid.
Step C
A solution of 3-(2-{2-[2-acetylamino-3-(lH-indol-3-yl)-propionylamino]- 4-tert-butoxycarbonyl-butyrylamino}-3-methyl-butyrylamino)-5-(naphthalen-l-yl- acetoxy)-4-oxo-pentanoic acid, tert-butyl ester (0.93 g, 1.05 mmol, Example 7, Step B) and 10 mL of trifluoroacetic acid in 20 mL of dichloromethane was stirred at room temperature for 2 hours. The sample was concentrated to a purple oil. Ether (-50 mL) was added and the oil slowly solidified. The sample was filtered and vacuum dried to give 0.78 g (96%) of 3-(2-{2-[2-acetylamino-3-(lH-indol-
3 -yl)-propionylamino] -4-carboxy-butyrylamino } -3 -methyl-butyrylamino)- 5-(naphthalen-l-yl-acetoxy)-4-oxo-pentanoic acid as a light purple solid. Analysis calculated for C40H45N5O11*0.50 H2O (780.839):
C, 61.53; H, 5.94; N, 8.97. Found: C, 61.45; H, 6.12; N, 8.81.
In a process analogous to Example 7, the corresponding compounds were prepared:
EXAMPLE 7a 3-[2-(2-Acetylamino-4-carboxy-butyrylamino)-3-methyl-butyrylamino]- 5 -(naphthalen- 1 -yl-acetoxy)-4-oxo-pentanoic acid as an off-white solid.
Analysis calculated for C29H35N3Oi o*H2O (603.632):
C, 57.70; H, 6.18; N, 6.96. Found: C, 57.59; H, 6.11; N, 7.28.
EXAMPLE 7b 3-(2-{2- 2-Acetylamino-3-(4-hydroxy-phenyl)-propionylamino -4-carboxy- butyrylamino|-3-methyl-butyrylamino)-5-(naphthalen-l-yl-acetoxy)-4-oxo- pentanoic acid as a white solid. Analysis calculated for C38H44N4O12Η2O (766.809):
C, 59.52; H, 6.00; N, 7.31. Found: C, 59.36. H, 5.79; N, 7.24.
EXAMPLE 8 3-[(2-Carboxy-cvclohexanecarbonyl)-amino]-5-(naphthalen-l-yl-acetoxy)-4-oxo- pentanoic acid Step A
A solution of the hydrochloride salt of 3 amino-5-(naphthalene-l-yl- acetoxy)-4-oxo-pentanoic acid tert-butyl ester (1.7 g, 4.6 mmol) (Example 2, Step A) and 1,2-trans-cyclohexanedicarboxylic anhydride (0.79 g, 5.1 mmol) in
30 mL of methylene chloride was treated with pyridine (5 mL) and a catalytic amount of dimethylaminopyridine (DMAP). The reaction mixture was stirred at room temperature overnight and the solvent was evaporated. The residue was partitioned between diethyl ether and 5% HC1, and the layers separated. The organic layer was washed with 5% HC1, dried (MgSO4), filtered, and concentrated. The crude product was purified by flash chromatography (silica gel , 15% acetone/1% formic acid/methylene chloride) to give 0.3 g of pure 3-[(2- carboxy-cyclohexanecarbonyl)-amino]-5-(naphthalen-l-yl-acetoxy)-4-oxo- pentanoic acid tert-butyl ester as a mixture of two diastereomers. MS (APCI) m/z 524 (M-l).
Step B
A solution of 3-[(2-carboxy-cyclohexanecarbonyl)-amino]-5-(naphthalen- 1 -yl-acetoxy)-4-oxo-pentanoic acid tert-butyl ester (0.181 g, 0.3444 mmol) in 6 mL methylene chloride was treated with 4 mL of 50% trifluoroacetic acid (in methylene chloride). The reaction mixture was stirred at room temperature for
4 hours, diluted with toluene (50 mL), and concentrated under reduced pressure to give 3-[(2-carboxy-cyclohexanecarbonyl)-amino]-5-(naphthalen-l-yl-acetoxy)- 4-oxo-pentanoic acid as a colorless solid (mixture of two diastereomers). MS (APCI m/z 470 (M+l) EXAMPLE 8a 3-[(2-Methoxycarbonyl-cvclohexanecarbonyl)-aminol-5-(naphthalen-l-yl- acetoxy -4-oxo-pentanoic acid Step A A solution of 3-[(2-carboxy-cyclohexanecarbonyl)-amino]-5-(naphthalen- l-yl-acetoxy)-4-oxo-pentanoic acid tert-butyl ester (2.3 mmol) (Example 8, Step A) in 5 mL methylene chloride was treated with excess of diazomethane in ether. The reaction mixture was stirred for 3 hours at room temperature and then quenched by the dropwise addition of glacial acetic. The solvent was evaporated under reduced pressure to give 3-[(2-methoxycarbonyl-cyclohexanecarbonyl)- amino]-5-(naphthalen-l-yl-acetoxy)-4-oxo-pentanoic acid tert-butyl ester. MS (APCI) m/z 540 (M+l)
Step B
The targeted compound was prepared from the corresponding tert-butyl ester as described for Example 8, Step B to yield 3-[(2-methoxycarbonyl- cyclohexanecarbonyl)-amino]-5-(naphthalen- 1 -yl-acetoxy)-4-oxo-pentanoic acid. MS (APCI) m/z 484 (M+l)
EXAMPLE 8b 3-[(2-Carbamoyl-cvclohexanecarbonyl)-aminό1-5-(naphthalen-l-yl-acetoxy)- 4-oxo-pentanoic acid
Step A
A solution of DCC (0.18 g, 0.88 mmol) and HOBT (0.12 g, 0.88 mmol) in 20 mL methylene chloride was added dropwise to a solution of 3-[(2-carboxy- cyclohexanecarbonyl)-amino]-5-(naphthalen- 1 -yl-acetoxy)-4-oxo-pentanoic acid tert-butyl ester (0.45 g, 0.85 mmol) (from Example 2, Step A) and triethylamine
(0.099 g, 0.98 mmol) in 25 mL methylene chloride and the reaction mixture was stirred for 30 minutes at room temperature. Hexamethyldisilazane (0.80 g, 4.9 mmol) was added, and the reaction mixture was stirred at room temperature overnight. The reaction mixture was poured into 100 mL ether and extracted three times with 5% HCl, then washed with saturated NaCI. The organic layer was dried (MgSO4), filtered and concentrated under reduced pressure. The residue was taken up in ether/hexane, filtered, and concentrated to give a sticky foam. After purification by flash chromatography, 3[(2-carbamoyl-cyclohexanecarbonyl)- amino]-5-(naphthalen-l-yl-acetoxy)-4-oxo-pentanoic acid tert-butyl ester (0.086 g) was obtained as a mixture of two diastereomers.
MS (APCI) m/z 525 (M+l)
Step B
The targeted compound was prepared from the corresponding tert-butyl ester as described for Example 8, Step B to yield 3-[(2-carbamoyl- cyclohexanecarbonyl)-amino] -5 -(naphthalen- 1 -yl-acetoxy)-4-oxo-pentanoic acid.
MS (APCI) m/z 467 (M-l).
EXAMPLE 9 3-(3-Benzylsulfanyl-2-methyl-propionylamino)-5-(naphthalen-l-yl-acetoxy)- 4-oxo-pentanoic acid Step A
To a solution of 3-benzylsulfanyl-2-methyl-propionic acid (3.3 g, 15.8 mmol) and H-Asp(OtBu)OMe«HCl (3.7 g, 15.8 mmol) in dimethylformamide (50 mL) was added at 0°C l-ethyl-3-(3'-dimethylaminopropyl)carbodiimide,HCl (3.25 g, 17.0 mmol) and triethylamine (4.4 g, 43.8 mmol). The mixture was stirred at room temperature for 16 hours. Most of the solvent was removed under reduced pressure, the residue was partitioned between ethyl acetate and 5% citric acid. The ethyl acetate extract was washed with sodium hydrogen carbonate and water, dried over sodium sulfate, and concentrated to give 6.3 g of an amorphous residue. The residue was dissolved in 100 mL of dioxane/water (1:1) and hydrolyzed in the presence of thymolphthalein by dropwise addition of IN NaOH (15.0 mL). After evaporation of most of the dioxane and dilution with water, the aqueous solution was extracted with ether, acidified with dilute HCl to pH 2-3, and the product extracted into ethyl acetate. The ethyl acetate extract was washed with water, dried over sodium sulfate, and concentrated to give 6.3 g of crude product. Chromatography over silica gel (dichloromethane/methanol 30:1) afforded 5.5 g of N-(3-benzylsulfanyl-2-methyl-propionyl)-aspartic acid 4-tert-butyl ester.
Step B
To a solution of N-(3-benzylsulfanyl-2-methyl-propionyl)-aspartic acid 4-tert-butyl ester (5.4 g, 14.2 mmol) in tetrahydrofuran (670 mL) at -15°C was added N-methylmorpholine (1.5 mL, 16.0 mmol) followed by dropwise addition of ethyl chloroformate (1.6 mL, 16.0 mmol). After 15 minutes at -10°C, 110 mL of a 0.2N solution of diazomethane in ether was added dropwise. The reaction was kept for 2 hours at room temperature, then 40 mL of a solution of 48% HBr in glacial acetic acid (1:1) was added dropwise at 0°C. After stirring for 15 minutes, the reaction mixture was poured into ethyl acetate. The organic phase was washed 3x with saturated aqueous sodium hydrogencarbonate then with water, dried over sodium sulfate, and concentrated under reduced pressure to give 3-(3- benzylsulfanyl-2-methyl-propion- 1 -yl)amino-5-bromo-4-oxo-pentanoic acid tert-butyl ester (4.2 g).
Step C
To a mixture of 3-(3-benzylsulfanyl-2-methyl-propionyl)amino-5-bromo- 4-oxo-pentanoic acid tert-butyl ester (0.92 g, 2.0 mmol) and potassium fluoride (0.35 g, 6.0 mmol) in dimethylformamide (40 mL) was added 1-naphthalenelacetic acid (0.37 g, 2.0 mmol). The mixture was stirred at room temperature for 16 hours. Most of the solvent was evaporated under reduced pressure, the residue was partitioned between ethyl acetate and water. The organic phase was washed successively with aqueous sodium hydrogen carbonate and water, dried over sodium sulfate, and evaporated under reduced pressure. Chromatography over silica (dichloromethane/acetone 40:1) gave 0.46 g 3-(3- benzylsulfanyl-2-methyl-propionyl)amino-5-(naphthalene-l-yl-acetoxy)-4-oxo- pentanoic acid tert-butyl ester. Step D
3-(3-Benzylsulfanyl-2-methyl-propionyl)amino-5-(naphthalene-l- yl)acetoxy-4-oxo-pentanoic acid tert-butyl ester (0.12 g, 0.21 mmol) in 10 mL of a 1 :1 mixture of dichloromethane/trifluoroacetic acid containing 0.1 mL of anisol was stirred at room temperature for 45 minutes. Evaporation under reduced pressure followed by chromatography over silica (dichloromethane/methanol 40:1 to 20:1) gave 3-(3-benzylsulfanyl-2-methyl-propionylamino)-5-(naphthalene-l-yl- acetoxy)-4-oxo-pentanoic acid (0.11 g). MS (ESI) m/z 508.4 (M+l)
EXAMPLE 9a
3-(2-Methyl-3-phenylmethanesulfonyl-propionylamino)-5-(naphthalen-l-yl- acetoxy)-4-oxo-pentanoic acid Step A
To 3-(3-phenylmethanesulfanyl-2-methyl-propionylamino)-5- (naphthalene- l-yl-acetoxy)-4-oxo-pentanoic acid tert-butyl ester (0.33 g,
0.58 mmol) in ethanol (10 mL) from Example 9, Step C in 10 mL of ethanol was added at 0°C under stirring potassium monoperoxysulfate (1.74 mmol as a solution of 0.54 g oxone in 2 mL of water). The resulting slurry was stirred for 4 hours at room temperature. The reaction mixture was partitioned between dichloromethane and water. The organic phase was washed with aqueous sodium hydrogen carbonate and water, dried over sodium sulfate, and evaporated under reduced pressure. Chromatography over silica (dichloromethane/acetone 40:1) gave 0.25 g of 3-(3-phenylmethanesulfanyl-2-methyl-propionyl)amino-5- (naphthalene-l-yl-acetoxy)-4-oxo-pentanoic acid tert-butyl ester.
Step B
3-(3-Phenylmethanesulfanyl-2-methyl-propionyl)amino-5-(naphthalene-l- yl-acetoxy)-4-oxo-pentanoic acid tert-butyl ester (0.2 lg, 0.35 mmol) in 20 mL of a 1 :1 mixture of dichloromethane/trifluoroacetic acid containing 0.2 mL of anisol was stirred at room temperature for 45 minutes. Evaporation under reduced pressure followed crystallization from dichloromethane/ether/hexane gave 3-(2-methyl-3-phenylmethanesulfonyl-propionylamino)-5-(naphthalene-l-yl- acetoxy)-4-oxo-pentanoic acid (0.16 g). MS (ESI) m/z 540.2 (M+l)
EXAMPLE 9b 3-[3-(2-Carboxy-ethanesulfanyl -2-methyl-propionylamino]-5-(naphthalen-l-yl- acetoxy)-4-oxo-pentanoic acid Step A
To a solution of 3-(2-tert-butyloxycarbonyl)ethanesulfanyl-2-methyl- propionic acid (5.0 g, 20.0 mmol) and H-Asp(OtBu)OMe«HCl (4.8 g, 20.0 mmol) in dimethylformamide (60 mL) was added at 0°C 1 -ethyl-3-(3'- dimethylaminopropyl)carbodiimide»HCl (3.85 g, 20.0 mmol) and triethylamine (6.0 g, 60 mmol). The mixture was stirred at room temperature for 16 hours. Most of the solvent was removed under reduced pressure, the residue was partitioned between ethyl acetate and 5% citric acid. The ethyl acetate extract was washed with sodium hydrogen carbonate and water, dried over sodium sulfate, and concentrated to give after silica gel chromatography (dichloromethane/acetone 15:1) 5.5 g of an amorphous residue. The residue was dissolved in 50 mL of dioxane/water (4:1) and hydrolyzed in the presence of thymolphthalein by dropwise addition of IN NaOH (12.5 mL). After evaporation of most of the dioxane and dilution with water, the aqueous solution was extracted with ether, acidified with dilute HCl to pH 2-3, and the product extracted into ethyl acetate. The ethyl acetate extract was washed with water, dried over sodium sulfate, and concentrated to give 5.2 g of N-(3-(2-tert-butyloxycarbonyl)ethanesulfanyl-2- methyl-propionyl))-aspartic acid 4-tert-butyl ester.
Step B
To a solution of N-(3-(2-tert-butyloxycarbonyl)ethanesulfanyl-2-methyl- propionyl)-aspartic acid 4-tert-butyl ester (4.5 g, 10.7 mmol) in tetrahydrofuran (60 mL) at -15°C was added N-methylmorpholine (1.65 mL, 15.0 mmol) followed by dropwise addition of ethyl chloroformate (1.35 mL, 13.5 mmol). After 15 minutes at -10°C, 105 mL of a ca 0.2N solution of diazomethane in ether was added dropwise. The reaction was kept for 2 hours at room temperature, then 30 mL of a solution of 48% HBr in glacial acetic acid (1 :1) was added dropwise at 0°C. After stirring for 15 minutes, the reaction mixture was poured into ethyl acetate. The organic phase was washed 3x with saturated aqueous sodium hydrogencarbonate then with water, dried over sodium sulfate, and concentrated under reduced pressure to give 3-(3-(2-tert-butyloxycarbonyl)ethanesulfanyl-2- methyl-propion-l-yl)amino-5-bromo-4-oxo-pentanoic acid tert-butyl ester (4.2 g).
Step C
To a mixture of 3-(3-(2-tert-butyloxycarbonyl)ethanesulfanyl-2-methyl- propionyl)amino-5-bromo-4-oxo-pentanoic acid tert-butyl ester (1.65 g, 3.3 mmol) and potassium fluoride (0.58 g, 10.0 mmol) in dimethylformamide (50 mL) was added 1-naphthalenelacetic acid (0.75 g, 4.0 mmol). The mixture was stirred at room temperature for 16 hours. Most of the solvent was evaporated under reduced pressure, the residue was partitioned between ethyl acetate and water. The organic phase was washed with aqueous sodium hydrogen carbonate and water, dried over sodium sulfate, and evaporated under reduced pressure. Chromatography over silica (dichloromethane/acetone 40:1) gave 0.89 g 3-(3-(2-tert-butyloxycarbonyl)- ethanesulfanyl-2-methyl-propionyl)amino-5-(naphthalene-l-yl-acetoxy)-4-oxo- pentanoic acid tert-butyl ester.
Step D
3-(3-(2-tert-Butyloxycarbonyl)ethanesulfanyl-2-methyl-propionyl)amino- 5-(naphthalene-l-yl)acetoxy-4-oxo-pentanoic acid tert-butyl ester (0.21 g, 0.33 mmol) in 10 mL of a 1 :1 mixture of dichloromethane/trifluoroacetic acid containing 0.1 mL of anisol was stirred at room temperature for 45 minutes. Evaporation under reduced pressure and treatment of the residue with dichloromethane/ether/hexane gave 0.08 g of 3-[(3-(2-carbethoxy-ethanesulfanyl)- 2-methyl-propionylamino] -5-(naphthalene- 1 -yl-acetoxy)-4-oxo-pentanoic acid (0.11 g). MS (ESI) m/z 490.3 (M+l) EXAMPLE 9c 5-(2-Benzyl-3-phenyl-propionyloxy)-3-[3-(2-carboxy-ethanesulfonvπ-2-methyl- propionylaminol -4-oxo-pentanoic acid Step A To 5 -(2-benzyl-3 -phenyl-propionyloxy)-3 - [3 -(2-carboxy-ethanesulfanyl)-
2-methyl-propionylamino]-4-oxo-pentanoic acid, tert-butyl ester (0.59 g, 0.9 mmol) prepared as described in Example 3 in 15 mL of ethanol was added at 0°C under stirring potassium monoperoxysulfate (2.8 mmol as a solution of 0.86 g Oxone in 3 mL of water). The resulting slurry was stirred for 3 hours at room temperature. The reaction mixture was partitioned between dichloromethane and water. The organic phase was washed with aqueous sodium hydrogen carbonate and water, dried over sodium sulfate, and evaporated under reduced pressure. Chromatography over silica (dichloromethane/acetone 30:1) gave 0.39 g of 5-(2- benzyl-3-phenyl-propionyloxy)-3-[3-(2-carboxy-ethanesulfonyl)-2-methyl- propionylamino] -4-oxo-pentanoic acid, tert-butyl ester.
Step B
5-(2-Benzyl-3-phenyl-propionyloxy)-3-[3-(2-carboxy-ethanesulfonyl)-2- methyl-propionylamino]-4-oxo-pentanoic acid, tert-butyl ester (0.33g, 0.48 mmol) in 20 mL of a 1 :1 mixture of dichloromethane/trifluoroacetic acid containing 0.1 mL of anisol was stirred at room temperature for 45 minutes. Evaporation under reduced pressure followed crystallization from ether/hexane gave 5-(2- benzyl-3-phenyl-propionyloxy)-3-[3-(2-carboxy-ethanesulfonyl)-2-methyl- propionylamino] -4-oxo-pentanoic acid, tert-butyl ester (0.12 g). MS (ESI) m/z 576.3 (M+l)
EXAMPLE 9d
5-(2-Benzyl-3-phenyl-propionyloxy)-3-[3-(3-carboxy-propane-l-sulfιnyl)-
2-methyl-propionylamino] -4-oxo-pentanoic acid
Step A
To 5 -(2-benzyl-3 -phenyl-propionyloxy)-3 - [3 -(3 -carboxy-propanesulfanyl)- 2-methyl-propionylamino]-4-oxo-pentanoic acid, tert-butyl ester (0.28 g, 0.42 mmol) prepared as described in Example 3 in 4 mL of dichloromethane was added at -50°C under stirring 0.13 of 70% 3-chloroperbenzoic acid (0.53 mmol). The reaction mixture kept for 1 hour at -30°C then partitioned between dichloromethane and water. The organic phase was washed with aqueous sodium hydrogen carbonate (2x) and water, dried over sodium sulfate, and evaporated under reduced pressure. Chromatography over silica (dichloromethane/acetone 10:1) gave 0.15 g of 5-(2-benzyl-3-phenyl-propionyloxy)-3-[3-(3-carboxy- propane- 1 -sulfinyl)-2-methyl-propionylamino]-4-oxo-pentanoic acid, tert-butyl ester.
Step B
5-(2-Benzyl-3-phenyl-propionyloxy)-3-[3-(3-carboxy-propane-l-sulfinyl)- 2-methyl-propionylamino]-4-oxo-pentanoic acid, tert-butyl ester (0.40 g, 0.57 mmol) in 30 mL of a 1 :1 mixture of dichloromethane/trifluoroacetic acid containing 0.1 mL of anisol was stirred at room temperature for 45 minutes. Evaporation under reduced pressure followed crystallization from ether/hexane gave the title compound (0.14 g). MS (ESI) m/z 574.3 (M+l)
In a process analogous to Example 9, using appropriately substituted sulfanyl carboxylic acids, the corresponding compounds were prepared:
EXAMPLE 9e
5-(Naphthalen- 1 -yl-acetoxy)-4-oxo-3 -(2-phenylmethanesulfanyl-propionylaminoV pentanoic acid
MS (ESI) m/z 494.3 (M+l)
EXAMPLE 9f 3-(2-Methyl-3-phenylsulfanyl-propionylamino)-5-(naphthalen-l-yl-acetoxy)-
4-oxo-pentanoic acid MS (El) m/z 493 (M+) EXAMPLE 9g 5-(2-Benzyl-3 -phenyl-propionyloxy)-3 -(2-methyl-3 -phenylsulfanyl- propionylamino)-4-oxo-pentanoic acid MS (ESI) m/z 548.3 (M+l)
EXAMPLE 9h
3-(2-Methyl-3-phenethylsulfanyl-propionylamino)-5-(naphthalen-l-yl-acetoxy)-
4-oxo-pentanoic acid
MS (ESI) m/z 522.2 (M+l)
EXAMPLE 9i 5-(2-Benzyl-3-phenyl-propionyloxy -3-(2-methyl-3-phenethylsulfanyl- propionylamino)-4-oxo-pentanoic acid MS (ESI) m/z 576.3 (M+l)
EXAMPLE 9j 5-(2-Benzyl-3-phenyl-propionyloxy)-3-(3-benzyIsulfanyl-2-methyl- propionylamino)-4-oxo-pentanoic acid
MS (ESI) m/z 562.3 (M+l)
EXAMPLE 9k 5-(2-Benzyl-3-phenyl-propionyloxy)-3-(2-benzylsulfanyl-propionylamino)-4-oxo- pentanoic acid MS (ESI) m/z 546.3 (M+l)
EXAMPLE 91 3-[2-Methyl-3-(3-phenyl-propylsulfanyl)-propionylamino]-5-(naphthalen-l-yl- acetoxy)-4-oxo-pentanoic acid MS (ESI) m/z 536.4 (M+l)
In a process analogous to Example 9a, using appropriately substituted sulfone carboxylic acids, the corresponding compounds were prepared: EXAMPLE 9m 3-(3-Benzenesulfonyl-2-methyl-propionylamino)-5-(naphthalen-l-yl-acetoxy)- 4-oxo-pentanoic acid (ESI) MS m/z 526.4 (M+l)
EXAMPLE 9n
3-(3-Benzenesulfonyl-2-methyl-propionylamino)-5-(2-benzyl-3-phenyl- propionyloxy)-4-oxo-pentanoic acid
MS (ESI) m/z 580.2 (M+l)
EXAMPLE 9o 5-(2-Benzyl-3-phenyl-propionyloxy)-3-[2-methyl-3-(2-phenyl-ethanesulfonyl)- propionylaminol-4-oxo-pentanoic acid MS (ESI) m/z 608.2 (M+l)
EXAMPLE 9p 3 - r2-Methyl-3 -(2-phenyl-ethanesulfonyl)-propionylamino] -5-(naphthalen- 1 -yl- acetoxyV4-oxo-pentanoic acid
MS (ESI) m/z 554.2 (M+l)
EXAMPLE 9q 5-(Naphthalen-l-yl-acetoxy -4-oxo-3-(2-phenylmethanesulfonyl-propionylamino)- pentanoic acid MS (ESI) m/z 526.2 (M+l)
EXAMPLE 9r 5-(2-Benzyl-3-phenyl-propionyloxy)-3-(2-methyl-3-phenylmethanesulfonyl- propionylamino)-4-oxo-pentanoic acid MS (ESI) m/z 594.2 (M+l) EXAMPLE 9s 5-(2-Benzyl-3-phenyl-propionyloxy)-4-oxo-3-(2-phenylmethanesulfonyl- propionylaminoVpentanoic acid MS (ESI) m/z 580.1 (M+l)
EXAMPLE 9t
3-[2-Methyl-3-(3-phenyl-propane-l-sulfonyl)-propionylaminol-5-(naphthalen- 1 -yl-acetoxy)-4-oxo-pentanoic acid MS (ESI) m/z 568.2 (M+l)
EXAMPLE 9u 5-(2-Benzyl-3-phenyl-propionyloxy)-3-[2-methyl-3-(3-phenyl-propane-
1 -sulfonyl)-propionylamino]-4-oxo-pentanoic acid MS (ESI) m/z 622.3 (M+l)
In a process analogous to Example 9b, using appropriately substituted sulfanyl carboxylic acids, the corresponding compounds were prepared:
EXAMPLE 9v
5-(2-Benzyl-3-phenyl-propionyloxy)-3-[3-(2-carboxy-ethylsulfanyl)-2-methyl- propionylamino] -4-oxo-pentanoic acid MS (ESI) m/z 544.4 (M+l)
EXAMPLE 9w 3-[3-(3-Carboxy-propylsulfanyl)-2-methyl-propionylamino1-5-(naphthalen-l-yl- acetoxy)-4-oxo-pentanoic acid MS (ESI) m/z 504.2 (M+l)
EXAMPLE 9x 5-(2-Benzyl-3-phenyl-propionyloxy)-3-r3-(3-carboxy-propylsulfanyl)-2-methyl- propionylaminol-4-oxo-pentanoic acid
MS (ESI) m/z 558.2 (M+l) EXAMPLE 9y 3-(3-Carboxymethylsulfanyl-2-methyl-propionylamino)-5-(naphthalen-l-yl- acetoxy)-4-oxo-pentanoic acid MS (ESI) m/z 476.1 (M+l)
EXAMPLE 9z
5-(2-Benzyl-3-phenyl-propionyloxy)-3-(3-carboxymethylsulfanyl-2-methyl- propionylamino)-4-oxo-pentanoic acid
MS (ESI) m/z 530.1 (M+l)
In a process analogous to Example 9c, using appropriately substituted sulfonyl carboxylic acids, the corresponding compounds were prepared:
EXAMPLE 9aa 3 - [3 -(2-Carboxy-ethanesulfonyl V2-methyl-propionylamino1 -5 -(naphthalen- 1 -yl- acetoxy)-4-oxo-pentanoic acid MS (ESI) m/z 522.3 (M+l)
EXAMPLE 9bb
3-[3-(3-Carboxy-propane-l-sulfonyl -2-methyl-propionylamino]-5-(naphthalen- 1 -yl-acetoxy -4-oxo-pentanoic acid MS (ESI) m/z 536.3 (M+l)
EXAMPLE 9cc 3-(3-Carboxymethanesulfonyl-2-methyl-propionylamino)-5-(naphthalen-l-yl- acetoxy -4-oxo-pentanoic acid MS (ESI) m/z 508.3 (M+l)
EXAMPLE 9dd 5-(2-Benzyl-3-phenyl-propionvIoxy)-3-[3-(3-carboxy-propane-l-sulfonvπ- 2-methyl-propionylamino] -4-oxo-pentanoic acid
MS (ESI) m/z 588.3 (M-H) EXAMPLE 9ee 5-(2-Benzyl-3-phenyl-propionyloxy)-3-(3-carboxymethanesulfonyl-2-methyl- propionylamino)-4-oxo-pentanoic acid MS (ESI) m/z 560.2 (M-H)
In a process analogous to Example 9d, using appropriately substituted sulfinyl carboxylic acids, the corresponding compounds were prepared:
EXAMPLE 9ff 3-[3-(3-Carboxy-propane-l-sulfιnyl)-2-methyl-propionylamino]-5-(naphthalen- 1 -yl-acetoxy)-4-oxo-pentanoic acid MS (ESI) m/z 520.4 (M+l)
EXAMPLE 9gg 3-[2-Methyl-3-(3-phenyl-propane-l-sulfinyl)-propionylamino]-5-(naphthalen-l-yl- acetoxy)-4-oxo-pentanoic acid MS (ESI) m/z 552.2 (M+l)
EXAMPLE 9hh
5-(2-Benzyl-3-phenyl-propionyloxy)-3-[2-methyl-3-(3-phenyl-propane-l-sulfinyl)- propionylamino] -4-oxo-pentanoic acid MS (ESI) m/z 606.3 (M+l)
EXAMPLE 10 3-(2-Carbamoylmethyl-3-methyl-butyrylamino)-5-(naphthalen-l-yl-acetoxy -4- oxo-pentanoic acid
Step A
A solution of (4S)-(-)-4-isopropyl-2-oxazolidinone (19.85 g, 0.154 mol) in 400 mL of THF at -78°C under N2 was treated dropwise with n-butyl lithium (64.5 mL, 0.161 mol, 2.5 M solution in hexanes). Solid formed. The mixture was stirred at -78°C for 30 minutes, then treated with dropwise addition of wo-valeryl chloride (20.6 mL, 0.169 mol). The reaction was allowed to warm to room temperature slowly overnight. The sample was concentrated then partitioned between EtOAc and saturated KH2θ4Sθlution. The organic extract was washed with brine, dried (MgSO4, and the resultant yellow oil was chromatographed (MPLC, silica gel, 10% EtOAc in hexanes) to give 29.8 g (91%) of
N-acyloxazolidone as a light yellow oil.
Step B
A solution of N-acyloxazolidone (20.8 g, 97.5 mmol, Example 10, Step A) in 500 mL of THF at -78°C under N2 was treated dropwise with sodium bis(trimethylsilyl)amide (107 mL, 107 mmol, 1.0 M solution in THF). The solution was stirred at -78°C for 30 minutes, then treated dropwise with a solution of tert-butyl bromoacetate (18.0 mL, 121.9 mmol) in 100 mL of THF. The sample was stirred at -78°C for 1 hour, then quenched by dropwise addition of saturated KH2PO4 solution (-125 mL). The mixture was warmed to room temperature, concentrated (to remove most of the THF), then extracted with ether. The organic extract was washed with saturated NaHCO3 and brine solutions, dried (MgSO4), concentrated and crystallized from ether-pet ether to give 21.1 g (66%) of [(S-(R*,R*)]-3-(4-isopropyl-2-oxo-oxazolidine-3-carbonyl)-4-methyl-pentanoic acid, tert-butyl ester, as a white solid. Analysis calculated for Ci 7H29NO5 (327.424):
C, 62.36; H, 8.93; N, 4.28. Found: C, 62.30; H, 9.07; N, 4.09.
Step C
The hydrolysis of the N-acyloxazolidone was achieved using lithium hydroperoxide following the procedure of Evans D.A., et al., Tet. Lett..
1987;28:6141-6144. To a stirring solution at 0°C of [(S-(R*,R*)]-3-(4-isopropyl- 2-oxo-oxazolidine-3-carbonyl)-4-methyl-pentanoic acid, tert-butyl ester (9.05 g, 27.64 mmol, Example 10, Step B) in 250 mL of THF was added dropwise hydrogen peroxide (14.1 mL, 138 mmol, 30 wt% solution in water) followed by 1.0 M lithium hydroxide solution (55.3 mL, 55.3 mmol). The reaction was allowed to warm to room temperature slowly overnight. The reaction was concentrated (to remove most of the THF), then the basic solution was washed with CH2CI2 (2 x 100 mL). The aqueous phase was cooled, acidified with saturated KH2PO4 solution to a pH -5 and extracted into EtOAc. The organic extract was washed with brine solution, dried (MgSO4), and concentrated to give 5.66 g (95%) of (S)-2 -isopropyl succinic acid 4-tert-butyl ester as a colorless oil, which was used without further purification.
Step D A mixture of (S)-2-isopropyl succinic acid 4-tert-butyl ester (10.77 g,
49.80 mmol), (S)-2-amino-succinic acid 1 -allyl ester 4-benzyl ester hydrochloride (14.93 g, 49.81 mmol), HOBTΗ2O (8.4 g, 54.8 mmol), EDCI-HC1 (10.5 g, 54.8 mmol), and 4-methylmorpholine (8.2 mL, 74.6 mmol) in 250 mL of CH2CI2 was stirred at room temperature for 12 hours. The mixture was concentrated, then partitioned between EtOAc and saturated NaHCO3 solution. The EtOAc extract was washed with saturated KH2PO4 and brine solutions, dried (MgSO4), filtered, concentrated, and chromatographed (MPLC, silica gel, 20% EtOAc in hexanes) to give 19.21 g (84%) of [S-(R*,R*)]-2-(2-tert-butoxycarbonylmethyl-3-methyl- butyrylamino)-succinic acid 1 -allyl ester 4-benzyl ester as light yellow oil.
Step E
A solution of [S-(R*,R*)]-2-(2-tert-butoxycarbonylmethyl-3-methyl- butyrylamino)-succinic acid 1 -allyl ester 4-benzyl ester (9.3 g, 23.0 mmol, Example 10, Step D) and trifluoroacetic acid (35 mL) in 35 mL of CH2CI2 was stirred at room temperature under N2 for 2 hours. The sample was concentrated, redissolved into CH2CI2, then treated with EDCIΗC1 (8.8 g, 46.0 mmol),
HOBT«H2θ (6.2 g, 46.0 mmol), and O-benzylhydroxylamine hydrochloride
(7.3 g, 46.0 mmol). 4-Methylmorpholine (11.6 g, 115 mmol) was added dropwise, and the reaction mixture was stirred at room temperature overnight. The sample was diluted with CH2CI2 and washed successively with 5% HCl and sat. nachθ3 solutions. The organic extract was dried (Na2SO4) and concentrated to afford
10.25 g (88%) of the O-benzyl hydroxamate as a white solid which was carried on to the next step without further purification.
Step F
The allyl ester was cleaved employing the procedure of Dessolin M., et al., Tet. Lett, 1995;36:5741-5744. A solution at 0°C under N2 of allyl ester (10.25 g,
19.7 mmol, Example 10, Step E) and tetrakis(triphenylphosphine)palladium (0) (0.462 g, 0.40 mmol) in CH2CI2 was treated dropwise with phenylsilane (4.26 g, 39.4 mmol). The reaction mixture was allowed to warm to room temperature over a period of 1 hour, then washed with saturated KH2PO4 solution. The organic layer was extracted with 0.5N NaOH. The basic aqueous phase was acidified with concentrated HCl and extracted with EtOAc. The organic extract was dried (Na2SO4), filtered, and concentrated to afford 6.2 g (72%) of the substituted succinic acid 4-benzyl ester as foamy white solid.
To a solution of above acid (6.0 g, 12.8 mmol) and 4-methylmorpholine (1.3 g, 12.8 mmol) in THF (50 mL) at -42°C was added isobutyl chloroformate (1.8 g, 12.8 mmol) dropwise. After stirring 30 minutes, the reaction mixture was added to a solution of diazomethane in diethyl ether (-0.5 M, 200 mL) at 0°C. The reaction mixture was stirred for 2 hours at room temperature then cooled to 0°C. A solution of 48% HBr (20 mL) and HO Ac (20 mL ) was added dropwise, and the reaction was stirred for 30 minutes at 0°C. The sample was diluted with diethyl ether and washed with water (2x) and saturated NaHCO3 solution (2x). The organic layer was dried (Na2SO4) and concentrated. The residue was dissolved in CH2CI2, and the product was precipitated with hexanes. The solid was collected by filtration, washed well with hexanes, and dried to afford 1.5 g (15%) of the bromomethyl ketone as a white solid.
A mixture of the bromomethyl ketone (0.440 g, 0.82 mmol), 1-naphthylacetic acid (0.300 g, 1.61 mmol), and potassium fluoride (0.116 g, 2.0 mmol) in 2.0 mL of DMF was stirred at room temperature for 12 hours. The reaction mixture was diluted with EtOAc and washed successively with water (2x) and saturated NaHCO3 solution. The organic layer was dried (Na2SO4) and concentrated. The residue was crystallized from CH2Cl2-hexanes to afford 0.430 g (80%) of napthyl acetic acid ester methyl ketone as a white solid.
Step G
To a solution of substituted succinic acid 4-benzyl ester (0.43 g, Example 10, Step F) in 75 mL of THF was treated with Pd/C (0.050 g), and the mixture was hydrogenated at 50 psi H2, room temperature for 2 hours. The reaction mixture was filtered and Raney Nickel (0.10 g) was added. The reaction mixture was again hydrogenated at 50 psi for 17 hours. The sample was filtered. The filtrate was concentrated, and the residue was crystallized from acetone- hexanes to afford 0.111 g (45%) of 3-(2-carbamoylmethyl-3-methyl- butyrylamino)-5-(naphthalen-l-yl-acetoxy)-4-oxo-pentanoic acid as a white solid. Analysis calculated for C24H28N2O7O.74 H2O:
C, 61.30; H, 6.32; N, 5.96. Found: C, 61.30; H, 6.37; N, 5.94.
In a process analogous to Example 10, the corresponding compounds were prepared:
EXAMPLE 10a
3-[3-Methyl-2-(phenethylcarbamoyl-methyl)-butyrylamino1-5-(naphthalen-l-yl- acetoxy)-4-oxo-pentanoic acid as a white solid.
Analysis calculated for C32H36N2θ7'1.5 H2O (587.676):
C, 65.40; H, 6.69; N, 4.77. Found: C, 65.23; H, 6.69; N, 4.74.
EXAMPLE 10b 3-(3-Carboxy-2-methyl-propionylamino)-5-(naphthalen-l-yl-acetoxy)-4-oxo- pentanoic acid EXAMPLE 11 3-(2-Methyl-3-suIfamoyl-propionylamino)-5-(naphthalen-l-yl-acetoxy)-4-oxo- pentanoic acid
To solution of D-(-)-S-acetyl-β-mercaptoisobutyric acid (14.0 g, 86.4 mmol) in 125 mL of toluene at 0°C under N2 was added dropwise l,8-diazabicyclo[5.4.0]undec-7-ene (DBU, 13.6 g, 89.5 mmol), and then benzyl bromide (15.3 g, 89.5 mmol) was added dropwise over a 5-minute period. The reaction was allowed to warm to room temperature overnight. The reaction was concentrated, diluted with saturated NaHCO3 solution, and extracted with EtOAc (3x). The combined organic extract was washed with brine, dried (MgSO4), filtered, and concentrated to give D-(-)-S-acetyl-β-mercaptoisobutyric acid, benzyl ester, which was carried on without further purification.
Chlorine gas was bubbled through a 0°C solution of D-(-)-S-aceryl-β- mercaptoisobutyric acid, benzyl ester (7.1 g, 20.5 mmol) in 80 mL of carbon tetrachloride: ethanol (9:1) for 90 minutes. The solution was concentrated. The resultant sulfonyl chloride was dissolved into 70 mL of CH2CI2, cooled to 0°C and treated with dropwise addition of a solution of triethylamine (2.4 g, 24.6 mmol) and bis(p-methoxy-benzyl)amine (5.5 g, 21.5 mmol, J. Org. Chem.. 1992;57:7065) in 10 mL of CH Cl2. The solution was stirred at 0°C for 3 hours, concentrated, diluted with water, and extracted into EtOAc (3x). The combined organic extract was washed with brine, dried (MgSO4), filtered, and concentrated.
The resultant brown oil was chromatographed (MPLC, silica gel, 30% EtOAc in hexanes) to give the sulfonamide as a light yellow oil.
A solution of the sulfonamide (8.45g, 17 mmol) in THF was treated with 20% palladium on carbon and hydrogenated at 50 psig H2 and room temperature for 4 hours. The sample was filtered through a pad of Celite and concentrated to give the sulfonamide acid as a colorless oil, which solidified upon standing.
To a solution of the sulfonamide acid (4.1 g, 10 mmol) and pyridine (0.8 g, 10 mmol) in 100 mL of CH2CI2 at 0°C was added dropwise cyanuric fluoride (2.76 g, 20 mmol). The sample was stirred at 0°C for 2 hours, diluted with water, and extracted into CH2CI2 (2x). The combined CH2CI2 extract was dried (MgSO4), filtered, and concentrated. The resultant oil was dissolved into 100 mL of CH2CI2, then treated with H-Asp(OtBu)OMe»HCl (4.08 g, 17 mmol) followed by dropwise addition of 4-methyl-morpholine (2.0 g, 20 mmol). The solution was stirred at room temperature for 12 hours, then partitioned between EtOAc and saturated NaHCO3 solution. The organic extract was washed with saturated
NaH2PO4 and brine solutions, dried (MgSO4), and concentrated to give an oil which solidified upon standing.
The methyl ester (4.58 g, 7.73 mmol) was stirred in methanol (50 mL) and 0.5N aqueous NaOH (20 mL) overnight at room temperature. Methanol was removed in vacuo, and the residue was diluted with water (100 mL), then acidified with concentrated HCl and extracted with EtOAc. The organic layer was dried (Na2SO4) and concentrated to afford 3.7 g (83%) of the free acid as a foamy yellow solid. To a solution of the acid (3.7 g, 6.4 mmol) and 4-methylmorpholine
(0.65 g, 6.4 mmol) in 50 mL of THF at -42°C was added isobutyl chloroformate (0.89 g, 6.4 mmol) dropwise. After stirring 30 minutes, the reaction mixture was added to a solution of diazomethane in diethyl ether (-0.3 M, 100 mL) at 0°C. The reaction mixture was stirred for 2 hours at room temperature, then cooled to 0°C. A solution of 48% HBr (15 mL) and HOAc (15 mL) was added dropwise, and the reaction was stirred for 30 minutes at 0°C. The sample was diluted with diethyl ether and washed with water (2x) and saturated NaHCO3 solution (2x). The organic layer was dried (Na2SO4) and concentrated to afford 3.88 g (97%) of the bromomethyl ketone as a yellow solid. A mixture of bromomethyl ketone (0.624 g, 1.0 mmol), 1-naphthylacetic acid (0.372 g, 2.0 mmol), and potassium fluoride (0.145 g, 2.5 mmol) in 2.0 mL of anhydrous DMF was stirred at room temperature for 12 hours. The reaction mixture was diluted with EtOAc and washed successively with water (2x) and saturated NaHCO3 solution. The organic layer was dried (Na2SO4), concentrated, and the residue was chromatographed (MPLC, silica gel, hexanes-EtOAc [2:1]) to afford 0.470 g (62%) of di-p-methoxybenzyl sulfonamide as a white solid.
A mixture of di-p-methoxybenzyl sulfonamide (0.760 g, 1.0 mmol) and ammonium cerium (IV) nitrate (CAN, 4.39 g, 8.0 mmol) was stirred in 95% CH3CN and 5% H O (20 mL) for 18 hours. The CH3CN was removed in vacuo, the sample was diluted with EtOAc, and washed with saturated NaHCO3 solution
(2x). The organic layer was dried (Na2SO4), concentrated, and the residue was chromatographed (MPLC, silica gel, 50% EtOAc-50% hexanes) to afford 0.280 g (54%) of the desired primary sulfonamide tert-butyl ester. The primary sulfonamide tert-butyl ester (0.375 g, 0.72 mmol) was treated with trifluoroacetic acid (5 mL) and CH2CI2 (5 mL) for 1 hour at room temperature. The solvents were removed in vacuo to afford a yellow solid. The residue was recrystallized from CH2θ2-hexanes to afford 0.090 g (27%) of 3-(2- methyl-3-sulfamoyl-propionylamino)-5-(naphthalen-l-yl-acetoxy)-4-oxo- pentanoic acid as an off-white solid.
Analysis calculated for C21H24N2O8S1O.27 CF3CO2H:
C, 52.23; H, 4.94; N, 5.66. Found: C, 52.23; H, 5.07; N, 5.54.
INHIBITION STUDIES
Compounds of Formula I are inhibitors of ICE as demonstrated by measurement of Kj (μM) and IC50 (μM) using the protocol described herein. ICE
(0.24 nM final concentration) is added to 400 μL of HGDE buffer (100 mM
HEPES, 20% glycerol, 5 mM DTT, 0.5 mM EDTA) containing 15 μM substrate
(Ac-Tyr-Val-Ala-Asp-AMC; KM = 15 μM) plus vehicle (DMSO) or inhibitor at concentrations bracketing the Kj. Substrate hydrolysis is monitored for
300 seconds by observing the fluorescence of released AMC using excitation at 380 nm and emission at 460 nm. Mean rates of substrate hydrolysis are evaluated by linear-regression analysis of the fluorescence vs time traces. To evaluate Kj, plots of percent inhibition vs inhibitor concentration are fit by non-linear regression to a reversible, competitive model:
where the competition factor (1 + [S]/KM) = 2.
PBMC Cellular Assay - IC5Q Determinations
Further evidence that compounds of Formula I are inhibitors of ICE is provided by their ability to inhibit IL-1 β production in human peripheral blood mononuclear cells (PBMCs) as described herein. PBMCs are isolated from heparinized blood by centrifugation over a Ficoll cushion, then washed three times with phosphate-buffered saline. PBMCs are suspended in a medium containing RPMI 1640 with glutamine, penicillin, streptomycin, and 2% human AB serum, then plated at 10^ cells per well in 96-well flat bottom plates. PBMCs are stimulated overnight with 10 ng/mL of lipopolysaccharide (LPS, E. coli strain 0111 :B4; Calbiochem) in the presence or absence of a compound of Formula I.
Medium is harvested and the level of mature IL-lβ was determined using an ELISA kit from R & D Systems. Compound inhibition (IC50) is assessed by determining the concentration of agent which reduced IL-lβ levels by 50%. Cells were cultured for an additional 4 hours in the presence of 3-(4,5-dimethylthiazol- 2-yl)-2,5-diphenyltetrazolium bromide (MTT) to determine viability. Compound toxicity can, therefore, be assessed by determining the concentration of agent which kills 50% of the cells (TC50).
ICE Coiorimetric Dose-Response (IC50) Assay
Diluted inhibitor stocks are prepared by two-fold serial dilution from a primary stock whose concentration is selected (based on screening results or on prior attempts at IC50 evaluation) to achieve approximately 95% inhibition in the most concentrated well. Aliquots of each dilution are transferred to a microtitre plate in triplicate.
ICE enzyme is diluted to approximately 24 nM in HGE buffer (100 mM Hepes pH 7.5, 0.5 mM EDTA, 20% glycerol, 0.1% Bovine Serum Albumin
(BSA), and activated by adding dithiothreitol (DTT) to a final concentration of 5 mM. The activated enzyme is then aliquoted into wells containing inhibitor or vehicle, and the plate is preincubated for 60 minutes at ambient temperature. Substrate (Ac-Tyr-Val-Ala-Asp-pNA) is added to each well to a final concentration of 50 μM, and plates are placed in the microtitre plate-reader thermostated to 25°C. Beginning 5 minutes after addition of substrate, absorbance (405 nm) of wells is monitored for 1 hour, and activity is calculated as the mean rate of change in absorbance during this interval.
Ich-2 (Caspase-4) Coiorimetric Dose-Response (IC50) Assay Inhibition of Ich-2 enzyme is assayed as described above for ICE, except that enzyme is used at 64 nM, and 60 μM of the Ich-2-specific substrate Ac-Leu- Glu-Val-Asp-pNA is used instead of the ICE substrate Ac-Tyr-Val-Ala-Asp-pNA. The results of these tests are shown below in Table 1.
TABLE 1
Example ICE ICE PBMC PBMC Ich-2
Number Ki(μM) IC50 (μM) ιc5o (μ ) TC50 (μM) (Caspase-4) IC50 (μM)
1 0.460 3.100 24.0 >100 3.60 la 4.500 32.000 >100 >100 73.00 lb 4.100 30.000 „ — 25.00 lc 0.990 3.600 >100 >100 3.00
Id 1.700 0.686 >100 >100 2.00 le 1.100 1.170 40.0 >100 0.93
If 1.300 8.100 47.5 >100 26.00 ig 1.300 9.200 >100 >100 26.00 lh 6.000 35.000 ~ — 38.00 li 0.760 7.600 57.5 95.0 23.00 ij 0.600 6.500 47.5 >100 8.60
Ik 1.900 8.500 >100 >100 13.00
11 0.970 8.200 47.5 >100 — lm 14.00 3.000 >100 >100 —
In 76.00 6.000 -- — 7.00 lo 6.40 35.00 — ~ 48.00 lp 2.80 1.100 >100 >100 3.90
Iq 5.60 29.000 — ~ 23.00 lr 3.90 9.70 50.0 >100 6.80
Is 8.10 66.60 — — 53.00
It 8.300 24.000 — — 52.00 lu 16.00 50.00 « — ~ lv 6.2 15.8 lw 1.3 5.8 65 >100 lx 9.1 32.2 iy 5.6 12 lz 4.4 12.5 laa 1.7 7.5 ~ lbb 7 19.5 lcc 4.3 6.7 ~ ldd 2.1 12 — lee 5 24 ~
Iff 7.625 14 27.5 igg 4.1 19 65 lhh 9 38 90 lii 2.015 20.7 90 ijj 6.9 16.6 >100 lkk 21 0.92
111 7.5 15 42.5
1mm 2.64 3.9 55
Inn 0.82 6.0 >100 TABLE 1 (cont)
Example ICE ICE PBMC PBMC Ich-2
Number Kj(μM) IC50 (μM) IC50 (μM) TC50 (μM) (Caspase-4) IC50 (μM) loo 1.2 9.5 >100 lpp 1.1 13 >100 lqq 3.1 1.2 >100 lrr 2 4.6 45 lss 5.6 4.78 45 ltt 8.75 43 >100 luu 3.3 3.1 37.5 lw 8.5 3.1 50 lww 20 1.6 lxx 1.7 11.3 40 lyy 7.7 1.06 >100 lzz 37 3.3 >100 lccc 6.2 54.2 >100 lddd 2.2 7 67.5 leee 1.6 3.2 55 lfff 2.4 23 85 iggg 3.1 9.5 >100
2 0.272 0.846 35.0 >100 1.15
2a 0.850 5.50 65.0 >100 3.1
2b 1.700 4.100 35.0 >100 1.20
2c 20.000 2.800 >100 >100 —
2d 3.15 6.70 >100 >100 6.9
2e 2.90 3.80 >100 >100 16.7
3 0.066 0.082 7.0 >100 0.065
3a 5.2 1.05 >100
3b 7.4 1.6 >100
3c 0.084 0.043 9
3d 0.077 0.078 19
3e 0.0815 0.01 1.2
3f 0.5 0.108 45
3g 0.16 0.065 14.5
3h 0.068 0.029 8
3i 0.129 0.081 16
3j 17 2 >100
3k 0.79 0.2 29
31 0.92 0.3 70
3m 1.8 3.8 >100
3n 0.283 1.33 32.5
3o 0.0024 0.0048 0.65
3p 0.041 0.0575 5
3q 0.092 0.0825 5 TABLE 1 (cont)
Example ICE ICE PBMC PBMC Ich-2
Number Kj(μM) IC50 (μM) IC50 (μM) TC50 (μM) (Caspase-4) IC50 (μM)
3r 0.048 0.10 7 0.074
3s 0.053 0.070 7.8 0.021
3t 0.17 0.54 12 0.05
3u 3.2 5.1 >100 1.9
3v 0.10 0.11 12 0.05
3w 3.8 7.7 >100 4.1
4 0.680 1.800 32.5 >100 17.00
4a 0.500 1.450 35.0 >100 1.20
4b 0.74 0.23 57.5
4c 0.14 0.018 9.5
4d 0.11 0.012 >100
4e 0.17 0.068 7
4f 0.21 0.107 16.5
4g 0.6 0.15 44
4h 1.7 2.38 65
4i 0.17 0.068 7
4j 0.189 0.096 25
4k 1.6 1.4 >100
41 0.48 0.96 47.5
5 1.4 0.835 90
5a 0.072 0.102 23
5b 5.55 1 >100
5c 0.78 1.65 80
5d 0.49 0.037 42.5
5e 6.1 1.2 70
5f 4.5 13.1 55
5g 3.7 7.2 39
5h 3.9 1.35 46.5
5i 0.535 0.082 11
5j 6.5 0.178 55
5k 1.3 3.35 52.5
51 6.1 26.8 55
5m 0.66 3.37 30
5n 3.4 0.196 80
5o 2.4 17.9 27.5
5p 0.42 0.563 72.5
5q 0.815 1.62 52.5
5r 1.8 1.14 90
5s 1.2 3.5 100
5t 0.11 0.043 14
5u 0.7 4.3 30 TABLE 1 (cont)
Example ICE ICE PBMC PBMC Ich-2
Number Ki(μM) IC50 (μM) IC50 (μM TC5o (μM) (Caspase-4) IC50 (μM)
5v 1.1 4.5 40
5w 1.2 6.9 52.5
5x 0.11 0.06 65
5y 0.44 2.6 32.5
6 0.000055 0.0019 1.6
6a 0.0019 0.55
6b 0.098 0.0215 9.5
6c 0.00091 0.0051 4.3
6d 0.0535 0.0075 6.8
6e 0.001 0.0029 2.9
6f 0.0015 0.0113 1.4
6g 0.0027 0.0015 0.5
6h 0.00012 0.0013 0.6
6i 0.00016 0.00343 2.8
6j 0.00005 0.0023 1
6k 0.082 0.27 9.5
61 0.42 0.058 9.3
6m 0.49 1.1 27.5
6n 0.0002 0.0035 1.5
6o 0.15 0.497 20
7 0.000056 0.0025 0.43
7a 0.0032 1.3
7b 0.077 0.0023 0.93
8 3.9 0.44 85
8a 4 0.127 75
8b 1.4 0.092 27.5
9 0.48 0.33 30
9a 0.11 0.095 30
9b 0.1465 0.021636 24
9c 0.1735 0.42797 22.7
9d 0.067 0.40277 23.3
9e 1.1 0.658 57.5
9f 0.37 0.27 11
9g 4.6 19 47.5
9h 0.49 0.32 10
9i 2.9 10 23.5
9j 6.8 22 37.5
9k 5 21.1 42.5
91 1.86 0.70227 26.7
9m 0.8 0.23 22.5
9n 2 12 52.5 TABLE 1 i (cont)
Example ICE ICE PBMC PBMC Ich-2
Number Kj(μM) IC50 (μM) IC50 (μM) TC5o (μM) (Caspase-4)
IC50 (μM)
9o 0.56 4 13
9p 0.107 0.047 25
9q 1.1 1 60
9r 0.16 3.3 32.5
9s 4.8 27.786 75
9t 1.2 0.13825 24
9u 1.6 7.3799 28.3
9v 0.297 0.74924 27.7
9w 0.1485 0.024696 37.5
9x 0.342 0.75009 32.7
9y 0.4575 0.058631 41.5
9z 0.7105 4.5923 47.5
9aa 0.0515 0.012147 15
9bb 0.0565 0.0124 21.7
9cc 0.0915 0.0248 33.5
9dd 0.358 0.81376 35
9ee 0.1845 1.2318 45
9ff 0.06 0.0235595 24.7
9gg 0.69 0.15775 24.3
9hh 0.48 4.3431 27
HEPES= 4-(2-hydroxymethyl)- 1 -piperazine : ethane sulfonic acid
DTT = Dithiothreitol
EDTA = Ethylene diamine tetra acetic acid
Ac Acetyl
Glu = Glutamic acid
Leu = Leucine
Tyr = Tyrosine
Val = Valine
Ala = Alanine
Asp = Aspartic Acid
AMC = 7-amino-4-methyl coumarin pNA = Para nitroaniline
HOBT - 1 -hydroxy benzotriazole
AA = An amino acid
Me Methyl
Et Ethyl
DMF = Dimethyl formamide
EDCI = N-ethyl-N'-dimethyl aminopropyl carbodiimide

Claims

A compound of the Formula I
O
II wherein R1 is R3OC-,
R3CO-,
R3SO2-,
Ra I R5NCHR6CO-,
each Ra is independently hydrogen, Ci -Cg alkyl, or -(CH2)n aryl; R is -(CRR)n-aryl,
-(CRR)n-X-aryl,
-(CRR)n-heteroaryl,
-(CRR)n-X-heteroaryl, -(CRR)n-(substituted-heteroaryl),
-(CRR)n-(substituted-aryl),
-(CRR)n-X-(substituted-aryl),
-(CRR)n-aryl-aryl, -(CRR)n-aryl-heteroaryl,
-(CRR)n-aryl-(CH2)n-aryl,
-(CRR)n-CH(aryl)2,
-(CRR)n-cycloalkyl,
-(CRR)n-X-cycloalkyl, -(CRR)n-heterocycle,
-(CRR)n-X-heterocycle,
-(CRR)n substituted heterocycle,
(CH ) - — substituted aryl
or substituted aryl] or substituted aryl]
aryl
/
■(CRR)n CH
NHaryl
each R is independently hydrogen, Ci -C6 alkyl, halogen or hydroxy;
X is O or S;
R3 is C1-C6 alkyl, aryl, heteroaryl,
-(CHR)n-aryl,
-(CHR)n-heteroaryl,
-(CHR)n-substituted heteroaryl,
-(CHR)n-substituted aryl,
O
II
-(CRR)nCORa,
-(CRR)nS(CH2)n-aryl, cycloalkyl, substituted cycloalkyl, heterocycle, substituted heterocycle, O
-(CRR)nCNRaRa O
II
-(CRR)n-S-(CH2)n aryl,
II O
O
II
-(CRR)n-SCι -C6 alkyl,
II O
R
I J-CH2CH-,
O II
-CHR6C-heteroaryl,
O
II
-(CRR)nS(CH2)nCORa O O
-(CRR)nS(CH2)nCORa
O
(CRR)nS(CH2)n- -aryl,
O
II
(CRR)nS(CH2)n' -aryl,
II O
O
II
<CRR)nSCCι- ) alkyl,
O
II
■(CRR)nS(CH2)n aryl,
O
-(CRR)nS(CH2)nCO2Ra O O
II
(CRR) — N T — NHCCrC6alkyl
O
II
-(CH2)nNHOCι-C6 alkyl, O
II
-(CH2)nCNRbRb,
(CRR) _—
o
CCrC6alkyl
each R' is independently Ci -Cg alkyl,
Ci -Cg alkylaryl, aryl, or hydrogen; each J is independently
-CO2Rb,
-CONR Rb
-SO2NRbRb, or
-SO2R ; each R is independently hydrogen, Ci -Cg alkyl, aryl, substituted aryl; arylalkyl, heteroarylalkyl, substituted arylalkyl, or substituted heteroarylalkyl;
R4 is hydrogen,
Ci-Cg alkyl, O
II CH3OC-,
-phenyl, or
O I
C1-C6 alkyl C-; R5 is Cι-C6 alkyl-CO-, -(CH2)n aryl,
O II
Cι -C6-alkylOC-,
C 1 -C6-alkyl-X-(CH2)nCO,
O
II Cι-C6-alkyl-X-(CH )nOC-, O
II
-C(CRR)naryl, O
II
-CNRaRa, O
II
-SCi-C alkyl,
II O
O O
II II
-C(CH2)nCNRaRa O
II
-CO(CH2)n aryl, O
II -CO(CH2)n substituted aryl,
O O
II II
-C(CRR)nNHCO(CH2)n-aryl,
-Ci-Cg alkyl X-Ci-Cg alkyl aryl, or O O O
II II II
-C-CH-NHC-CH-NHCC i -C6alkyl;
I I
(CH2)n CH2-heteroaryl
I
CO2Ra R5 is
O
II
CCι-C6 alkyl, O
II
-COCι-C6 alkyl, O O
II II -C-CH-NHCC i -C6 alkyl,
I (CH2)n
I aryl or substituted aryl, O
II
CO(CH2)n ryl, O
II C(CH )n aryl, or
O O
CCHNHCCi -C6 alkyl;
I
CH2 heteroaryl
R6 is hydrogen,
C!-C6 alkyl, -(CH2)n aryl, -(CH2)nCO2Ra, hydroxyl substituted C1 -C6 alkyl, or imidazole substituted Ci -Cg alkyl; each n is independently 0 to 3, and the pharmaceutically acceptable, salts, esters, amides, and prodrugs thereof.
O
II
2. A compound according to Claim 1 wherein Rl is phenyl-CH2~OC-.
3. A compound according to Claim 1 wherein Rl is phenyl-SO2-. O
II
4. A compound according to Claim 1 wherein Rl is CH3-OC-.
5. A compound according to Claim 1 wherein Rl is phenyl-CH2CH2-CO-.
6. A compound according to Claim 1 wherein R
A compound according to Claim 1 wherein Rl is
8. A compound according to Claim 1 wherein Rl is phenyl-CH2-CO-
9. A compound according to Claim 1 wherein Rl is
10. A compound according to Claim 1 wherein each Ra is hydrogen.
11. A compound according to Claim 1 wherein R2 is -(CH2)n-phenyl.
12. A compound according to Claim 1 wherein R2 is -(CH2)n-naphthyl.
13. A compound according to Claim 1 wherein R2 is -(CH2)n-O-phenyl.
14. A compound according to Claim 1 wherein R2 is -(CH2)n-O-naphthyl.
15. A compound according to Claim 1 wherein R2 is -(CH2)n-S-phenyl.
16. A compound according to Claim 1 wherein R2 is-(CH2)n-CH(phenyl)2.
17. A compound according to Claim 1 wherein each Ra is hydrogen; Rl is benzyloxycarbonyl; R2 is aryl-X(CRR)n-, aryl-(CRR)n-, heteroaryl- (CRR)n-, or cycloalkyl-(CRR)n-; n is 1, 2, or 3; X is O or S; and R is hydrogen, methyl, or benzyl.
18. A compound according to Claim 1 wherein each Ra is hydrogen; Rl is benzyloxycarbonyl; and
R2 is -(CH2)n-naphthyl, -(CH2)n-phenyl, -(CH2)n-cycloalkyl,
-(CH2)nO(CH2)n-naphthyl,
-(CH2)nO(CH2)n-phenyl, or
-(CH2)nS(CH2)n-phenyl.
19. A compound according to Claim 1 wherein each Ra is hydrogen; Rl is benzyloxycarbonyl; and
R2 is -CH -naphthyl.
20. A compound in accordance with Claim 1 wherein each Ra is hydrogen; R2 is benzyloxycarbonyl,
O
II
-C-CH-CH -S-aryl, or
I
CH3 O O
-C-CHCH2-S-aryl.
I II
CH3 O
21. A method of inhibiting interleukin- 1 β converting enzyme, the method comprising administering to a patient in need of inhibition of interleukin-lβ converting enzyme a therapeutically effective amount of a compound of Claim 1.
22. A method of inhibiting Caspase-4, the method comprising administering to a patient in need of inhibition of Caspase-4 inhibition a Caspase-4 inhibiting amount of a compound of Claim 1.
23. A method of treating stroke, the method comprising administering to a patient having a stroke or having had a stroke a therapeutically effective amount of a compound of Claim 1.
24. A method of treating inflammatory diseases, the method comprising administering to a patient having an inflammatory disease a therapeutically effective amount of a compound of Claim 1.
25. The method of Claim 24 wherein the inflammatory disease is arthritis.
26. The method of Claim 24 wherein the inflammatory disease inflammatory bowel disease.
27. A method of treating reperfusion injury, the method of comprising administering to a patient having reperfusion injury a therapeutically effective amount of a compound of Claim 1.
28. A method of treating Alzheimer's disease, the method comprising administering to a patient having Alzheimer's disease a therapeutically effective amount of a compound of Claim 1.
29. A method of treating shigellosis, the method comprising administering to a patient having shigellosis a therapeutically effective amount of a compound of Claim 1.
30. A pharmaceutically acceptable composition that contains a compound of Claim 1.
31. The compounds :
3-Benzyloxycarbonylamino-5-(naphthalen-l-yl-acetoxy)-4-oxo- pentanoic acid;
3 -Benzyloxycarbonylamino-4-oxo-5 -(3 -phenyl-propionyloxy)- pentanoic acid;
3-Benzyloxycarbonylamino-5-(3-cyclohexyl-propionyloxy)-4-oxo- pentanoic acid; 3 -Benzyloxycarbonylamino-5 - [(naphthalene- 1 -yl-oxy)-acetoxy] -4- oxo-pentanoic acid; 3-Benzyloxycarbonylamino-4-oxo-5-phenoxyacetoxy-pentanoic acid;
3-Benzyloxycarbonylamino-4-oxo-5-phenylsulfanylacetoxy- pentanoic acid; 3-Benzyloxycarbonylamino-5-[(6-methoxy-naphthalene-l-yl)- acetoxy] -4-oxo-pentanoic acid;
3-Benzyloxycarbonylamino-5-(naphthalene-2-yl-acetoxy)-4-oxo- pentanoic acid;
3-Benzyloxycarbonylamino-5-(3-naphthalene-2-yl-propionyloxy)- 4-oxo-pentanoic acid;
3-Benzyloxycarbonylamino-5-(3,3-diphenyl-propionyloxy)-4-oxo- pentanoic acid;
3 -Benzyloxycarbonylamino-5 - [( 1 H-indol-3 -yl)-acetoxy] -4-oxo- pentanoic acid; 3-Benzyloxycarbonylamino-5-(indol- 1 -yl-acetoxy)-4-oxo- pentanoic acid;
3-Benzyloxycarbonylamino-5-(2 -naphthalene- 1 -yl-propionyloxy)- 4-oxo-pentanoic acid;
3-Benzyloxycarbonylamino-4-oxo-5-[(2-oxo-pyrrolidin- 1 -yl)- acetoxy] -pentanoic acid;
5-[(Acetyl-phenyl-amino)-acetoxy]-3-benzyloxycarbonyl-amino-4- oxo-pentanoic acid;
3-Benzyloxycarbonylamino-5-(2-benzyl-3-phenyl-propionyloxy)-4- oxo-pentanoic acid; 3-Benzyloxycarbonylamino-5-(hydroxy-naphthalene-l -yl-acetoxy)-
4-oxo-pentanoic acid;
3-Benzyloxycarbonylamino-4-oxo-5-[(phenyl-amino)-acetoxy]- pentanoic acid;
3-Benzyloxycarbonylamino-5-[(6-hydroxy-naphthalene- 1 -yl)- acetoxy]-4-oxo-pentanoic acid;
3-Benzyloxycarbonylamino-5-[3-(4-hydroxy-phenyl)- 2-naphthalene-l -yl-propionyloxy)-4-oxo-pentanoic acid; (S)-3-Benzyloxycarbonylamino-4-oxo-5-phenylacetoxy-pentanoic acid;
(S)-3-Benzyloxycarbonylamino-4-oxo-5-(4-phenyl-butyryloxy)- pentanoic acid; 3-Benzyloxycarbonylamino-4-oxo-5-[(4-phenyl-naphthalen-l-yl)- acetoxy] -pentanoic acid;
3-Benzyloxycarbonylamino-5-[(4-methyl-naphthalen-l-yl)- acetoxy]-4-oxo-pentanoic acid;
3-Benzyloxycarbonylamino-4-oxo-5-[(4-thiophen-2-yl-naphthalen- l-yl)-acetoxy] -pentanoic acid;
3-Benzyloxycarbonylamino-5-[(4-fluoro-naphthalen-l-yl)- acetoxy] -4-oxo-pentanoic acid;
3-Benzyloxycarbonylamino-5-[(2-methyl-naphthalen- 1 -yl)- acetoxy] -4-oxo-pentanoic acid; 3-Benzyloxycarbonylamino-5-[(2-fluoro-naphthalen- 1 -yl)- acetoxy]-4-oxo-pentanoic acid;
5-(Benzofuran-4-yl-acetoxy)-3-benzyloxycarbonylamino-4-oxo- pentanoic acid;
5-(Benzo[b]thiophen-7-yl-acetoxy)-3-benzyloxycarbonylamino-4- oxo-pentanoic acid;
5-(Benzo [b]thiophen-4-yl-acetoxy)-3 -benzyloxycarbonylamino-4- oxo-pentanoic acid;
5-[(4-Benzyl-naphthalen- 1 -yl)-acetoxy]-3- benzyloxycarbonylamino-4-oxo-pentanoic acid; 3-Benzyloxycarbonylamino-5-[(3,4-dihydro-naphthalen-l-yl)- acetoxy] -4-oxo-pentanoic acid;
3-Benzyloxycarbonylamino-5-[(5-bromo-lH-indol-3-yl)-acetoxy]- 4-oxo-pentanoic acid;
3 -Benzyloxycarbonylamino-5-(3 ,4-diphenyl-butyryloxy)-4-oxo- pentanoic acid;
3-Benzyloxycarbonylamino-4-oxo-5-(3-phenyl-3-phenylamino- propionyloxy)-pentanoic acid; 3-Benzyloxycarbonylamino-4-oxo-5-[(l,2,3,4-tetrahydro- naphthalen-2-yl)-acetoxy] -pentanoic acid;
3-Benzyloxycarbonylamino-5-[(l-methanesulfonyl-piperidin-4-yl)- acetoxy] -4-oxo-pentanoic acid; 3 -Benzyloxycarbonylamino-4-oxo-5-[(2,3 ,5 ,6-tetramethyl-phenyl)- acetoxy] -pentanoic acid;
5-(Benzothiazol-4-yl-acetoxy)-3-benzyloxycarbonylamino-4-oxo- pentanoic acid;
5-(Benzofuran-3-yl-acetoxy)-3-benzyloxycarbonylamino-4-oxo- pentanoic acid;
5-(Benzo[b]thiophen-3-yl-acetoxy)-3-benzyloxycarbonylamino-4- oxo-pentanoic acid;
3-Benzyloxycarbonylamino-4-oxo-5-(3-phenyl-3-pyridin-2-yl- propionyloxy)-pentanoic acid; 3-Benzyloxycarbonylamino-5-[(2,3-dichloro-phenyl)-acetoxy]-4- oxo-pentanoic acid;
3 -Benzyloxycarbonylamino-5 - [(5 -methyl-naphthalen- 1 -yl)- acetoxy]-4-oxo-pentanoic acid;
3-Benzyloxycarbonylamino-5-[(2-iodo-phenyl)-acetoxy]-4-oxo- pentanoic acid;
3 -Benzyloxycarbonylamino-4-oxo-5 -(3 -pyridin-3 -yl- propionyloxy)-pentanoic acid;
3-Benzyloxycarbonylamino-5-[(5-methoxy-naphthalen- 1 -yl)- acetoxy] -4-oxo-pentanoic acid; 3-Benzyloxycarbonylamino-5-[(8-methyl-naphthalen- 1 -yl)- acetoxy] -4-oxo-pentanoic acid;
3-Benzyloxycarbonylamino-5-[(9H-fluoren-9-yl)-acetoxy]-4-oxo- pentanoic acid;
3 -Benzyloxycarbonylamino-5 -[(10,11 -dihydro-5H- dibenzo[a,d]cyclohepten-5-yl)-acetoxy]-4-oxo-pentanoic acid;
5-Oxo- 1 -(toluene-4-sulfonyl)-pyrrolidine-2-carboxylic acid 3 -benzyloxycarbonylamino-4-carboxy-2-oxo-butyl ester; 5-Oxo-pyrrolidine-l,2-dicarboxylic acid 1-benzyl ester 2-(3- benzyloxycarbonylamino-4-carboxy-2-oxo-butyl) ester;
1 -Benzoyl-pyrrolidine-2-carboxylic acid 3 -benzyloxycarbonylamino-4-carboxy-2-oxo-butyl ester; Pyrrolidine-l,2-dicarboxylic acid 1-benzyl ester 2-(3- benzyloxycarbonylamino-4-carboxy-2-oxo-butyl) ester;
3-Benzyloxycarbonylamino-5-(2-benzyl-3-phenyl-propionyloxy)-4- oxo-pentanoic acid;
3-Benzyloxycarbonylamino-5-[(5-cyano-naphthalen-l-yl)-acetoxy]- 4-oxo-pentanoic acid;
3 -Benzyloxycarbonylamino-4-oxo-5 -(3 -phenyl-3 -pyridin-3 -yl- propionyloxy)-pentanoic acid;
3 -Benzyloxycarbonylamino-4-oxo-5 -(3 -phenyl-3 -pyridin-4-yl- propionyloxy)-pentanoic acid; and 3-Benzyloxycarbonylamino-4-oxo-5-[(l-oxo-3,4-dihydro-lH- isoquinolin-2-yl)-acetoxy]-pentanoic acid.
32. The compounds:
3-Benzenesulfonylamino-5-(naphthalen- 1 -yl-acetoxy)-4-oxo- pentanoic acid; 3-Methoxycarbonylamino-5-(naphthalene- 1 -yl-acetoxy)-4-oxo- pentanoic acid;
5-(Naphthalene- 1 -yl-acetoxy)-4-oxo-3-(3-phenyl-propionylamino)- pentanoic acid;
3-Methoxycarbonylamino-4-oxo-5-phenoxyacetoxy-pentanoic acid; and
3-(2-Methanesulfonyl- 1 -methyl-ethylsulfanylamino)-5- (naphthalen- 1 -yl-acetoxy)-4-oxo-pentanoic acid.
33. The compounds :
[S-(R*,R*)]-3-(2-Acetylamino-propionylamino)-5-(naphthalene- l-yl-acetoxy)-4-oxo-pentanoic acid; 5 -(Naphthalen- 1 -yl-acetoxy)-4-oxo-3- [(thiophene-3 -carbonyl)- amino] -pentanoic acid;
3 - [(Furan-3 -carbonyl)-amino] -5 -(naphthalen- 1 -yl-acetoxy)-4-oxo- pentanoic acid; 5-(Naphthalen-l-yl-acetoxy)-4-oxo-3-[2-(4-phenyl-butyrylamino)- propylamino] -pentanoic acid;
3-(2-Methanesulfonylamino-propionylamino)-5-(naphthalen- 1 -yl- acetoxy)-4-oxo-pentanoic acid;
3 - [2-(2- Acetylamino-4-phenyl-butyrylamino)-propionylamino] -5 - (naphthalen- l-yl-acetoxy)-4-oxo-pentanoic acid;
3-(2-Acetylamino-butyrylamino)-5-(naphthalen- 1 -yl-acetoxy)-4- oxo-pentanoic acid;
3-[2-(4-Carbamoyl-butyrylamino)-propionylamino]-5-(naphthalen- 1 -yl-acetoxy)-4-oxo-pentanoic acid; 3-(2-Benzyloxycarbonylamino-propionylamino)-5-(naphthalen-l- yl-acetoxy)-4-oxo-pentanoic acid;
5-(Naphthalen- 1 -yl-acetoxy)-4-oxo-3-(2-ureido-propionylamino)- pentanoic acid;
3 -(2- Acetylamino-propionylamino)-5 -(naphthalen- 1 -yl-acetoxy)-4- oxo-pentanoic acid;
3-[(l-Acetyl-pyrrolidine-2-carbonyl)-amino]-5-(naphthalen-l-yl- acetoxy)-4-oxo-pentanoic acid;
3 -(2-Methyl-3 -oxo-3 -thiophen-2-yl-propionylamino)-5 - (naphthalen- 1 -yl-acetoxy)-4-oxo-pentanoic acid; 3-(2-Acetylamino-acetylamino)-5-(naphthalen-l-yl-acetoxy)-4- oxo-pentanoic acid;
3 -(2- Acetylamino-propionylamino)-5 -(3 ,3 -diphenyl-propionyloxy)- 4-oxo-pentanoic acid;
3-[2-(2-Acetylamino-4-carboxy-butyrylamino)-propionylamino]-5- (naphthalen- l-yl-acetoxy)-4-oxo-pentanoic acid;
5-(Naphthalen-l-yl-acetoxy)-4-oxo-3-[2-(3-phenyl- propionylamino)-propionylamino]-pentanoic acid; 3 - [2-(3 -Methyl-butyrylamino)-propionylamino] -5 -(naphthalen- 1 - yl-acetoxy)-4-oxo-pentanoic acid;
3-[(l-Acetyl-4-benzyloxy-pyrrolidine-2-carbonyl)-amino]-5- (naphthalen- 1 -yl-acetoxy)-4-oxo-pentanoic acid; 3-(4-Carbamoyl-butyrylamino)-5-(naphthalen- 1 -yl-acetoxy)-4-oxo- pentanoic acid; and
3 - [2-( 1 -Methyl- 1 H-imidazol-4-yl)-acetylamino] -5 -(naphthalen- 1 - yl-acetoxy)-4-oxo-pentanoic acid.
34. The compounds: (S)-5-(Naphthalene-l-yl-acetoxy)-4-oxo-3-phenylacetylamino- pentanoic acid;
(S)-5-(Naphthalene-l-yl-acetoxy)-4-oxo-3-(2-thiophene-2-yl- acetylamino)-pentanoic acid;
3-[(2-Carbamoyl-cyclopentanecarbonyl)-amino]-5-(naphthalen-l- yl-acetoxy)-4-oxo-pentanoic acid;
3 - [(3 -Carbamoyl-bicyclo [2.2.1] heptane-2-carbonyl)-amino] -5 - (naphthalen- 1 -yl-acetoxy)-4-oxo-pentanoic acid;
3 -(3 -Methanesulfonyl-2-methyl-propionylamino)-5 -(naphthalen- 1 - yl-acetoxy)-4-oxo-pentanoic acid; 3-(3-Benzenesulfonyl-2-methyl-propionylamino)-5-(naphthalen-l- yl-acetoxy)-4-oxo-pentanoic acid;
3-Butyrylamino-5-(naphthalen-2-yl-acetoxy)-4-oxo-pentanoic acid; 3 -Acetylamino-5 -(naphthalen- 1 -yl-acetoxy)-4-oxo-pentanoic acid; 3 -(3 -Methanesulfonyl-2-methyl-propionylamino)-5 -(naphthalen- 1 - yl-acetoxy)-4-oxo-pentanoic acid;
3-(3-Methyl-butyrylamino)-5-(naphthalen-l-yl-acetoxy)-4-oxo- pentanoic acid;
3-(3-Carbamoyl-propionylamino)-5-(naphthalen-l-yl-acetoxy)-4- oxo-pentanoic acid; [S-(R* ,R* )] -3 -(3 - Acetylsulfanyl-2-methyl-propionylamino)-5 -
(naphthalen- 1 -yl-acetoxy)-4-oxo-pentanoic acid; and trans-2) - [(3 -Carbamoyl-cyclopentanecarbonyl)-amino] -5 - (naphthalen- 1 -yl-acetoxy)-4-oxo-pentanoic acid.
35. The compounds:
3 -( 1 ,2,3 ,4-tetrahydro- 1 -oxo-isoquinoline-2-yl)- acetamino-5-(naphthalene-l-yl acetoxy)-4-oxo-pentanoic acid;
3-(2-Methyl-3-phenethylcarbamoyl-propionylamino)- 5 -(naphthalen- 1 -yl-acetoxy)-4-oxo-pentanoic acid;
5-(Naphthalen-2-yl-acetoxy)-4-oxo-3-[2-(2-oxo-6-phenyl- piperidin- 1 -yl)-acetylamino] -pentanoic acid; 5-(Naphthalen-l-yl-acetoxy)-4-oxo-3-[2-(2-oxo-6-phenyl- piperidin- 1 -yl)-acetylamino] -pentanoic acid;
3 - [3 -Methyl-2-(3 -phenyl-propionylamino)-butyrylamino] -4-oxo- 5-[(l-oxo-l,2,3,4-tetrahydro-naphthalen-2-yl)-acetoxy]-pentanoic acid; 5-(Naphthalen-2-yl-acetoxy)-4-oxo-3 - [2-( 1 -oxo-3 ,4-dihydro- 1 H- isoquinolin-2-yl)-acetylamino]-pentanoic acid;
5-(2-Benzyl-3-phenyl-propionyloxy)-4-oxo-3-[2-(l-oxo- 3 ,4-dihydro- 1 H-isoquinolin-2-yl)-acetylamino] -pentanoic acid;
5-(2-Benzyl-3-phenyl-propionyloxy)-4-oxo-3-[2-(2-oxo-6-phenyl- piperidin- 1 -yl)-acetylamino]-pentanoic acid; 5 -(Naphthalen- 1 -yl-acetoxy)-4-oxo-3 - [2-( 1 -oxo-
1 ,2,3,4-tetrahydro-naphthalen-2-yl)-acetylamino]-pentanoic acid;
5-(Naphthalen- 1 -yl-acetoxy)-4-oxo-3 - [2-( 1 -oxo-3 ,4-dihydro- 1 H- isoquinolin-2-yl)-propionylamino]-pentanoic acid;
5-(Naphthalen-2-yl-acetoxy)-4-oxo-3-[2-(l -oxo-3 ,4-dihydro- 1 H- isoquinolin-2-yl)-propionylamino]-pentanoic acid;
3-[4-(l-Benzenesulfonyl-lH-pyrrol-2-yl)-4-oxo-butyrylamino]- 5-(naphthalen-l -yl-acetoxy)-4-oxo-pentanoic acid;
5-(2-Benzyl-3-phenyl-propionyloxy)-4-oxo-3-[2-(l-oxo- 1 ,2,3 ,4-tetrahydro-naphthalen-2-yl)-acetylamino] -pentanoic acid; 5-(2-Benzyl-3-phenyl-propionyloxy)-4-oxo-3-[2-(l-oxo-
3,4-dihydro-lH-isoquinolin-2-yl)-propionylamino]-pentanoic acid; 4-0x0-3 -[2-(l-oxo-3 ,4-dihydro- 1 H-isoquinolin-2-yl)- propionylamino]-5-[(l-oxo-l,2,3,4-tetrahydro-naphthalen-2-yl)-acetoxy]- pentanoic acid;
3 - [4-( 1 -Benzenesulfonyl- 1 H-pyrrol-2-yl)-4-oxo-butyrylamino] - 5-(2-benzyl-3-phenyl-propionyloxy)-4-oxo-pentanoic acid;
4-Oxo-5 - [( 1 -oxo- 1,2,3 ,4-tetrahydro-naphthalen-2-yl)-acetoxy] - 3-[2-(l-oxo-l,2,3,4-tetrahydro-naphthalen-2-yl)-acetylamino]-pentanoic acid;
5-(Naphthalen- 1 -yl-acetoxy)-4-oxo-3-[2-(2-oxo-3-phenyl- imidazolidin-l-yl)-ρropionylamino] -pentanoic acid;
5 -(Naphthalen- 1 -yl-acetoxy)-4-oxo-3 - [2-(2-oxo-3 -phenyl- tetrahydro-pyrimidin- 1 -yl)-propionylamino] -pentanoic acid;
5-(Naphthalen-l-yl-acetoxy)-4-oxo-3-[2-(2-oxo-3-phenyl- tetrahydro-pyrimidin- 1 -yl)-acetylamino] -pentanoic acid; 3-(2-Acetylamino-3-methyl-butyrylamino)-5-(naphthalen-l -yl- acetoxy)-4-oxo-pentanoic acid;
3-(2-Acetylamino-3-methyl-butyrylamino)-5-(2-benzyl-3-phenyl- propionyloxy)-4-oxo-pentanoic acid;
3-(2-Acetylamino-3-methyl-butyrylamino)-5-(3-benzyl-4-phenyl- butyryloxy)-4-oxo-pentanoic acid;
3-(2-Acetylamino-3-methyl-butyrylamino)-5-(4-benzyl-5-phenyl- pentanoyloxy)-4-oxo-pentanoic acid;
3 -(2- Acetylamino-3 -methyl-butyrylamino)-4-oxo-5 - [( 1 -oxo- 1 ,2,3 ,4-tetrahydro-naphthalen-2-yl)-acetoxy]-pentanoic acid; 5 -(3 -Benzyl-4-phenyl-butyryloxy)-3 - [3 -methyl-2-(3 -phenyl- propionylamino)-butyrylamino] -4-oxo-pentanoic acid;
3-[2-(3-Acetylamino-2-oxo-2H-pyridin-l-yl)-acetylamino]-5-(3,3- diphenyl-propionyloxy)-4-oxo-pentanoic acid; and
3 - [2-(3 - Acetylamino-2-oxo-2H-pyridin- 1 -yl)-acetylamino] -5 -(2- benzyl-3-phenyl-propionyloxy)-4-oxo-pentanoic acid.
6. The compounds:
3-[2-(2-Benzyloxycarbonylamino-4-carboxy-butyrylamino)- 3 -methyl-butyrylamino] -5 -(naphthalen- 1 -yl-acetoxy)-4-oxo-pentanoic acid; 3-[2-(2-Benzyloxycarbonylamino-3-methyl-butyrylamino)- propionylamino]-5-(naphthalen-l-yl-acetoxy)-4-oxo-pentanoic acid;
3-(2-Acetylamino-3-methyl-butyrylamino)-5-(naphthalen- 1 -yl- acetoxy)-4-oxo-pentanoic acid;
3-[2-(2-Benzyloxycarbonylamino-3-methyl-butyrylamino)- propionylamino]-5-(3,3-diphenyl-propionyloxy)-4-oxo-pentanoic acid;
3 - [2-(2-Benzyloxycarbonylamino-3 -methyl-butyrylamino)- propionylamino]-5-(2-benzyl-3-phenyl-propionyloxy)-4-oxo-pentanoic acid;
3-[2-(2-Benzyloxycarbonylamino-3-methyl-butyrylamino)- propionylamino]-5-(naphthalen- 1 -yl-acetoxy)-4-oxo-pentanoic acid;
5-(2-Benzyl-3-phenyl-propionyloxy)-3-{2-[4-carboxy-2-(3-phenyl- propionylamino)-butyrylamino]-3-methyl-butyrylamino}-4-oxo-pentanoic acid;
3-(2-Benzyloxycarbonylamino-3-methyl-butyrylamino)- 5-(3,3-diphenyl-propionyloxy)-4-oxo-pentanoic acid;
3-(2-Acetylamino-3-hydroxy-butyrylamino)-5-(naphthalen-l-yl- acetoxy)-4-oxo-pentanoic acid;
3-(2-Acetylamino-3-hydroxy-butyrylamino)-5-(3,3-diphenyl- propionyloxy)-4-oxo-pentanoic acid; 3-(2-{2- [2- Acetylamino-3 -(1 H-indol-3 -yl)-propionylamino] -
4-carboxy-butyrylamino}-3-methyl-butyrylamino)-5-(2-benzyl-3-phenyl- propionyloxy)-4-oxo-pentanoic acid; and
5-(3,3-Diphenyl-propionyloxy)-4-oxo-3-[2-(4-phenyl- butyrylamino)-propionylamino] -pentanoic acid.
37. The compounds:
3 -(2- { 2- [2- Acetylamino-3 -(1 H-indol-3 -yl)-propionylamino] - 4-carboxy-butyrylamino } -3-methyl-butyrylamino)-5 -(naphthalen- 1 -yl- acetoxy)-4-oxo-pentanoic acid; and 3-(2- {2-[2-Acetylamino-3-(4-hydroxy-phenyl)-propionylamino]-
4-carboxy-butyrylamino } -3 -methyl-butyrylamino)-5 -(naphthalen- 1 -yl- acetoxy)-4-oxo-pentanoic acid.
38. The compounds:
3-[(2-Carboxy-cyclohexanecarbonyl)-amino]-5-(naphthalen-l-yl- acetoxy)-4-oxo-pentanoic acid;
3-[(2-Methoxycarbonyl-cyclohexanecarbonyl)-amino]- 5-(naphthalen-l-yl-acetoxy)-4-oxo-pentanoic acid; and
3-[(2-Carbamoyl-cyclohexanecarbonyl)-amino]-5-(naphthalen- 1 -yl- acetoxy)-4-oxo-pentanoic acid.
39. The compounds:
3-(3-Benzylsulfanyl-2-methyl-propionylamino)-5-(naphthalen- 1 -yl- acetoxy)-4-oxo-pentanoic acid;
3-(2-Methyl-3-phenylmethanesulfonyl-propionylamino)- 5 -(naphthalen- 1 -yl-acetoxy)-4-oxo-pentanoic acid; 3 - [3 -(2-Carboxy-ethanesulfanyl)-2-methyl-propionylamino] -
5-(naphthalen-l -yl-acetoxy)-4-oxo-pentanoic acid;
5-(2-Benzyl-3 -phenyl-propionyloxy)-3 - [3-(2-carboxy- ethanesulfonyl)-2-methyl-propionylamino]-4-oxo-pentanoic acid;
5 -(2-Benzyl-3 -phenyl-propionyloxy)-3 - [3 -(3 -carboxy-propane- l-sulfinyl)-2-methyl-propionylamino]-4-oxo-pentanoic acid;
5-(Naphthalen-l-yl-acetoxy)-4-oxo-3-(2-phenylmethanesulfanyl- propionylamino)-pentanoic acid;
3-(2-Methyl-3-phenylsulfanyl-propionylamino)-5-(naphthalen-l-yl- acetoxy)-4-oxo-pentanoic acid; 5-(2-Benzyl-3-phenyl-propionyloxy)-3-(2-methyl-3-phenylsulfanyl- propionylamino)-4-oxo-pentanoic acid;
3-(2-Methyl-3-phenethylsulfanyl-propionylamino)-5-(naphthalen- 1 -yl-acetoxy)-4-oxo-pentanoic acid; 5-(2-Benzyl-3-phenyl-propionyloxy)-3-(2-methyl-
3-phenethylsulfanyl-propionylamino)-4-oxo-pentanoic acid;
5-(2-Benzyl-3-phenyl-propionyloxy)-3-(3-benzylsulfanyl-2-methyl- propionylamino)-4-oxo-pentanoic acid;
5 -(2-Benzyl-3 -phenyl-propionyloxy)-3 -(2-benzylsulfanyl- propionylamino)-4-oxo-pentanoic acid;
3-[2-Methyl-3-(3-phenyl-propylsulfanyl)-propionylamino]- 5-(naphthalen- 1 -yl-acetoxy)-4-oxo-pentanoic acid;
3-(3-Benzenesulfonyl-2-methyl-propionylamino)-5-(naphthalen- 1 -yl-acetoxy)-4-oxo-pentanoic acid; 3-(3-Benzenesulfonyl-2-methyl-propionylamino)-5-(2-benzyl-
3 -phenyl-propionyloxy)-4-oxo-pentanoic acid;
5-(2-Benzyl-3-phenyl-propionyloxy)-3-[2-methyl-3-(2-phenyl- ethanesulfonyl)-propionylamino]-4-oxo-pentanoic acid;
3 - [2-Methyl-3 -(2-phenyl-ethanesulfonyl)-propionylamino] - 5-(naphthalen-l-yl-acetoxy)-4-oxo-pentanoic acid;
5-(Naphthalen-l-yl-acetoxy)-4-oxo-3-(2-phenylmethanesulfonyl- propionylamino)-pentanoic acid;
5-(2-Benzyl-3-phenyl-propionyloxy)-3-(2-methyl- 3 -phenylmethanesulfonyl-propionylamino)-4-oxo-pentanoic acid; 5-(2-Benzyl-3-phenyl-propionyloxy)-4-oxo-
3 -(2-phenylmethanesulfonyl-propionylamino)-pentanoic acid;
3-[2-Methyl-3-(3-phenyl-propane-l-sulfonyl)-propionylamino]- 5-(naphthalen- 1 -yl-acetoxy)-4-oxo-pentanoic acid;
5-(2-Benzyl-3 -phenyl-propionyloxy)-3 - [2-methyl-3-(3 -phenyl- propane- l-sulfonyl)-propionylamino]-4-oxo-pentanoic acid;
5-(2-Benzyl-3-phenyl-propionyloxy)-3-[3-(2-carboxy- ethylsulfanyl)-2 -methyl -propionylamino] -4-oxo-pentanoic acid; 3-[3-(3-Carboxy-propylsulfanyl)-2-methyl-propionylamino]- 5 -(naphthalen- 1 -yl-acetoxy)-4-oxo-pentanoic acid;
5 -(2-Benzyl-3 -phenyl-propionyloxy)-3 - [3 -(3 -carboxy- propylsulfanyl)-2-methyl-propionylamino]-4-oxo-pentanoic acid; 3 -(3 -Carboxymethylsulfanyl-2-methyl-propionylamino)-
5-(naphthalen- 1 -yl-acetoxy)-4-oxo-pentanoic acid;
5-(2-Benzyl-3-phenyl-propionyloxy)-3-(3-carboxymethylsulfanyl- 2-methyl-propionylamino)-4-oxo-pentanoic acid;
3-[3-(2-Carboxy-ethanesulfonyl)-2-methyl-propionylamino]- 5-(naphthalen-l-yl-acetoxy)-4-oxo-pentanoic acid;
3 - [3 -(3 -Carboxy-propane- 1 -sulfonyl)-2-methyl-propionylamino] - 5 -(naphthalen- 1 -yl-acetoxy)-4-oxo-pentanoic acid;
3-(3-Carboxymethanesulfonyl-2-methyl-propionylamino)- 5-(naphthalen- 1 -yl-acetoxy)-4-oxo-pentanoic acid; 5-(2-Benzyl-3-phenyl-propionyloxy)-3-[3-(3-carboxy-propane-
1 -sulfonyl)-2-methyl-propionylamino]-4-oxo-pentanoic acid;
5-(2-Benzyl-3-phenyl-propionyloxy)-3-(3-carboxymethanesulfonyl- 2-methyl-propionylamino)-4-oxo-pentanoic acid;
3-[3-(3-Carboxy-propane-l-sulfinyl)-2-methyl-propionylamino]- 5-(naphthalen-l-yl-acetoxy)-4-oxo-pentanoic acid;
3-[2-Methyl-3-(3-phenyl-propane- 1 -sulfinyl)-propionylamino]- 5 -(naphthalen- l-yl-acetoxy)-4-oxo-pentanoic acid; and
5-(2-Benzyl-3-phenyl-propionyloxy)-3-[2-methyl-3-(3-phenyl- propane- 1 -sulfinyl)-propionylamino]-4-oxo-pentanoic acid.
40. The compounds:
3 - [3 -Methyl-2-(phenethylcarbamoyl-methyl)-butyrylamino] -5 - (naphthalen- 1 -yl-acetoxy)-4-oxo-pentanoic acid; and
3-(3-Carboxy-2-methyl-propionylamino)-5-(naphthalen-l-yl- acetoxy)-4-oxo-pentanoic acid.
41. The compound:
3-(2-Methyl-3-sulfamoyl-propionylamino)-5-(naphthalen-l-yl- acetoxy)-4-oxo-pentanoic acid.
42. The compounds: 3-(3-Carbamoyl-2-methyl-propionylamino)-5-(naphthalen-l-yl- acetoxy)-4-oxo-pentanoic acid;
3-(2-Benzyloxycarbonylamino-3-methyl-naphthalen- 1 -yl-acetoxy)- 4-oxo-pentanoic acid;
3-[(2-Carbamoyl-cyclopentanecarbonyl)-amino]-5-(naphthalen-l- yl-acetoxy)-4-oxo-pentanoic acid;
3-[( 1 -Carbamoyl-pyrrolidine-2-carbonyl)-amino]-5-(naphthalen- 1 - yl-acetoxy)-4-oxo-pentanoic acid;
3 -(2- { 2- [2- Acetylamino-3 -(4-hydroxy-phenyl)-propionylamino] - 4-carboxy-butyrylamino } -3 -methyl-butyrylamino)-5 -(2-benzyl-3 -phenyl- propionyloxy)-4-oxo-pentanoic acid;
3-(3-Carbamoyl-2-methyl-propionylamino)-5-(naphthalen-l-yl- acetoxy)-4-oxo-pentanoic acid;
3-(2-Carbamoylmethyl-3-methyl-butyrylamino)-5-(naphthalen-l- yl-acetoxy)-4-oxo-pentanoic acid; 3-(3-Benzyloxy-2-ureido-propionylamino)-5-(naphthalen-l-yl- acetoxy)-4-oxo-pentanoic acid;
3-[2-(2-Benzyloxycarbonylamino-4-carboxy-butyrylamino)- 3 -methyl-butyrylamino] -5 -(2-benzyl-3 -phenyl-propionyloxy)-4-oxo- pentanoic acid; 3-{2-[4-Carboxy-2-(3-phenyl-propionylamino)-butyrylamino]-
3-methyl-butyrylamino}-5-(naphthalen-l-yl-acetoxy)-4-oxo-pentanoic acid; and
3-[2-(2-Acetylamino-4-carboxy-butyrylamino)-3-methyl- butyrylamino]-5-(naphthalen-l -yl-acetoxy)-4-oxo-pentanoic acid.
3. A compound of the Formula I
wherein R s O
II
-COCH2 phenyl, O
II
-S-phenyl,
II o o
II -COCH3, o
II
CCH CH2 phenyl, O O
II II
C-CHNHCCH3,
I
CH3
O
II
-CCH2 thienyl, O
II
-CCι-C6 alkyl,
-(CH2)3 phenyl,
CH2phenyl ,
O O
-CCH-NHS-CH3,
I II
CH3 O O O O
II II II
-C-CH-NH-C-CH-NHCCH3,
CH3 (CH2)2
I phenyl
O O
-C-CH-NHCCH3,
I
CH2
I
CH3 O O O
II II II
-CCHNHC(CH2)3CNH2,
I CH3
O O
II II
-C-CHCH S-phenyl,
CH3 O
O
-C-furyl,
phenyl
O O
II II
-C-CH-NHCNH2,
CH3
O O
II II
-CCH-C-thienyl,
I CH3
O O
II II
-C-CHCH2-S-CH3,
I II
CH3 o o o
II II
-C(CH2)2CNH2, O O
II II
-C(CH2)3CNH2, O O
II II
-CCHCH2CNH2,
CH3
O O
II II
-S(CH2)„SCH3,
II II
O O
O O
II II
-CCHCH2SCH3
I II
CH3 O
O O
II COCH2phenyl
O O O
II II II
C-CH-NHC-CHNHCCH3,
I I
CH3 (CH2)2
I
CO2H O
O
— C— CH— N Λ N-phenyl I V-J
CH,
O
-CCH-SCH2 phenyl,
CH3
O
O
II
-C- ■CH-N N-phenyl
CH.
OCH2phenyl
CO2H O CCH,
(CH2)2phenyl
CO2H
O O
-C-CH-NHC(CH2)2 phenyl,
CH3
H.
O O
II II NHCCH3
O O
II II
-CCHCH2CNH(CH2)2 phenyl,
I CH3 O HCCH 3
O
II
-CCH-CH -S-phenyl,
I CH3
O O
II II
-CCHCH2-S-phenyl,
I II CH3 O
O
-C-CHCH2-S-(CH2)2 phenyl,
CH3
O O
-C-CH-CH2-S(CH2)2 phenyl,
CH3 O
O
-C-CHCH2SCH2 phenyl,
CH3
O O
II II
-C-CH-CH -S(CH2)2 phenyl,
I II CH3 O
O O
II II
-C-CH — SCH2 phenyl,
I II CH3 O
CH2CH2phenyl ,
O O
II
— - rCrCυH2-— — N - :NHCCH,
O O
-S-CHCH SCH3,
II I II
OCH3 o o o
II II
-CCHCH2SCCH3,
CH3
O
-CCHCH2CO2H,
CH3
O
-CCHCH S-(CH )3-phenyl,
CH3 O O
II II
-C-CH-CH2S-(CH2)3 phenyl,
I II CH3 O
O
II
-C-CH-CH2S(CH2)2 CO2H,
I CH3
O O
-C-CHCH2S(CH2)2CO2H, or
I II CH3 O
O
II
-CCHCH S-(CH2)2CO2H; and
I II CH3 O
R2 is
-CH2CH2 phenyl, -CH2 naphthyl, -CH2CH2 cyclohexyl, -CH2O naphthyl,
-CH2O phenyl, -CH2S-phenyl, -CH2-substituted naphthyl, -CH2CH(phenyl)2, -CH2-imidazole,
-(CH2)3-phenyl, -CH-naphthyl,
I
CH3 H3^c.O
I
— CH2— N — phenyl
-CH[CH2phenyl]2,
-CH-naphthyl,
I OH
-CH2-NH phenyl,
, CH2substituted phenyl
- CH2— CH naphthyl
-CH2-naphthyl-phenyl, -CH2-fluorenyl,
-CH2 naphthyl-thienyl,
phenyl ,
O
A N- 9COCH2phenyl,
-CH2-benzofuranyl, -CH2-benzothienyl,
-CH2-naphthyl-CH2 phenyl, -CH2-substituted phenyl,
-CH2-substituted indolyl, O
II
C— phenyl
O
II
COCH2phenyl
phenyl
/
- CH7— CH
NHphenyl
pyridyl
CH — CH \ phenyl
-(CH2)2 pyridyl or
each n is independently 0 to 3, and the pharmaceutically acceptable, salts, esters, amides, and prodrugs thereof.
EP97911715A 1996-10-11 1997-10-09 ASPARTATE ESTER INHIBITORS OF INTERLEUKIN-1$g(b) CONVERTING ENZYME Withdrawn EP0932598A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2832296P 1996-10-11 1996-10-11
US2832P 1996-10-11
PCT/US1997/018514 WO1998016502A1 (en) 1996-10-11 1997-10-09 ASPARTATE ESTER INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME

Publications (1)

Publication Number Publication Date
EP0932598A1 true EP0932598A1 (en) 1999-08-04

Family

ID=21842807

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97911715A Withdrawn EP0932598A1 (en) 1996-10-11 1997-10-09 ASPARTATE ESTER INHIBITORS OF INTERLEUKIN-1$g(b) CONVERTING ENZYME

Country Status (9)

Country Link
EP (1) EP0932598A1 (en)
JP (1) JP2001506974A (en)
KR (1) KR20000049048A (en)
AU (1) AU738341B2 (en)
BR (1) BR9712530A (en)
CA (1) CA2268098A1 (en)
IL (1) IL129091A0 (en)
NO (1) NO991677L (en)
WO (1) WO1998016502A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005115362A1 (en) 2004-05-15 2005-12-08 Vertex Pharmaceuticals Incorporated Treating seizures using ice inhibitors
EP2295054A1 (en) 2004-05-27 2011-03-16 Vertex Pharmaceuticals Incorporated Ice inhibitors for the treatment of autoinflammatory diseases
US9116157B2 (en) 2010-11-05 2015-08-25 Brandeis University Ice-cleaved alpha-synuclein as a biomarker

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1095018B1 (en) 1998-07-08 2004-01-14 Harbor Branch Oceanographic Institution, Inc. Aminoiminoquinone and aminoquinone alkaloid compounds as caspase inhibitors
US6339101B1 (en) * 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
WO2000061542A1 (en) * 1999-04-09 2000-10-19 Cytovia, Inc. Caspase inhibitors and the use thereof
AU4826900A (en) * 1999-05-07 2000-11-21 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
US6723711B2 (en) 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
AR026748A1 (en) * 1999-12-08 2003-02-26 Vertex Pharma A CASPASE INHIBITING COMPOUND, A PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, A METHOD FOR THE SYNTHESIS OF THE SAME AND AN INTERMEDIATE COMPOUND PARADICHA SYNTHESIS
EP1923386A3 (en) 2000-03-29 2008-05-28 Vertex Pharmceuticals Incorporated Carbamate caspase inhibitors and uses thereof
TWI318207B (en) 2000-03-29 2009-12-11 Vertex Pharma Carbamate caspase inhibitors and uses thereof
PE20011350A1 (en) 2000-05-19 2002-01-15 Vertex Pharma PROPHARMAC OF AN INHIBITOR OF INTERLEUKIN-1ß CONVERTER ENZYME (ICE)
EP1289993B9 (en) * 2000-06-07 2008-08-20 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
US6355666B1 (en) 2000-06-23 2002-03-12 Medinox, Inc. Protected forms of pharmacologically active agents and uses therefor
JP2004521080A (en) 2000-09-08 2004-07-15 メルク フロスト カナダ アンド カンパニー Gamma-keto acid dipeptides as caspase-3 inhibitors
AU2007201841B2 (en) * 2000-09-13 2008-09-04 Vertex Pharmaceuticals Incorporated Caspase Inhibitors and Uses Thereof
PE20020500A1 (en) 2000-09-13 2002-06-25 Vertex Pharma DERIVATIVES OF PIPERIDINE, TETRAHYDROQUINOLINE, TETRAHYDROISOQUINOLINE AS DANDRUFF INHIBITORS
US7473691B2 (en) 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
AU2001296871A1 (en) 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
ES2272567T3 (en) 2000-12-21 2007-05-01 Vertex Pharmaceuticals Incorporated PIRAZOL COMPOUNDS USED AS PROTEIN KINASE INHIBITORS.
US20030096737A1 (en) 2001-04-19 2003-05-22 Anita Diu-Hercend Caspase inhibitors and uses thereof
US7351702B2 (en) 2001-05-23 2008-04-01 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
WO2003024955A2 (en) * 2001-09-18 2003-03-27 Sunesis Pharmaceuticals, Inc. Small molecule inhibitors of caspases
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
JP4616643B2 (en) 2002-06-28 2011-01-19 バーテックス ファーマシューティカルズ インコーポレイテッド Caspase inhibitors and their uses
EA200500299A1 (en) 2002-08-02 2005-08-25 Вертекс Фармасьютикалз Инкорпорейтед PYRAZOL COMPOSITIONS USED AS GSK-3 INHIBITORS
AU2003303345A1 (en) 2002-12-20 2004-07-22 Vertex Pharmaceuticals, Inc. 4-oxo-3-(1-oxo-1h-isoquinolin-2-ylacetylamino)-pentanoic acid ester and amide derivatives and their use as caspase inhibitors
PE20050159A1 (en) * 2003-05-27 2005-04-19 Vertex Pharma DERIVATIVES OF 3- [2- (3-AMINO-2-OXO-2H-PYRIDIN-1-IL) -ACETILAMINO] -4-OXO-PENTANOICO AS CASPASE INHIBITORS
DK1725548T3 (en) 2004-03-12 2015-03-23 Vertex Pharma Process and intermediates for the preparation of asparagine acetal caspase inhibitors
WO2006057961A1 (en) 2004-11-24 2006-06-01 Vertex Pharmaceuticals Incorporated 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives and their use as caspase inhibitors
CA2616337A1 (en) 2005-07-28 2007-02-08 Vertex Pharmaceuticals Incorporated Caspase inhibitor prodrugs
US7507842B2 (en) 2005-08-12 2009-03-24 Radiorx, Inc. Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
TW200736250A (en) 2005-11-03 2007-10-01 Vertex Pharma Aminopyrimidines useful as kinase inhibitors
CN101209976B (en) * 2006-12-29 2012-01-11 中国人民解放军军事医学科学院毒物药物研究所 Substituted tartaric acid derivatives and use thereof for preparing beta-secretase inhibitor
CA2685876A1 (en) 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
WO2009018415A1 (en) 2007-07-31 2009-02-05 Vertex Pharmaceuticals Incorporated Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
MX2011002312A (en) 2008-09-03 2011-04-26 Vertex Pharma CO-CRYSTALS AND PHARMACEUTICAL FORMULATIONS THAT UNDERSTAND THE SAME.
US9956260B1 (en) 2011-07-22 2018-05-01 The J. David Gladstone Institutes Treatment of HIV-1 infection and AIDS
WO2013052803A2 (en) 2011-10-07 2013-04-11 Radiorx, Inc. Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products
US9987270B1 (en) 2015-10-29 2018-06-05 Epicentrix, Inc. Treatment of gliomas using organonitro compound combination therapy
US11576895B2 (en) 2016-01-11 2023-02-14 Epicentrx, Inc Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone
EP3526195A4 (en) * 2016-10-14 2020-05-20 EpicentRx, Inc. Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine
WO2019010447A1 (en) 2017-07-07 2019-01-10 Epicentrx, Inc. Compositions for parenteral administration of therapeutic agents
WO2019164593A2 (en) 2018-01-08 2019-08-29 Epicentrx, Inc. Methods and compositions utilizing rrx-001 combination therapy for radioprotection
CN108997155A (en) * 2018-09-17 2018-12-14 吉尔生化（上海）有限公司 A kind of polypeptide raw material aspartic acid β-tert-butyl ester α-methyl ester hydrochloride preparation method

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0618223A3 (en) * 1993-03-08 1996-06-12 Sandoz Ltd Peptides inhibit the release of interleukin 1-beta useful as anti-inflammatory agents.
TW494094B (en) * 1993-04-29 2002-07-11 Vertex Pharma Peptide analogs as irreversible interleukin-1β protease inhibitors and pharmaceutical compositions comprising the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9816502A1 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005115362A1 (en) 2004-05-15 2005-12-08 Vertex Pharmaceuticals Incorporated Treating seizures using ice inhibitors
EP2295054A1 (en) 2004-05-27 2011-03-16 Vertex Pharmaceuticals Incorporated Ice inhibitors for the treatment of autoinflammatory diseases
US9116157B2 (en) 2010-11-05 2015-08-25 Brandeis University Ice-cleaved alpha-synuclein as a biomarker

Also Published As

Publication number Publication date
AU4902397A (en) 1998-05-11
NO991677L (en) 1999-06-09
JP2001506974A (en) 2001-05-29
BR9712530A (en) 1999-10-19
AU738341B2 (en) 2001-09-13
IL129091A0 (en) 2000-02-17
CA2268098A1 (en) 1998-04-23
KR20000049048A (en) 2000-07-25
NO991677D0 (en) 1999-04-09
WO1998016502A1 (en) 1998-04-23

Similar Documents

Publication Publication Date Title
EP0932598A1 (en) ASPARTATE ESTER INHIBITORS OF INTERLEUKIN-1$g(b) CONVERTING ENZYME
EP0358398B1 (en) Cycloalkyl-substituted glutaramide antihypertensive agents
US6878743B2 (en) Small molecule inhibitors of caspases
KR20000015785A (en) Phenyl sulfone amid derivative
EP0950046B1 (en) 3,4-disubstituted azetidin-2-one derivatives useful as cysteine proteinase regulators
WO1991015487A1 (en) Novel 4h-3,1-benzoxazin-4-one derivative
EP0946502B1 (en) Sulfonamide interleukin-beta converting enzyme inhibitors
KR20000022532A (en) Aryl (sulfide, sulfoxide and sulfone) derivatives and drugs containing the same as the active ingredient
WO1998046597A1 (en) Serine protease inhibitors
SK67394A3 (en) Alpha (-heteroaryloxymethylketones,pharmaceutical agents with their contents and using of these ketones or pharmaceutical agent for production of medicine
EP0666842A1 (en) Hydroxyethylamino sulfamic acid derivatives useful as retroviral protease inhibitors
EP1082127B1 (en) Succinamide inhibitors of interleukin-1beta converting enzyme
CZ145598A3 (en) Mercaptoalkylpeptidyl compound, its use for preparing a preparation for treating or prevention of a state connected with metalloproteinase or tnf alpha, and pharmaceutical composition containing thereof
US5830869A (en) Thiadiazole amide MMP inhibitors
JPH10204054A (en) Phenylsulfonamide derivative
JPH1135557A (en) Phenylsulfonamide derivative
CZ20004084A3 (en) Succinamide inhibitors of interleukin-1beta conversion enzyme
MXPA00010886A (en) SUCCINAMIDE INHIBITORS OF INTERLEUKIN-1&amp;bgr;CONVERTING ENZYME

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990329

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 19990329;LT PAYMENT 19990329;LV PAYMENT 19990329;RO PAYMENT 19990329;SI PAYMENT 19990329

17Q First examination report despatched

Effective date: 19991027

RTI1 Title (correction)

Free format text: ASPARTATE ESTER INHIBITORS OF INTERLEUKIN-1BETA CONVERTING ENZYME

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ABBOTT GMBH & CO. KG

Owner name: WARNER-LAMBERT COMPANY

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAU Approval following communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOSNAGR4

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040501